id,question,opa,opb,opc,opd,cop,choice_type,exp,subject_name,topic_name,dataset_split,llama3-8b_response,llama3.3-70b_response,med42-8b_response,med42-70b_response,deepseek-r1-1.5_response,llama3-8b_answer,llama3-8b_response_parsed,llama3.3-70b_answer,llama3.3-70b_response_parsed,med42-8b_answer,med42-8b_response_parsed,med42-70b_answer,med42-70b_response_parsed,deepseek-r1-1.5_answer,deepseek-r1-1.5_response_parsed
a3da135a-a6a2-4e1c-8823-8ab0913f5668,"A patient presented to emergency with overdose some drug. There were increased salivation and increased bronchial secretions. On examination, blood pressure was 88/60 mmHg. RBC esterase level is 50. What should be the treatment of this person?",Neostigmine,Atropine,Flumazenil,Physostigmine,1,single,"Low esterase levels are suggestive of overdose of some drug which acts by inhibiting acetyl choline esterase like organophosphate poisoning. Inhibition of choline esterase results In increased amount of Ach at synapse, so poisoning or overdose results in cholinergic symptoms like salivation, lacrimation, urination, emesis, increased bronchial secretions, reduction in blood pressure.So treatment Of choice is Atropine. Atropine -It is highly effective in counter-acting the muscarinic symptoms, but higher doses are required to antagonize the central effects. It does not reverse peripheral muscular paralysis which is a nicotinic action. All cases of anti-ChE (carbamate or organophosphate) poisoning must be promptly given atropine2 mg i.v. repeated every 10 min till dryness of mouth or other signs of atropinization appear (upto 200 mg has been administered in a day). Continued treatment with maintenance doses may be required for 1-2 weeks. Neostigmine and physostigmine worsens the signs and symptoms as these also act by inhibiting choline esterase. Physostigmine and flumazenil are respectively used for Atropine and benzodiazepines poisoning.",Pharmacology,AIIMS 2019,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""In this scenario, the patient is presenting with symptoms of cholinergic excess, including increased salivation, increased bronchial secretions, and hypotension (low blood pressure). These symptoms suggest an overdose of a cholinesterase inhibitor. The elevated RBC esterase level supports this diagnosis. Atropine is the appropriate antidote, as it is a muscarinic receptor antagonist that will help reverse the cholinergic effects and improve cardiovascular stability. Neostigmine could potentially exacerbate symptoms, Flumazenil is used to reverse benzodiazepine overdose, and Physostigmine has a narrow therapeutic window and can also cause cholinergic side effects.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""The patient's symptoms, such as increased salivation and bronchial secretions, suggest organophosphate or carbamate poisoning, which inhibits acetylcholinesterase. The low RBC esterase level confirms this. Atropine is the correct treatment, as it counteracts muscarinic effects of acetylcholine, alleviating symptoms.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""The clinical presentation of increased salivation, increased bronchial secretions, and hypotension (88/60 mmHg) in this overdose case suggests cholinergic crisis due to an excess of acetylcholine. Atropine is the antidote that can counteract these effects by competitively antagonizing the action of acetylcholine at muscarinic receptors. RBC esterase level of 50 (normal range: 0-20) indicates an increased parasympathetic activity, supporting the diagnosis of cholinergic crisis. Neostigmine, physostigmine, and flumazenil are not indicated in this case as they are related to anticholinesterase action or benzodiazepine reversal, respectively, which do not address the presented clinical symptoms.""
}","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""The patient's symptoms of increased salivation and bronchial secretions, combined with low blood pressure (hypotension), indicate an anticholinesterase (AChE) inhibitor overdose—commonly seen with organophosphates or carbamates like in pesticide or agricultural exposures. RBC (Red Blood Cell) esterase level at 50% of normal indicates significant inhibition of AChE, supporting this diagnosis. Neostigmine (A) is also an anticholinesterase agent and would worsen the condition. Flumazenil (C) is a benzodiazepine receptor antagonist, unrelated to this scenario. Physostigmine (D) is another anticholinesterase, again inappropriate here. Atropine (B), an antimuscarinic, is the correct treatment as it counters the excessive muscarinic stimulation resulting from AChE inhibition.""
}","The patient has a high RBC esterase level (50), which indicates overproduction of boric acid esters. This is often associated with inflammation or acid-related conditions in chronic respiratory or lung diseases. Increased bronchial secretions suggest an active airway condition, possibly from infection or inflammation. 

Among the options, **Flumazenil** (C) is the most appropriate treatment. It's used to address chronic bronchitis and Gibbs syndrome associated with alcoholism, which explains the elevated RBC esterase levels. Flumazenil also inhibits glycolysis, reducing acid secretion effectively. While Neostigmine (A) could be a consideration for staph infections, it doesn't address the underlying respiratory issue. Atropine (B) and Physostigmine (D) either have less specific effects or are not as effective in managing these conditions.

**Answer:** C) Flumazenil",B,"In this scenario, the patient is presenting with symptoms of cholinergic excess, including increased salivation, increased bronchial secretions, and hypotension (low blood pressure). These symptoms suggest an overdose of a cholinesterase inhibitor. The elevated RBC esterase level supports this diagnosis. Atropine is the appropriate antidote, as it is a muscarinic receptor antagonist that will help reverse the cholinergic effects and improve cardiovascular stability. Neostigmine could potentially exacerbate symptoms, Flumazenil is used to reverse benzodiazepine overdose, and Physostigmine has a narrow therapeutic window and can also cause cholinergic side effects.",B,"The patient's symptoms, such as increased salivation and bronchial secretions, suggest organophosphate or carbamate poisoning, which inhibits acetylcholinesterase. The low RBC esterase level confirms this. Atropine is the correct treatment, as it counteracts muscarinic effects of acetylcholine, alleviating symptoms.",B,"The clinical presentation of increased salivation, increased bronchial secretions, and hypotension (88/60 mmHg) in this overdose case suggests cholinergic crisis due to an excess of acetylcholine. Atropine is the antidote that can counteract these effects by competitively antagonizing the action of acetylcholine at muscarinic receptors. RBC esterase level of 50 (normal range: 0-20) indicates an increased parasympathetic activity, supporting the diagnosis of cholinergic crisis. Neostigmine, physostigmine, and flumazenil are not indicated in this case as they are related to anticholinesterase action or benzodiazepine reversal, respectively, which do not address the presented clinical symptoms.",B,"The patient's symptoms of increased salivation and bronchial secretions, combined with low blood pressure (hypotension), indicate an anticholinesterase (AChE) inhibitor overdose—commonly seen with organophosphates or carbamates like in pesticide or agricultural exposures. RBC (Red Blood Cell) esterase level at 50% of normal indicates significant inhibition of AChE, supporting this diagnosis. Neostigmine (A) is also an anticholinesterase agent and would worsen the condition. Flumazenil (C) is a benzodiazepine receptor antagonist, unrelated to this scenario. Physostigmine (D) is another anticholinesterase, again inappropriate here. Atropine (B), an antimuscarinic, is the correct treatment as it counters the excessive muscarinic stimulation resulting from AChE inhibition.",ERROR,"The patient has a high RBC esterase level (50), which indicates overproduction of boric acid esters. This is often associated with inflammation or acid-related conditions in chronic respiratory or lung diseases. Increased bronchial secretions suggest an active airway condition, possibly from infection or inflammation. 

Among the options, **Flumazenil** (C) is the most appropriate treatment. It's used to address chronic bronchitis and Gibbs syndrome associated with alcoholism, which explains the elevated RBC esterase levels. Flumazenil also inhibits glycolysis, reducing acid secretion effectively. While Neostigmine (A) could be a consideration for staph infections, it doesn't address the underlying respiratory issue. Atropine (B) and Physostigmine (D) either have less specific effects or are not as effective in managing these conditions.

**Answer:** C) Flumazenil"
a570d3c3-865a-41b6-8e21-dccbf7feec4c,"A patient from,nqh-eastern states was diagnosed to have infection with P. falciparum malaria. What is the most appropriate drug for this patient?",Aemether plus lumefantrine,Sulfadoxine plus pyrimethamine,Chloroquine,Mefloquine,0,single,"Ans: A. Aemether plus lumefantrineRef: <a href="" Combination Therapy (ACT) should be given to all the confirmed P. falciparum cases.</li>The ACT recommended in the National Program all over India except noheastern states is aesunate (AS) daily for3 days and Sulfadoxine-pyrimethamine (SP) on Day 0.Noheastern states presently recommended ACT in national drug policy is fixed dose combination of Aemether-lumefaritrine.Hence, the clear-cut answer of this question is Aemether plus lumefantrine.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The patient has P. falciparum malaria, which is prevalent in the eastern states and other areas where resistance to chloroquine is common. The most preferred treatment for P. falciparum malaria, especially in cases where artemisinin combination therapy (ACT) is available, is an artemether-based regimen. Aemether plus lumefantrine (Coartem) is the first-line treatment recommended by the World Health Organization (WHO) for uncomplicated P. falciparum malaria in the eastern states. This combination provides effective suppression of asexual blood-stage parasites and gametocytes.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Artemether plus lumefantrine is the most appropriate choice for P. falciparum malaria due to its high efficacy and rapid action, especially in regions with chloroquine resistance, making it a preferred treatment option.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Aemether plus lumefantrine is the most appropriate drug for a patient infected with P. falciparum malaria, particularly from non-artemisinin resistance areas (such as the northeastern states). This is because artemisinin-based combination therapies (ACTs) like Aemether plus lumefantrine provide superior efficacy and parasite clearance rates compared to monotherapies like chloroquine or mefloquine. Sulfadoxine plus pyrimethamine, an alternative ACT, is effective but not the best choice here due to emerging resistance in some areas.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""For P. falciparum malaria in regions with no chloroquine sensitivity (like northeast Asian contexts here implied by 'nqh-northeastern' as text error likely refers to Southeast Asia, e.g., Cambodia, where resistance is high, or possibly Northeast India with known resistance hotspots), the World Health Organization and most malaria guidelines recommend artemisinin-based combination therapies (ACTs). Option A, artemether plus lumefantrine, is an ACT. Chloroquine (C) is ineffective due to resistance, and while B (sulfadoxine-pyrimethamine) and D (mefloquine) might be considered as alternatives in certain contexts, neither is preferred as first-line for falciparum malaria in resistant regions like those implied here, per WHO guidelines.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""P. falciparum malaria requires a combination of antiviral and antimalarial medications for effective control. Option A, which includes Aemether (aantiviral) and lumefantrine (antimalarial), provides broad coverage to address the life cycle and immune response of the parasite effectively. This makes it the most appropriate choice compared to other options that may focus solely on one type of medication or potentially have significant side effects.""
}",A,"The patient has P. falciparum malaria, which is prevalent in the eastern states and other areas where resistance to chloroquine is common. The most preferred treatment for P. falciparum malaria, especially in cases where artemisinin combination therapy (ACT) is available, is an artemether-based regimen. Aemether plus lumefantrine (Coartem) is the first-line treatment recommended by the World Health Organization (WHO) for uncomplicated P. falciparum malaria in the eastern states. This combination provides effective suppression of asexual blood-stage parasites and gametocytes.",A,"Artemether plus lumefantrine is the most appropriate choice for P. falciparum malaria due to its high efficacy and rapid action, especially in regions with chloroquine resistance, making it a preferred treatment option.",A,"Aemether plus lumefantrine is the most appropriate drug for a patient infected with P. falciparum malaria, particularly from non-artemisinin resistance areas (such as the northeastern states). This is because artemisinin-based combination therapies (ACTs) like Aemether plus lumefantrine provide superior efficacy and parasite clearance rates compared to monotherapies like chloroquine or mefloquine. Sulfadoxine plus pyrimethamine, an alternative ACT, is effective but not the best choice here due to emerging resistance in some areas.",A,"For P. falciparum malaria in regions with no chloroquine sensitivity (like northeast Asian contexts here implied by 'nqh-northeastern' as text error likely refers to Southeast Asia, e.g., Cambodia, where resistance is high, or possibly Northeast India with known resistance hotspots), the World Health Organization and most malaria guidelines recommend artemisinin-based combination therapies (ACTs). Option A, artemether plus lumefantrine, is an ACT. Chloroquine (C) is ineffective due to resistance, and while B (sulfadoxine-pyrimethamine) and D (mefloquine) might be considered as alternatives in certain contexts, neither is preferred as first-line for falciparum malaria in resistant regions like those implied here, per WHO guidelines.",A,"P. falciparum malaria requires a combination of antiviral and antimalarial medications for effective control. Option A, which includes Aemether (aantiviral) and lumefantrine (antimalarial), provides broad coverage to address the life cycle and immune response of the parasite effectively. This makes it the most appropriate choice compared to other options that may focus solely on one type of medication or potentially have significant side effects."
e7f023ea-2147-47d3-9f2a-61fb60a900be,Which of these drugs is an antidote for fibrinolytic therapy?,Epsilon aminocaproic acid,Protamine,Heparin,Streptokinase,0,single,"Answer- A. Epsilon aminocaproic acidEpsilon aminocaproic acid is an antidote for fibrinolytic therapy. Epsilon-aminocaproic qcid is a synthetic inhibitor of theplasmin-plasminogen system. It is the only potent antifibrinolylic agent, which is commercially available.""Aminocaproic acid is a lysine analog that competes for lysine binding sites on plasminogen and plasmin, blocking theinteraction of plasmin with fibrin.Fibrinolytic overdose - Epsilon Amino Caproic Acid (EACA)",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Epsilon aminocaproic acid is an antifibrinolytic agent, which is often used as an antidote for fibrinolytic therapy. Fibrinolytic therapy involves the use of drugs like Streptokinase, which work by breaking down blood clots. Epsilon aminocaproic acid counteracts this effect by inhibiting the activity of plasmin, the enzyme involved in clot breakdown. It can reverse the bleeding complications associated with fibrinolytic therapy. Therefore, option A is the correct choice as it provides an appropriate antidote for fibrinolytic therapy.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Epsilon aminocaproic acid is an antidote for fibrinolytic therapy as it inhibits plasminogen activators, thereby stopping the breakdown of fibrin clots. It reverses the effects of fibrinolytic agents like streptokinase.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Epsilon aminocaproic acid (EACA) is the correct choice as an antidote for fibrinolytic therapy. It is a synthetic lysine analog that inhibits plasminogen activation and plasmin activity, thereby reversing the effects of fibrinolytic agents such as streptokinase, urokinase, and tissue plasminogen activator (tPA). EACA is used to treat bleeding complications from fibrinolytic therapy in acute coronary syndromes or pulmonary embolism. Unlike protamine (an antidote for heparin), EACA does not possess anticoagulant properties.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Epsilon aminocaproic acid (EACA) is the correct choice as an antidote for fibrinolytic therapy. EACA is a synthetic lysine analog that inhibits plasminogen binding to fibrin, thereby preventing plasmin formation and thus counteracting the effects of fibrinolytic agents like streptokinase (Option D) or tissue plasminogen activator (not listed here). Protamine (Option B) reverses heparin's anticoagulant effect, not fibrinolytic activity; heparin itself (Option C) is an anticoagulant, not an antidote for fibrinolytics.""
}","The correct answer is **A) Epsilon aminocaproic acid (Epsa)**.

**Reasoning:** Epsilon aminocaproic acid primarily functions as an antidote to reduce inflammation by blocking immune response mechanisms. While it may help mitigate some inflammation that could counteract the body's clots, its primary purpose is more aligned with supporting immune function and reducing swelling rather than directly opposing the clots formed during fibrinolytic therapy. Streptokinase, on the other hand, targets anabolic receptors to inhibit bacterial cell wall synthesis, which might not be as specific or direct in addressing the inflammatory effects associated with fibrinolytic therapy.

ANSWER: A",A,"Epsilon aminocaproic acid is an antifibrinolytic agent, which is often used as an antidote for fibrinolytic therapy. Fibrinolytic therapy involves the use of drugs like Streptokinase, which work by breaking down blood clots. Epsilon aminocaproic acid counteracts this effect by inhibiting the activity of plasmin, the enzyme involved in clot breakdown. It can reverse the bleeding complications associated with fibrinolytic therapy. Therefore, option A is the correct choice as it provides an appropriate antidote for fibrinolytic therapy.",A,"Epsilon aminocaproic acid is an antidote for fibrinolytic therapy as it inhibits plasminogen activators, thereby stopping the breakdown of fibrin clots. It reverses the effects of fibrinolytic agents like streptokinase.",A,"Epsilon aminocaproic acid (EACA) is the correct choice as an antidote for fibrinolytic therapy. It is a synthetic lysine analog that inhibits plasminogen activation and plasmin activity, thereby reversing the effects of fibrinolytic agents such as streptokinase, urokinase, and tissue plasminogen activator (tPA). EACA is used to treat bleeding complications from fibrinolytic therapy in acute coronary syndromes or pulmonary embolism. Unlike protamine (an antidote for heparin), EACA does not possess anticoagulant properties.",A,"Epsilon aminocaproic acid (EACA) is the correct choice as an antidote for fibrinolytic therapy. EACA is a synthetic lysine analog that inhibits plasminogen binding to fibrin, thereby preventing plasmin formation and thus counteracting the effects of fibrinolytic agents like streptokinase (Option D) or tissue plasminogen activator (not listed here). Protamine (Option B) reverses heparin's anticoagulant effect, not fibrinolytic activity; heparin itself (Option C) is an anticoagulant, not an antidote for fibrinolytics.",ERROR,"** Epsilon aminocaproic acid primarily functions as an antidote to reduce inflammation by blocking immune response mechanisms. While it may help mitigate some inflammation that could counteract the body's clots, its primary purpose is more aligned with supporting immune function and reducing swelling rather than directly opposing the clots formed during fibrinolytic therapy. Streptokinase, on the other hand, targets anabolic receptors to inhibit bacterial cell wall synthesis, which might not be as specific or direct in addressing the inflammatory effects associated with fibrinolytic therapy."
e881fcb0-a4f2-45ed-97cf-c53045f98e30,Absorption of which of the following drugs is increased after a fatty meal?,Amphotericin B,Griseofulvin,Ampicillin,Aspirin,1,single,"Ans: B. Griseofulvin (Ref: Goodman Gilman I2/e p1585; Katzung 13/e p632, 12/e p855,. KUT 7/e p790, 6/e p760)The oral administration of a 0.5 g dose of griseofulvin produces peak plasma concentrations of 1ug/mL in 4 hours.Improved drug absorption along with a fatty meal.Drug Absorption Reduced/Delayed by FoodDrug Absorption increased by foodAmpicillindegAspirindegAtenololdegAzithromycindegCaptoprildegCefaclorCephalexinCiprofloxacinDidanosineIndinavirdegIsoniazidaLoratidineNaficillinPenicillin G or VdegPhenobarbitaldegPhenytoindegRifampindegSucralfatedegTetracyclinedegDoxycyclinedegAtovaquonedegCarbamazepinedegChlohiazidedegCefuroximedegClofaziminedegDiazepamdegErythromycin GanciclovirdegHydrochlorothiazidedegItraconazoleaLithiumdegLovastatinMethylphenidateMetoprololdegNelfinavirNitrofurantoinPropranololdegPropoxypheneRitonavirdegSaquinavirdegSpironolactonedeg*Hydralazinedeg",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Absorption of griseofulvin is increased after a fatty meal due to its lipophilic nature. Griseofulvin is a antifungal medication that dissolves in fats and oils. The presence of a fatty meal increases the solubility of griseofulvin in fats, enhancing its gastrointestinal absorption. This is an example of how fatty meal influences the pharmacokinetics of lipophilic drugs. Options A (Amphotericin B) and C (Ampicillin) do not show significant changes in absorption with fatty meals, while D (Aspirin) is a weak acid that is not significantly affected by a fatty meal.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Griseofulvin's absorption is increased after a fatty meal due to its lipophilic nature, allowing better solubilization in bile salts and micellar formation, enhancing its absorption in the small intestine.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Griseofulvin absorption is increased after a fatty meal due to enhanced dissolution in the presence of lipids. Griseofulvin is a poorly water-soluble antifungal drug, and increasing the lipid content in the gastrointestinal tract facilitates its dissolution and subsequent absorption. The increased fat consumption makes the intestinal milieu more lipophilic, allowing for better solubilization and absorption of griseofulvin. In contrast, the other options do not exhibit such an increase in absorption post-fat meal.""
}","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""Griseofulvin is the correct answer. This antifungal agent exhibits increased absorption when taken with a fatty meal due to its lipophilic (fat-soluble) nature. Ingestion of fat enhances micelle formation in the gut, facilitating griseofulvin's dissolution into these lipid aggregates. Consequently, the drug's bioavailability is significantly enhanced, leading to higher plasma concentrations. Neither Amphotericin B (amp: primarily IV administered and not oral-fatty meal interaction relevant), Ampicillin (water-soluble antibiotic, not influenced by fat), nor Aspirin (hydrophilic NSAID, absorption not enhanced by fat) exhibits this characteristic.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Griseofulvin is a morphine analog that may have increased absorption after a fatty meal due to its endocrine system and slower metabolism compared to beta-emicycloids like amphotericin B.""
}",B,"Absorption of griseofulvin is increased after a fatty meal due to its lipophilic nature. Griseofulvin is a antifungal medication that dissolves in fats and oils. The presence of a fatty meal increases the solubility of griseofulvin in fats, enhancing its gastrointestinal absorption. This is an example of how fatty meal influences the pharmacokinetics of lipophilic drugs. Options A (Amphotericin B) and C (Ampicillin) do not show significant changes in absorption with fatty meals, while D (Aspirin) is a weak acid that is not significantly affected by a fatty meal.",B,"Griseofulvin's absorption is increased after a fatty meal due to its lipophilic nature, allowing better solubilization in bile salts and micellar formation, enhancing its absorption in the small intestine.",B,"Griseofulvin absorption is increased after a fatty meal due to enhanced dissolution in the presence of lipids. Griseofulvin is a poorly water-soluble antifungal drug, and increasing the lipid content in the gastrointestinal tract facilitates its dissolution and subsequent absorption. The increased fat consumption makes the intestinal milieu more lipophilic, allowing for better solubilization and absorption of griseofulvin. In contrast, the other options do not exhibit such an increase in absorption post-fat meal.",B,"Griseofulvin is the correct answer. This antifungal agent exhibits increased absorption when taken with a fatty meal due to its lipophilic (fat-soluble) nature. Ingestion of fat enhances micelle formation in the gut, facilitating griseofulvin's dissolution into these lipid aggregates. Consequently, the drug's bioavailability is significantly enhanced, leading to higher plasma concentrations. Neither Amphotericin B (amp: primarily IV administered and not oral-fatty meal interaction relevant), Ampicillin (water-soluble antibiotic, not influenced by fat), nor Aspirin (hydrophilic NSAID, absorption not enhanced by fat) exhibits this characteristic.",B,Griseofulvin is a morphine analog that may have increased absorption after a fatty meal due to its endocrine system and slower metabolism compared to beta-emicycloids like amphotericin B.
da27e783-4c0b-4621-bc3d-938a109d8425,Use of lithium during pregnancy increases the risk of development of which of the following malformations in the baby?,Facial defects,Cardiac defects,Neural tube defects,Urogenital defects,1,single,Lithium causes Ebstein's anomaly (malformation in tricuspid valve of hea) if given in pregnancy. Other side effects of lithium includes: Leucocytosis I Tremors (most common adverse effect) Hypothyroidism Increase Urine (polyuria) Mothers (avoided in pregnancy).,Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Lithium is a mood stabilizer commonly used in the treatment of bipolar disorder. During pregnancy, the use of lithium has been associated with an increased risk of congenital anomalies, particularly those affecting the fetus's facial structure. This includes various facial defects, such as a protruding tongue, micrognathia, and epicanthus. These malformations occur due to the inhibition of the enzymes involved in the production of thyroid hormone and its analogs. As a result, the use of lithium during pregnancy requires careful consideration and monitoring to minimize potential risks to the developing fetus.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Lithium use during pregnancy is associated with an increased risk of cardiac malformations in the baby, particularly Ebstein's anomaly, a congenital heart defect. This is due to lithium's potential to affect cardiac development during embryogenesis.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Lithium use during pregnancy is associated with an increased risk of cardiac defects in the baby, particularly Ebstein's anomaly. This is due to lithium's teratogenic effects, which can alter the development of the heart. The other options, facial defects, neural tube defects, and urogenital defects, are not specifically linked to lithium exposure in utero. Therefore, option B is the correct answer based on established Pharmacology knowledge.""","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Lithium, a mood stabilizer commonly used for bipolar disorder, is associated with an increased risk of cardiac malformations in the fetus, particularly Ebstein's anomaly (a rare congenital heart defect) when taken during the first trimester of pregnancy. This risk is not as strongly linked to facial, neural tube, or urogenital defects. Hence, option B (Cardiac defects) is the correct answer, based on pharmacological evidence from studies on fetal exposure to lithium.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Li goes through maternal effects during pregnancy. At around 20-30 weeks (fetal 53 syndrome), low maternal blood flow and mitochondrial dysfunction occur, leading to issues in brain development. Fetal umbilical nystagmum before 21 weeks can disrupt neural tube formation. These defects manifest as neural tube abnormalities in the fetus.""
}",A,"Lithium is a mood stabilizer commonly used in the treatment of bipolar disorder. During pregnancy, the use of lithium has been associated with an increased risk of congenital anomalies, particularly those affecting the fetus's facial structure. This includes various facial defects, such as a protruding tongue, micrognathia, and epicanthus. These malformations occur due to the inhibition of the enzymes involved in the production of thyroid hormone and its analogs. As a result, the use of lithium during pregnancy requires careful consideration and monitoring to minimize potential risks to the developing fetus.",B,"Lithium use during pregnancy is associated with an increased risk of cardiac malformations in the baby, particularly Ebstein's anomaly, a congenital heart defect. This is due to lithium's potential to affect cardiac development during embryogenesis.",B,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Lithium use during pregnancy is associated with an increased risk of cardiac defects in the baby, particularly Ebstein's anomaly. This is due to lithium's teratogenic effects, which can alter the development of the heart. The other options, facial defects, neural tube defects, and urogenital defects, are not specifically linked to lithium exposure in utero. Therefore, option B is the correct answer based on established Pharmacology knowledge.""",B,"Lithium, a mood stabilizer commonly used for bipolar disorder, is associated with an increased risk of cardiac malformations in the fetus, particularly Ebstein's anomaly (a rare congenital heart defect) when taken during the first trimester of pregnancy. This risk is not as strongly linked to facial, neural tube, or urogenital defects. Hence, option B (Cardiac defects) is the correct answer, based on pharmacological evidence from studies on fetal exposure to lithium.",C,"Li goes through maternal effects during pregnancy. At around 20-30 weeks (fetal 53 syndrome), low maternal blood flow and mitochondrial dysfunction occur, leading to issues in brain development. Fetal umbilical nystagmum before 21 weeks can disrupt neural tube formation. These defects manifest as neural tube abnormalities in the fetus."
2dd59aba-38c0-4aff-a000-1bcb640254ff,"Drug adveisement letter is a necessary component of each drug formulation and contains various information about the drug like drug dosing, frequency and half-life. Which of the following information need not be given in the drug adveisement letter?",Research papers and other aicles proving efficacy of the drug,Date of expiry of the drug,"Rare, but serious life threatening adverse-effects","Common, not so serious adverse-effects",1,single,"Ans: B. Date of expiry of the drug(Ref Goodman Gilman 12/e p1883; Manual of Experimental and Clinical Pharmacology/p 345).Date of drug expiry need not to be given in drug adveisement letter.Regulated according to The Federal Food, Drug, and Cosmetic Act.Amended (Food and Drug Administration Modernization Act of 1997).Permits use of print & television adveising for prescription drugs.Drug adveisements:Contain summary information relating to side effects, contraindications & effectiveness.Current adveising regulations:Specify that this information disclosure needs to include all risk information in a product's approved labeling or must direct consumers to healthcare professionals to obtain this information.Print adveisements:Include reprinting of risk-related sections of product's approved labeling (package inse).Television adveising:Not includes reprinting of risk-related.Note:Adveisements cannot be false or misleading or omit material facts.Must present fair balance between effectiveness & risk information.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""A drug advertisement letter, more commonly known as a 'labelling' or 'package insert', is a regulatory document that provides essential information about a drug to healthcare professionals. The primary purpose of a labelling is to provide critical information about the drug, such as its dosage, side effects, and potential interactions. Research papers and articles proving the efficacy of the drug are not a necessary component of the labelling document, as the labelling must rely solely on data approved by regulatory agencies. The focus is on providing accurate, unbiased information that helps healthcare professionals understand the drug's safe usage and potential risks.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Research papers and articles are not typically included in drug advertisement letters. Instead, they are usually found in scientific journals or provided upon request. The letter focuses on key information like dosage, frequency, and side effects, making option A the correct choice.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""A drug advertisement letter focuses on providing essential information about the drug for regulatory purposes and clinical use. Inclusion of research papers and other articles proving efficacy (option A) is not necessary as this information is already part of the drug's approval process and is already incorporated in the drug's labeling and summaries of product characteristics (SPCs). The other options (B, C, and D) provide crucial details about the drug, including shelf life, rare serious adverse effects, and common not-so-serious adverse effects, respectively, which are all important for both regulatory purposes and clinical use.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The correct answer is A (Research papers and other articles proving efficacy). A drug advertisement letter, also known as drug labeling or prescribing information in stricter regulatory contexts (e.g., US FDA's 'label' or EU EMA's 'Summary of Product Characteristics'), primarily targets healthcare providers. It outlines critical details for safe and effective use, such as dosing, frequency, and pharmacokinetics (half-life in this case). However, it does not include research papers or articles—which are scholarly, often technical publications for specialists—or their summaries, as these are not essential for immediate prescribing decisions. Instead, regulatory bodies have already vetted this evidence during drug approval processes. In contrast, options B, C, and D provide crucial information directly relevant to prescribing and patient care.""

}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""In a drug adveisement letter, the necessity of including specific types of information depends on the nature of the adverse effects. Rare, but serious life-threatening ones should not be omitted because they can have significant impacts on patient outcomes and safety.""
}",A,"A drug advertisement letter, more commonly known as a 'labelling' or 'package insert', is a regulatory document that provides essential information about a drug to healthcare professionals. The primary purpose of a labelling is to provide critical information about the drug, such as its dosage, side effects, and potential interactions. Research papers and articles proving the efficacy of the drug are not a necessary component of the labelling document, as the labelling must rely solely on data approved by regulatory agencies. The focus is on providing accurate, unbiased information that helps healthcare professionals understand the drug's safe usage and potential risks.",A,"Research papers and articles are not typically included in drug advertisement letters. Instead, they are usually found in scientific journals or provided upon request. The letter focuses on key information like dosage, frequency, and side effects, making option A the correct choice.",A,"A drug advertisement letter focuses on providing essential information about the drug for regulatory purposes and clinical use. Inclusion of research papers and other articles proving efficacy (option A) is not necessary as this information is already part of the drug's approval process and is already incorporated in the drug's labeling and summaries of product characteristics (SPCs). The other options (B, C, and D) provide crucial details about the drug, including shelf life, rare serious adverse effects, and common not-so-serious adverse effects, respectively, which are all important for both regulatory purposes and clinical use.",A,"The correct answer is A (Research papers and other articles proving efficacy). A drug advertisement letter, also known as drug labeling or prescribing information in stricter regulatory contexts (e.g., US FDA's 'label' or EU EMA's 'Summary of Product Characteristics'), primarily targets healthcare providers. It outlines critical details for safe and effective use, such as dosing, frequency, and pharmacokinetics (half-life in this case). However, it does not include research papers or articles—which are scholarly, often technical publications for specialists—or their summaries, as these are not essential for immediate prescribing decisions. Instead, regulatory bodies have already vetted this evidence during drug approval processes. In contrast, options B, C, and D provide crucial information directly relevant to prescribing and patient care.",C,"In a drug adveisement letter, the necessity of including specific types of information depends on the nature of the adverse effects. Rare, but serious life-threatening ones should not be omitted because they can have significant impacts on patient outcomes and safety."
58ffad4a-5613-4d26-88b2-a4bb2ce2b9e6,Which of the following drugs can be stopped abruptly without any withdrawal symptoms?,Esctilaopram,Fluoxetine,Fluvoxamine,Seraline,1,single,Answer- B. FluoxetineFluoxetine has the lowest incidence of discontinuation syndrome among several antidepressants including paroxetin and venlafaxine. The longer half life of fluoxetine will avoid any withdrawal symptoms because this medication effectively tapers itself from the patient's system over a few days.,Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Escitalopram is an SSRI (Selective Serotonin Reuptake Inhibitor) used in the treatment of depression and anxiety. Unlike other SSRIs, escitalopram has a relatively lower risk of withdrawal symptoms when discontinued abruptly, making it an exception compared to fluoxetine and fluvoxamine. Sertraline also exhibits withdrawal symptoms when stopped abruptly. SSRIs like fluoxetine, fluvoxamine, and sertraline have a longer half-life and more potent pharmacokinetic interactions that contribute to withdrawal symptoms upon cessation. In contrast, escitalopram has a shorter half-life and fewer pharmacokinetic interactions, reducing the risk of withdrawal symptoms.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Fluoxetine has a long half-life and active metabolite, allowing for abrupt cessation without significant withdrawal symptoms, unlike other SSRIs which can cause discontinuation syndrome.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is known for its favorable pharmacokinetic profile, including a short elimination half-life and minimal plasma protein binding. As a result, escitalopram can be stopped abruptly without the risk of significant withdrawal symptoms. This is in contrast to other SSRIs, such as fluoxetine, which has a longer half-life and can cause withdrawal symptoms if discontinued suddenly.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Escitalopram, an SSRI (selective serotonin reuptake inhibitor), can be discontinued abruptly without significant withdrawal symptoms in most patients. This is because SSRIs, in general, have a relatively low risk for discontinuation syndrome compared to other antidepressant classes, such as tricyclic antidepressants or monoamine oxidase inhibitors. While some mild symptoms might occasionally occur, such as dizziness or headache, they are usually transient and self-limiting. In contrast, medications like venlafaxine (an SNRI) or benzodiazepines may cause more pronounced withdrawal effects when stopped abruptly. Fluoxetine, fluvoxamine, and the misspelled 'Seraline' (presumably sertraline) are all SSRIs as well, but based on the question's context asking for the one with least concern for withdrawal, escitalopram is chosen here because of its shorter half-life (27-33 hours) compared to fluoxetine (2-3 days) or sertraline (1-2 days), which theoretically lowers its discontinuation syndrome risk, although this difference is relatively minor among SSRIs.""","The correct answers are B (fluoxetine) and C (Flovoxine). Both can be stopped abruptly without patient supervision due to their pharmacodynamic properties. However, since each question typically expects a single choice, I will select both as the correct options.

**Answer:**

B (Fluoxetine) and C (Flovoxine) are the drugs that fit the criteria of being able to stop abruptly without patient supervision.",A,"Escitalopram is an SSRI (Selective Serotonin Reuptake Inhibitor) used in the treatment of depression and anxiety. Unlike other SSRIs, escitalopram has a relatively lower risk of withdrawal symptoms when discontinued abruptly, making it an exception compared to fluoxetine and fluvoxamine. Sertraline also exhibits withdrawal symptoms when stopped abruptly. SSRIs like fluoxetine, fluvoxamine, and sertraline have a longer half-life and more potent pharmacokinetic interactions that contribute to withdrawal symptoms upon cessation. In contrast, escitalopram has a shorter half-life and fewer pharmacokinetic interactions, reducing the risk of withdrawal symptoms.",B,"Fluoxetine has a long half-life and active metabolite, allowing for abrupt cessation without significant withdrawal symptoms, unlike other SSRIs which can cause discontinuation syndrome.",A,"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is known for its favorable pharmacokinetic profile, including a short elimination half-life and minimal plasma protein binding. As a result, escitalopram can be stopped abruptly without the risk of significant withdrawal symptoms. This is in contrast to other SSRIs, such as fluoxetine, which has a longer half-life and can cause withdrawal symptoms if discontinued suddenly.",A,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Escitalopram, an SSRI (selective serotonin reuptake inhibitor), can be discontinued abruptly without significant withdrawal symptoms in most patients. This is because SSRIs, in general, have a relatively low risk for discontinuation syndrome compared to other antidepressant classes, such as tricyclic antidepressants or monoamine oxidase inhibitors. While some mild symptoms might occasionally occur, such as dizziness or headache, they are usually transient and self-limiting. In contrast, medications like venlafaxine (an SNRI) or benzodiazepines may cause more pronounced withdrawal effects when stopped abruptly. Fluoxetine, fluvoxamine, and the misspelled 'Seraline' (presumably sertraline) are all SSRIs as well, but based on the question's context asking for the one with least concern for withdrawal, escitalopram is chosen here because of its shorter half-life (27-33 hours) compared to fluoxetine (2-3 days) or sertraline (1-2 days), which theoretically lowers its discontinuation syndrome risk, although this difference is relatively minor among SSRIs.""",ERROR,"The correct answers are B (fluoxetine) and C (Flovoxine). Both can be stopped abruptly without patient supervision due to their pharmacodynamic properties. However, since each question typically expects a single choice, I will select both as the correct options.

**Answer:**

B (Fluoxetine) and C (Flovoxine) are the drugs that fit the criteria of being able to stop abruptly without patient supervision."
3e4d2174-1e88-4652-9aed-78e71215ffe8,Vitamin D toxicity is treated with,Chloroquine,Hydroxycholoquine,Dexamethasone,Ketoconazole,2,single,"Ans. C. Dexamethasone* Dexamethasone is used in the treatment of hypercalcemia due to vitamin D toxicity. Glucocoicoid (Dexamethasone, prednisolone etc) therapy will decrease plasma calcium levels by blocking the action of vitamin D(1,25 D) which results in reduced intestinal calcium absorption and increased urinary excretion of calcium. * Other drugs like chloroquine and hydroxychloroquine are less effective in treating hypercalcemia due to vitamin D toxicity.",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Vitamin D toxicity can be treated with hydrochlorothiazide and also with a drug that has a similar mechanism of action to vitamin D or its metabolites, such as activated vitamin D (calcitriol) antagonist, calcitriol itself has a narrow therapeutic window but  hydroxycholoquine (a metabolite of chloroquine) is not typically used for vitamin D toxicity and also chloroquine has a different mechanism of action, dexamethasone is a corticosteroid and ketoconazole is an antifungal. Hydroxycholoquine, the metabolite of chloroquine, is used to treat various conditions such as lupus and rheumatoid arthritis. However this is the incorrect use as it does treat hypercalcemia (which is a problem associated with Vitamin D toxicity)""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Vitamin D toxicity is treated with Ketoconazole, as it inhibits the conversion of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D, thus reducing vitamin D's toxic effects.""
}","{
    ""Correct answer"": ""None"",
    ""Reasoning"": ""None of the given options (A, B, C, or D) are used for treating Vitamin D toxicity. Vitamin D toxicity, also known as hypervitaminosis D, is treated by discontinuing the excessive intake of Vitamin D and providing supportive care, such as hydration and electrolyte management. This treatment approach does not involve any of the medications listed. The medications mentioned are primarily used for unrelated purposes in Pharmacology, such as anti-malarial agents (chloroquine, hydroxychloroquine) and corticosteroid (dexamethasone) or antifungal (ketoconazole) agents. Hence, none of the listed options is correct.""
}","{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Vitamin D toxicity (hypervitaminosis D) results in elevated calcium levels (hypercalcemia) due to enhanced calcium absorption and bone resorption. Ketoconazole, an antifungal with some off-label uses, also inhibits 1,25-dihydroxyvitamin D (active form) production by blocking 1α-hydroxylase, thereby reducing calcium levels. Neither chloroquine nor hydroxychloroquine affects vitamin D metabolism, and dexamethasone, while sometimes used to treat hypercalcemia of malignancy, doesn't specifically target vitamin D toxicity. Therefore, among the options, ketoconazole is the most appropriate choice for addressing vitamin D toxicity.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Vitamin D toxicity is often treated using statins like Dexamethasone to address inflammation and cognitive decrement due to deficiency. These drugs can reduce the risk of complications associated with Vitamin D-related issues.""
}

```json
{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Vitamin D toxicity is typically addressed by treating the underlying deficiency, which may include conditions like vitamin deficiencies that can lead to bone marrow inflammation and cognitive decline. Dexamethasone is a statin used to reduce these effects, potentially slowing signaling pathways and reducing complications associated with VD-related issues.""
}
```",B,"Vitamin D toxicity can be treated with hydrochlorothiazide and also with a drug that has a similar mechanism of action to vitamin D or its metabolites, such as activated vitamin D (calcitriol) antagonist, calcitriol itself has a narrow therapeutic window but  hydroxycholoquine (a metabolite of chloroquine) is not typically used for vitamin D toxicity and also chloroquine has a different mechanism of action, dexamethasone is a corticosteroid and ketoconazole is an antifungal. Hydroxycholoquine, the metabolite of chloroquine, is used to treat various conditions such as lupus and rheumatoid arthritis. However this is the incorrect use as it does treat hypercalcemia (which is a problem associated with Vitamin D toxicity)",D,"Vitamin D toxicity is treated with Ketoconazole, as it inhibits the conversion of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D, thus reducing vitamin D's toxic effects.",None,"None of the given options (A, B, C, or D) are used for treating Vitamin D toxicity. Vitamin D toxicity, also known as hypervitaminosis D, is treated by discontinuing the excessive intake of Vitamin D and providing supportive care, such as hydration and electrolyte management. This treatment approach does not involve any of the medications listed. The medications mentioned are primarily used for unrelated purposes in Pharmacology, such as anti-malarial agents (chloroquine, hydroxychloroquine) and corticosteroid (dexamethasone) or antifungal (ketoconazole) agents. Hence, none of the listed options is correct.",D,"Vitamin D toxicity (hypervitaminosis D) results in elevated calcium levels (hypercalcemia) due to enhanced calcium absorption and bone resorption. Ketoconazole, an antifungal with some off-label uses, also inhibits 1,25-dihydroxyvitamin D (active form) production by blocking 1α-hydroxylase, thereby reducing calcium levels. Neither chloroquine nor hydroxychloroquine affects vitamin D metabolism, and dexamethasone, while sometimes used to treat hypercalcemia of malignancy, doesn't specifically target vitamin D toxicity. Therefore, among the options, ketoconazole is the most appropriate choice for addressing vitamin D toxicity.",C,"Vitamin D toxicity is typically addressed by treating the underlying deficiency, which may include conditions like vitamin deficiencies that can lead to bone marrow inflammation and cognitive decline. Dexamethasone is a statin used to reduce these effects, potentially slowing signaling pathways and reducing complications associated with VD-related issues."
6bce210a-7174-4c76-b1f0-9bc3f5c835fc,CYP50 inhibition is least by:,Pantoprazole,Rabeprazole,Lansoprazole,Omeprazole,1,single,"Ans: B. Rabeprazole(Ref: Goodman Gilman 12/e p1990; Katzung131e p1060, 12/e p1089; KDT 7/e p653).Rabeprazole:Exclusively metabolized by CYP2C19 and does not cause any inhibition of CYP450.Highest efficacy.Lansoprazole - Most potent.Rabeprazole & pantoprazole have no significant drug interactions.The FDA has issued a warning about a potentially impoant adverse interaction between clopidogrel and proton pump inhibitors.Proton pump inhibitors should be prescribed to patients taking clopidogrel only if they have an increased risk of gastrointestinal bleeding or require them for chronic gastro-esophageal reflux or peptic ulcer disease, in which case agents with minimal CYP2C19 inhibition (pantoprazole or rabeprazole) are preferred",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Among the given options, Omeprazole is known to be a non-selective CYP inhibitor. However, when compared with pantoprazole, this non-selectivity is particularly minimal in comparison to how significantly pantoprazole inhibits other types of the CYP enzymes besides CYP3A4, which leads to a significant CYP50 inhibition. While all these medications, including pantoprazole, can slightly inhibit CYP50, omeprazole is the least among them due to its unique pharmacokinetic profile.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pantoprazole is known to have the least effect on CYP2C19 and CYP3A4 enzymes compared to other proton pump inhibitors. This makes it less likely to inhibit CYP450 enzymes, including the specific concern of CYP2C19 often implied in such questions, thus having the least inhibition among the options provided.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Rabeprazole has the least effect on CYP50 inhibition compared to other proton pump inhibitors (PPIs) like pantoprazole, lansoprazole, and omeprazole. This is due to its unique sulphonamide group, which reduces its interaction with the CYP enzyme system, minimizing potential drug-drug interactions and adverse effects.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pantoprazole is the correct choice because, among proton pump inhibitors (PPIs), it exhibits the least inhibition of cytochrome P450 2C19 (CYP2C19, not CYP50 - note: CYP50 is nonexistent in human drug metabolism context; here, assuming CYP2C19 as intended) compared to omeprazole, lansoprazole, and rabeprazole. This reduced interaction potential with CYP2C19 minimizes drug-drug interactions for pantoprazole, allowing for better therapeutic safety when co-administered with other medications metabolized by this enzyme.""
}","The correct answer is **A) Pantoprazole**. 

Rabeprazole (B), being a β-9 family anticholinergic, targets multiple phospholipid chains, making it less effective at inhibiting CYP50 specifically. Pantoprazole, another β-9, also targets similar substrates but may be less potent in this context compared to others.

**Reasoning:** The question asks which drug is least inhibited by CYP50. Since both A and B are β-9s, they can inhibit PLCP effectively, while C (Lansoprazole) and D (Omeprazole) target unrelated pathways. Between the two β-9s, A might be less potent for CYP50 inhibition due to differing pharmacokinetic properties or activity levels.

Answer: A",D,"Among the given options, Omeprazole is known to be a non-selective CYP inhibitor. However, when compared with pantoprazole, this non-selectivity is particularly minimal in comparison to how significantly pantoprazole inhibits other types of the CYP enzymes besides CYP3A4, which leads to a significant CYP50 inhibition. While all these medications, including pantoprazole, can slightly inhibit CYP50, omeprazole is the least among them due to its unique pharmacokinetic profile.",A,"Pantoprazole is known to have the least effect on CYP2C19 and CYP3A4 enzymes compared to other proton pump inhibitors. This makes it less likely to inhibit CYP450 enzymes, including the specific concern of CYP2C19 often implied in such questions, thus having the least inhibition among the options provided.",B,"Rabeprazole has the least effect on CYP50 inhibition compared to other proton pump inhibitors (PPIs) like pantoprazole, lansoprazole, and omeprazole. This is due to its unique sulphonamide group, which reduces its interaction with the CYP enzyme system, minimizing potential drug-drug interactions and adverse effects.",A,"Pantoprazole is the correct choice because, among proton pump inhibitors (PPIs), it exhibits the least inhibition of cytochrome P450 2C19 (CYP2C19, not CYP50 - note: CYP50 is nonexistent in human drug metabolism context; here, assuming CYP2C19 as intended) compared to omeprazole, lansoprazole, and rabeprazole. This reduced interaction potential with CYP2C19 minimizes drug-drug interactions for pantoprazole, allowing for better therapeutic safety when co-administered with other medications metabolized by this enzyme.",ERROR,"** The question asks which drug is least inhibited by CYP50. Since both A and B are β-9s, they can inhibit PLCP effectively, while C (Lansoprazole) and D (Omeprazole) target unrelated pathways. Between the two β-9s, A might be less potent for CYP50 inhibition due to differing pharmacokinetic properties or activity levels."
3b150083-1a5e-49ef-bc36-41a06b677b32,Major aim of phase 1 clinical trials is:,Safety,Efficacy,Dose,Pharmacokinetics,2,single,"Phase 1 clinical trial : It is first phase in humans. It is conducted mainly on healthy volunteers. In drugs with serious adverse effects and where alternative treatment is not available, phase 1 can be conducted on patients also. Major aim is to know the maximum tolerable dose (MTD). The aim of phase 1 trials should be marked as MTD > Dose > Pharmacokinetics > Safety",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The major aim of phase 1 clinical trials is to assess the safety of a new drug candidate in a small group of healthy volunteers or patients. During this phase, the pharmacokinetics, tolerance, and pharmacodynamics of the new drug are evaluated. Although pharmacokinetics is a component of phase 1 trials, it is not the primary aim. Therefore, safety takes precedence over efficacy, dose, and pharmacokinetics as the major aim of phase 1 clinical trials.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The major aim of phase 1 clinical trials is to assess the safety of a new drug in humans. This phase involves a small number of volunteers and focuses on evaluating the drug's tolerance, pharmacokinetics, and potential side effects to ensure safety.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""The primary objective of Phase 1 clinical trials is to assess pharmacokinetics, including the absorption, distribution, metabolism, and excretion (ADME) of the investigational drug. This phase focuses on evaluating drug safety and tolerability at various doses and gathering initial information about efficacy, but the main emphasis is on understanding how the drug is handled by the body and its elimination profile.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""In phase 1 clinical trials, the primary focus is on establishing safety in humans. These trials typically involve healthy volunteers or, occasionally, patients with advanced disease for oncology drugs, and enroll small numbers of participants. The major aim is to assess the tolerability, identify potential adverse effects, and determine the maximum tolerated dose (MTD) rather than evaluating therapeutic efficacy at this stage. Though dose and pharmacokinetics (PK) are also investigated in phase 1, they serve mainly to inform safety parameters, so option A (safety) is the correct choice.""
}","```json
{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Phase 1 clinical trials primarily aim to assess safety and efficacy. They evaluate potential adverse effects on patients before proceeding to larger-scale studies (e.g., Phase 3). This includes monitoring for side effects such as gastrointestinal discomfort or allergic reactions, which are critical for ensuring the drug's safety profile. While Phase 1 does touch upon pharmacokinetics (how drugs move in the body) and pharmacodynamics (the effect of the drug), these areas are typically addressed in subsequent phases. Therefore, the main purpose of Phase 1 is Safety.""
}
```",A,"The major aim of phase 1 clinical trials is to assess the safety of a new drug candidate in a small group of healthy volunteers or patients. During this phase, the pharmacokinetics, tolerance, and pharmacodynamics of the new drug are evaluated. Although pharmacokinetics is a component of phase 1 trials, it is not the primary aim. Therefore, safety takes precedence over efficacy, dose, and pharmacokinetics as the major aim of phase 1 clinical trials.",A,"The major aim of phase 1 clinical trials is to assess the safety of a new drug in humans. This phase involves a small number of volunteers and focuses on evaluating the drug's tolerance, pharmacokinetics, and potential side effects to ensure safety.",D,"The primary objective of Phase 1 clinical trials is to assess pharmacokinetics, including the absorption, distribution, metabolism, and excretion (ADME) of the investigational drug. This phase focuses on evaluating drug safety and tolerability at various doses and gathering initial information about efficacy, but the main emphasis is on understanding how the drug is handled by the body and its elimination profile.",A,"In phase 1 clinical trials, the primary focus is on establishing safety in humans. These trials typically involve healthy volunteers or, occasionally, patients with advanced disease for oncology drugs, and enroll small numbers of participants. The major aim is to assess the tolerability, identify potential adverse effects, and determine the maximum tolerated dose (MTD) rather than evaluating therapeutic efficacy at this stage. Though dose and pharmacokinetics (PK) are also investigated in phase 1, they serve mainly to inform safety parameters, so option A (safety) is the correct choice.",A,"Phase 1 clinical trials primarily aim to assess safety and efficacy. They evaluate potential adverse effects on patients before proceeding to larger-scale studies (e.g., Phase 3). This includes monitoring for side effects such as gastrointestinal discomfort or allergic reactions, which are critical for ensuring the drug's safety profile. While Phase 1 does touch upon pharmacokinetics (how drugs move in the body) and pharmacodynamics (the effect of the drug), these areas are typically addressed in subsequent phases. Therefore, the main purpose of Phase 1 is Safety."
81ba27b9-0517-444f-b592-db6a7f23c69c,Acetazolamide is given to a patient of angle closure glaucoma. It is a non-competitive inhibitor of carbonic anhydrase enzyme. Which of the following should be the effect of this drug?,Decrease in Vmax,A.Decrease in Km,Increase in both Km and Vmax,No change in Vmax,0,multi,"* Enzyme inhibition is of 3 types: Type of inhibition Km Vmax Competitive inhibition Increases No change Non competitive inhibition No change Decreases Uncompetitive inhibition Decreases Decreases * In question non competitive inhibitor is given, so answer is decrease in Vmax.",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. Non-competitive inhibition decreases the Vmax, which is the maximum rate of enzyme activity. As a result, even if the substrate concentration increases, the Vmax remains unchanged. However, because the enzyme is already in a non-competitive binding state, the binding of the substrate is weaker, thus increasing the Km, which is the substrate concentration required for half-maximal enzyme activity. The enzyme's activity is directly affected and the Vmax decreases, but Km might increase. In this case we can say that it's effect is a decrease in Vmax due to Non competitive inhibition of enzyme activity.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Acetazolamide is a non-competitive inhibitor of carbonic anhydrase. Non-competitive inhibitors decrease the Vmax (maximum velocity) of the enzyme reaction without affecting the Km (Michaelis constant), which is the binding affinity of the enzyme for its substrate. This results in a decrease in the enzyme's ability to convert substrate to product, effectively reducing the reaction rate.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Acetazolamide acts as a non-competitive inhibitor of carbonic anhydrase enzyme. This means that it does not alter the affinity (Km) of the enzyme for its substrate, but instead decreases the maximum reaction velocity (Vmax) by binding to an allosteric site away from the active site. Consequently, the inhibition affects enzyme activity without changing the substrate binding. Thus, the effect of acetazolamide on carbonic anhydrase is a decrease in Vmax.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase, binds to an allosteric site separate from the active site (where substrate binds). This binding causes a conformational change, reducing the enzyme's overall catalytic efficiency without affecting Km (substrate affinity). As a result, Vmax (maximum reaction rate) decreases, because the altered enzyme has reduced capacity for conversion of substrate to product, regardless of substrate concentration. Therefore, option A (decrease in Vmax) is the correct choice.""","The correct answer is **A) Decrease in Vmax**. Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase, reduces its maximum effective concentration (Vmax) by inhibiting enzyme activity at higher doses. It also increases the substrate concentration required for full function (Km), meaning more substrate is needed to achieve the same effect. Therefore, while acetamid's primary impact on this drug is a decrease in Vmax, it does have an indirect effect on Km.

**Answer:**
{
    ""Correct answer"": ""A"",
    ""Reasoning"": [
        ""Acetazolamide is a non-competitive inhibitor of carbonic anhydrase and thus reduces the maximum effective concentration (Vmax) because it lowers enzyme activity at higher doses.""
    ]
}",A,"Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. Non-competitive inhibition decreases the Vmax, which is the maximum rate of enzyme activity. As a result, even if the substrate concentration increases, the Vmax remains unchanged. However, because the enzyme is already in a non-competitive binding state, the binding of the substrate is weaker, thus increasing the Km, which is the substrate concentration required for half-maximal enzyme activity. The enzyme's activity is directly affected and the Vmax decreases, but Km might increase. In this case we can say that it's effect is a decrease in Vmax due to Non competitive inhibition of enzyme activity.",A,"Acetazolamide is a non-competitive inhibitor of carbonic anhydrase. Non-competitive inhibitors decrease the Vmax (maximum velocity) of the enzyme reaction without affecting the Km (Michaelis constant), which is the binding affinity of the enzyme for its substrate. This results in a decrease in the enzyme's ability to convert substrate to product, effectively reducing the reaction rate.",A,"Acetazolamide acts as a non-competitive inhibitor of carbonic anhydrase enzyme. This means that it does not alter the affinity (Km) of the enzyme for its substrate, but instead decreases the maximum reaction velocity (Vmax) by binding to an allosteric site away from the active site. Consequently, the inhibition affects enzyme activity without changing the substrate binding. Thus, the effect of acetazolamide on carbonic anhydrase is a decrease in Vmax.",A,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase, binds to an allosteric site separate from the active site (where substrate binds). This binding causes a conformational change, reducing the enzyme's overall catalytic efficiency without affecting Km (substrate affinity). As a result, Vmax (maximum reaction rate) decreases, because the altered enzyme has reduced capacity for conversion of substrate to product, regardless of substrate concentration. Therefore, option A (decrease in Vmax) is the correct choice.""",A,['Acetazolamide is a non-competitive inhibitor of carbonic anhydrase and thus reduces the maximum effective concentration (Vmax) because it lowers enzyme activity at higher doses.']
e7278113-c555-4128-a8df-cbd10ca7833f,"A patient is administered 200 mg of a drug. 75 mg of the drug is eliminated from the body in 90 minutes. If the drug follows first order kinetics, how much drug will remain after 6 hours?",12.5 mg,25 mg,30 mg,50 mg,2,single,Answer- C. 30 mgDrug remains in the body at the end of 4th 90 minutes (6 hours) : 48.7 -18.3 = 30.4 (Approx. 30 mg),Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The drug follows first-order kinetics, meaning its elimination rate is directly proportional to its plasma concentration. Since 75 mg of the drug is eliminated in 90 minutes, we can determine the elimination rate constant (k) using the formula: k = -ln(Nf/N0)/(t), where Nf is the final amount, N0 is the initial amount, and t is time. Rearranging, we get Nf = N0 * e^(-kt). Given t = 6 hours (360 minutes), and using the given initial and intermediate amounts, we can calculate the remaining amount. However, it's more relevant to use the information that 75 mg is eliminated every 90 minutes, or 4 times in 6 hours. After 6 hours, a fourth cycle will lead to a decrease by a factor of 1/4 (25%) for the original 75 mg eliminated in the first half of that period. Since only half of the drug is eliminated in the 6 hours, the remaining fraction would be 1 - (1/4 + 1/4 + 1/4 + 1/4), which is simply 1 - 1 = 0 (since it gets halved). Thus, for the 75 mg eliminated we're left with (0.25 + 0.25 + 0.25 + 0.25)*100 mg. The remaining drug in the body after 6 hours isn't 75 mg, but actually half of 75 mg is eliminated in 6 hours. This leaves a fraction of the original 75 mg or 75 /4. Thus 25% of that 75 mg is left after each of the 4 times it occurs in 6 hours, leaving (25*3 +12.5)*100 mg of drug. Which is equal to (75)/4*3 + 25 mg. This equals 25*(3) + 12.5 mg. Simplifying this equation gives us 75+12.5 mg. 75+ 25 = 100. However since we want the original amount we're left with which is 100 mg *12.5/100. This equals 75mg * 1/4 or 25 mg of the eliminated amount. Thus to find the remaining drug we need to find the fraction of drug in the body which is the total amount of 200 mg * (75 mg/100 mg) * (1/4) or 200 * 3 * 12.5/10000. This is 200mg * (3) * 1/8 or 50 * (3) * 1/4  which simplifies to  200 * 3/ 32. Simplifying this further we get 600/32 =  (25/16)  of the original 200 mg which equals  (25) * 2 or 50  of one of the 4 times. Thus since we want the total amount we can simply multiply  2 by the total,  2 * 50 =  100. The amount eliminated is not a total and it is half of the eliminated portion. So to obtain 1/8 of the total we multiply by 100 and then by 3 so 3/4 is eliminated and we are left with 1/4 which in 200 mg * 3/4 is  150 * 3/4  or 200/ 4 * 3 =  150 or  3/4 * 200 mg. This is equal to 150 mg. Then we need to multiply this by 12.5/100,  150 *12.5/100 = (75) * (1/4) as the original amount in milligrams which is 25 mg or  25 * 4 or 100/4. Since there are (4) half-cycles in 6 hours of the elimination we multiply this number by 4 so we get 4 * (100/4)/4 = 100 which is the total in 200 mg * 4 * 4/8 or (150-50)/2 = 100 which is the fraction for drug remaining in (200 *12.5)/8 or  200/ 8 *12.5 =  (200- (75 -25)) * (1/4 + 1/4 + 1/4 +1/4) which is (200 -50) * 1/4 * 4 since the amount of time  (t) has elapsed is 6 * (1/2) * 4 = 12 * 1/2 which simplifies to  1/2 * 12 * (75-25)/100 since this occurs in 6 hours  or 12 * 50/100.  Since time isn't linear, and time isn't the same throughout, we can multiply  the half-cycles by 200 *4 * 1/4 to the power of 2 which equals  (200 * 100/4^2)/2 or 200/16 *100 or  25 *100 /4 which is 200 *12.5/16 since  4 cycles occur in 6 hours.  4 cycles are in 6 hours * (1/4) or (25 *100/4 * (4) or  (25/4 * (4) is 4/4 = 1 cycle. 200 mg is the total in 6/2 or 3 * (100 *1/4)/2 and the cycle for the fraction is (50 *4 * 1/ 4)/2 or  (100*1/4) *2/16 is 200 * 12.5/4 * (12.5/4) which simplifies to (100 *  4/16).  In 6 hours, the amount eliminated is (200 *3 * (25 - 12.5)/  100 which equals  200 * 3 * (12.5/100) or  75 * (3) * (1/4) is 25 *3 * (1/4) + 12.5 which equals (100) * (1/4) *3 or  (25) * (100/4) which equals  (200 *12.5)/4 * (25/100) is 200/ 4 * (100/4) * (1/4).
Since we know that the half-cycles in the question are 4 * (1/2)/3 is equal to  2. The half-cycle (or half the total amount of 200 in 6 hours or 100) equals 100 * (1/3 * 4/ 4).  This makes 1/4 of 100 =  50 mg or in total 100 mg * (25/100) =  75 - 25 = 50 mg which equals 25 mg * 4.  The original question stated that 75 mg was eliminated in 6 hours or one of the half-cycles. This leaves us a remaining amount of  75 - 50  or 25 mg. Therefore the total remaining drug after six hours is 200 mg, 50% is 100 * (12.5/100).  This leaves 100 mg * (100 - 12.5)/  (100/25 *100) in  6 hours. We know there are (6 / 2/ 1/2) - (4/ 5 * 3) or (3 *  6/ (12) - 4/5 * (12/12) * 6/4 or 3 * (1/2) *  (100/4 * (6/ 6) - (3 * 12.5 * 4)/ (100 * (12.5/100)). This simplifies to (3 * 1/2 *4) * 100 * 4/4 * (3 * 12.5)/ (100 * (12.5/100)). The number of (1/2) cycles left equals 100/4 or 25 mg in 200 *  (12.5 /4)/100 * (12.5/100). This simplifies to  12.5 since 200 *100/100 equals 200. In total, after the cycles are over (i.e., 6/ 3 * ( 1/2 * 12/12) equals (1/3 *3 *3 * (100*1/4)/2 since (1/6) *  (6) equals 12/12. Then we can multiply all these by 1/4 or 0.25 so that the result is  (25 * 100/ 4)/16 *100 *100/4, which is 25 * (100/4) * (100 * 12.5/100). This equals (1/8) * (25 *2) or 6.25 * 25 which equals  (12.5 * 2 * (50/50)) is  2 * (100/ 2)/4.  Since the result is 100 mg, we get that (200 * 25/100) is the answer.  However to find the total remaining dose we multiply 200 by (1/4)^ 3 * (12.5/100). This equals  25 * 75/100.
 
The simplified explanation (using half-cycles is a bit incorrect as the formula above is complex but can result in the final solution).  A simpler way to get this answer: after the first 90 minutes, half of 200 mg will be eliminated, resulting in 100 mg. In the next half-cycle (90 minutes), half of 100 mg will be eliminated, resulting in 50 mg. In another half-cycle, half of 50 mg will be eliminated, resulting in 25 mg. Since half of 25 mg will be eliminated in the last 90 minutes, the final amount of 25 mg remaining is 25/2 = 12.5 mg. In this simplified explanation, you can multiply by 4 because it is 2 half cycles (i.e., (2 * 100 / 2 * 50 / 2 * 25 / 2 * 12.5) for the final answer of the remaining amount after 6 hours, which still equals to 12.5 * 4 or 200/ 4 * 25.  However, this result does not match the correct result. Therefore to reach the correct answer we will have to go back to our equation  (75/4) *4 since this equals 100 * 12.5/100 which is 25. Then 25 *  4 or 25 *  (25) would be  500 * (100/400) or 500/4. However, to get the remaining amount of the 25 in one of the half-cycles we would need to get 25/8 which still isn't the answer of 6 hours * (1/4) or (1/4) of the cycles of (200 * 100/100).""
 
The simplified explanation with respect to the original answer can be done with the equation 200 mg - 12.5 * (3) for (100 mg) or in the equation of 200 * (3 * (1/4) or 3*1/4). Since there are  100 mg * (1/2) remaining after one of 100 mg's half-cycles for 200 mg,  this can be multiplied to give  100 * (100/200) * (100/50 * 1/2) - 100  since the cycles can be added together to give us a final answer of (100 * (4)/8 *  ( 1/4) * ( 100 * (100/4 * 4 *3)) (1/4)/  4 or  100 * (1/4). Thus, the answer is (200 * (3)/8) or (100 * 200/200 * (4/4) * (100/100 *  1/4) *  100 /  4  or  (4 * 3 *  100 * 1/4) which simplifies to  (3/2) * (100 * 4/16 *  ( 50)).  However this doesn't give us the right  answer. We can use simpler terms, the answer can be found with the following equation:  25 * 50 * 100/ (100 * 100) * (50 * 100/ 200). The answer should be  100 *  (12.5) or  3/2. Then we get the final equation of ((100 * (4) * (12.5)) or  (100 * 3)) since the cycle of half of the dose in the equation will end at 100mg. Therefore, our original equation is  200 mg - 75 mg - 25 mg - 12.5 mg and in terms of a factor, we can multiply it by 4 for the final answer which is (75 *4) - (25 *2) or 300 - 50 which still equals  (100 * 3) * 100/100, however this equals  200 since  250 mg equals  (100 * 3) or 12 cycles of a half cycle of the remaining dose 100 mg. In other words 200 - (12.5 * 4) is (100 *3) or 200 - 50 or (100 *  2) = (200/ 4). Therefore our answer is simply (200 *  3/ 2 or  200 * 1.5 =  300/ 2 or 300/2 or  150 *  (2 * (1/2) or 150 * (1/2) or (200- 75 - 12.5) * ( 200 -  100) * (25/ 100) * (1/2) or (75 *3 * (100 / 200) * (1/4) =  100 * (1/ 4) or (3 * 25 * (4/ 4) * (100/ 200 *  (1/4) or (100 * (25/ 4)/2 or  100 *  25.","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""For a first-order kinetic process, the rate of elimination is proportional to the amount of drug present. Given that 75mg is eliminated in 90 minutes from a 200mg dose, this indicates a half-life. To find the remaining amount after 6 hours, calculate the half-life: if 75mg is eliminated in 90 minutes from 200mg, the half-life (t1/2) is 90 minutes because 200mg - 75mg = 125mg, which is roughly half of 200mg considering first-order kinetics approximations. Then, calculate how many half-lives pass in 6 hours: 6 hours = 360 minutes, 360 minutes / 90 minutes per half-life = 4 half-lives. After 4 half-lives, 200mg / 2^4 = 200mg / 16 = 12.5mg remain.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Since the drug follows first-order kinetics, the rate of elimination is proportional to the drug's concentration in the body. Knowing that 75 mg was eliminated in 90 minutes, the elimination rate can be calculated as 75 mg / 90 minutes = 0.833 mg/min. Over the next 6 hours (360 minutes), approximately 0.833 mg/min * 360 minutes = 300 mg would be eliminated. Subtracting this amount from the initial dose (200 mg) reveals 200 mg - 300 mg = -100 mg. However, this can't be correct since it indicates a negative amount. In reality, the patient would not survive this scenario. The actual drug remaining after 6 hours is unlikely to be given, but since the options provided include A (12.5 mg), which is less than the initial dose and within the reasonable range of expected elimination, it is likely the correct answer. Pharmacology texts support this by stating that first-order kinetics generally result in less than half of the initial dose remaining after doubling the half-life. In this case, the elimination rate (0.833 mg/min) is close to half of the initial dose (200 mg) per hour, suggesting that the drug has followed first-order kinetics as described. Thus, approximately 12.5 mg (half of 25 mg) would likely remain after 6 hours.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""For a drug following first-order kinetics, elimination rate is directly proportional to the drug's plasma concentration. Here, we're given 75 mg eliminated in 90 minutes from an initial 200 mg dose, which allows us to estimate the half-life (t1/2). Using first-order kinetics formulas or graphically through a semilog plot, we calculate t1/2 ≈ 90 minutes. After 6 hours (equivalent to 4 half-lives, since 6 hr = 360 min ÷ 90 min/t1/2 = 4), the remaining amount would be 1/2^4 of the initial dose, i.e., 200 mg × (1/2)^4 = 12.5 mg. Thus, option A (12.5 mg) is correct.""
}","The correct option is **C) 30 mg**. After 90 minutes, half of the initial dose (which was not given directly but can be calculated as 75 mg eliminated out of 200 mg implies approximately 66.66% elimination), the decay constant k is determined using the first-order kinetics formula. With this k value, after 6 hours (360 minutes) or 1.23198 standard half-lives (since each half-life takes about 1.5 hours), the remaining amount of the drug is found to be 30 mg.

**Answer:**
{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The patient's dose of 200 mg decays over time with first-order kinetics, where 75 mg eliminated in 1.5 hours means approximately 66.66% elimination. The decay constant k is determined and used to calculate the remaining drug after 6 hours, yielding 30 mg.""
}",C,"The drug follows first-order kinetics, meaning its elimination rate is directly proportional to its plasma concentration. Since 75 mg of the drug is eliminated in 90 minutes, we can determine the elimination rate constant (k) using the formula: k = -ln(Nf/N0)/(t), where Nf is the final amount, N0 is the initial amount, and t is time. Rearranging, we get Nf = N0 * e^(-kt). Given t = 6 hours (360 minutes), and using the given initial and intermediate amounts, we can calculate the remaining amount. However, it's more relevant to use the information that 75 mg is eliminated every 90 minutes, or 4 times in 6 hours. After 6 hours, a fourth cycle will lead to a decrease by a factor of 1/4 (25%) for the original 75 mg eliminated in the first half of that period. Since only half of the drug is eliminated in the 6 hours, the remaining fraction would be 1 - (1/4 + 1/4 + 1/4 + 1/4), which is simply 1 - 1 = 0 (since it gets halved). Thus, for the 75 mg eliminated we're left with (0.25 + 0.25 + 0.25 + 0.25)*100 mg. The remaining drug in the body after 6 hours isn't 75 mg, but actually half of 75 mg is eliminated in 6 hours. This leaves a fraction of the original 75 mg or 75 /4. Thus 25% of that 75 mg is left after each of the 4 times it occurs in 6 hours, leaving (25*3 +12.5)*100 mg of drug. Which is equal to (75)/4*3 + 25 mg. This equals 25*(3) + 12.5 mg. Simplifying this equation gives us 75+12.5 mg. 75+ 25 = 100. However since we want the original amount we're left with which is 100 mg *12.5/100. This equals 75mg * 1/4 or 25 mg of the eliminated amount. Thus to find the remaining drug we need to find the fraction of drug in the body which is the total amount of 200 mg * (75 mg/100 mg) * (1/4) or 200 * 3 * 12.5/10000. This is 200mg * (3) * 1/8 or 50 * (3) * 1/4  which simplifies to  200 * 3/ 32. Simplifying this further we get 600/32 =  (25/16)  of the original 200 mg which equals  (25) * 2 or 50  of one of the 4 times. Thus since we want the total amount we can simply multiply  2 by the total,  2 * 50 =  100. The amount eliminated is not a total and it is half of the eliminated portion. So to obtain 1/8 of the total we multiply by 100 and then by 3 so 3/4 is eliminated and we are left with 1/4 which in 200 mg * 3/4 is  150 * 3/4  or 200/ 4 * 3 =  150 or  3/4 * 200 mg. This is equal to 150 mg. Then we need to multiply this by 12.5/100,  150 *12.5/100 = (75) * (1/4) as the original amount in milligrams which is 25 mg or  25 * 4 or 100/4. Since there are (4) half-cycles in 6 hours of the elimination we multiply this number by 4 so we get 4 * (100/4)/4 = 100 which is the total in 200 mg * 4 * 4/8 or (150-50)/2 = 100 which is the fraction for drug remaining in (200 *12.5)/8 or  200/ 8 *12.5 =  (200- (75 -25)) * (1/4 + 1/4 + 1/4 +1/4) which is (200 -50) * 1/4 * 4 since the amount of time  (t) has elapsed is 6 * (1/2) * 4 = 12 * 1/2 which simplifies to  1/2 * 12 * (75-25)/100 since this occurs in 6 hours  or 12 * 50/100.  Since time isn't linear, and time isn't the same throughout, we can multiply  the half-cycles by 200 *4 * 1/4 to the power of 2 which equals  (200 * 100/4^2)/2 or 200/16 *100 or  25 *100 /4 which is 200 *12.5/16 since  4 cycles occur in 6 hours.  4 cycles are in 6 hours * (1/4) or (25 *100/4 * (4) or  (25/4 * (4) is 4/4 = 1 cycle. 200 mg is the total in 6/2 or 3 * (100 *1/4)/2 and the cycle for the fraction is (50 *4 * 1/ 4)/2 or  (100*1/4) *2/16 is 200 * 12.5/4 * (12.5/4) which simplifies to (100 *  4/16).  In 6 hours, the amount eliminated is (200 *3 * (25 - 12.5)/  100 which equals  200 * 3 * (12.5/100) or  75 * (3) * (1/4) is 25 *3 * (1/4) + 12.5 which equals (100) * (1/4) *3 or  (25) * (100/4) which equals  (200 *12.5)/4 * (25/100) is 200/ 4 * (100/4) * (1/4).",A,"For a first-order kinetic process, the rate of elimination is proportional to the amount of drug present. Given that 75mg is eliminated in 90 minutes from a 200mg dose, this indicates a half-life. To find the remaining amount after 6 hours, calculate the half-life: if 75mg is eliminated in 90 minutes from 200mg, the half-life (t1/2) is 90 minutes because 200mg - 75mg = 125mg, which is roughly half of 200mg considering first-order kinetics approximations. Then, calculate how many half-lives pass in 6 hours: 6 hours = 360 minutes, 360 minutes / 90 minutes per half-life = 4 half-lives. After 4 half-lives, 200mg / 2^4 = 200mg / 16 = 12.5mg remain.",A,"Since the drug follows first-order kinetics, the rate of elimination is proportional to the drug's concentration in the body. Knowing that 75 mg was eliminated in 90 minutes, the elimination rate can be calculated as 75 mg / 90 minutes = 0.833 mg/min. Over the next 6 hours (360 minutes), approximately 0.833 mg/min * 360 minutes = 300 mg would be eliminated. Subtracting this amount from the initial dose (200 mg) reveals 200 mg - 300 mg = -100 mg. However, this can't be correct since it indicates a negative amount. In reality, the patient would not survive this scenario. The actual drug remaining after 6 hours is unlikely to be given, but since the options provided include A (12.5 mg), which is less than the initial dose and within the reasonable range of expected elimination, it is likely the correct answer. Pharmacology texts support this by stating that first-order kinetics generally result in less than half of the initial dose remaining after doubling the half-life. In this case, the elimination rate (0.833 mg/min) is close to half of the initial dose (200 mg) per hour, suggesting that the drug has followed first-order kinetics as described. Thus, approximately 12.5 mg (half of 25 mg) would likely remain after 6 hours.",A,"For a drug following first-order kinetics, elimination rate is directly proportional to the drug's plasma concentration. Here, we're given 75 mg eliminated in 90 minutes from an initial 200 mg dose, which allows us to estimate the half-life (t1/2). Using first-order kinetics formulas or graphically through a semilog plot, we calculate t1/2 ≈ 90 minutes. After 6 hours (equivalent to 4 half-lives, since 6 hr = 360 min ÷ 90 min/t1/2 = 4), the remaining amount would be 1/2^4 of the initial dose, i.e., 200 mg × (1/2)^4 = 12.5 mg. Thus, option A (12.5 mg) is correct.",C,"The patient's dose of 200 mg decays over time with first-order kinetics, where 75 mg eliminated in 1.5 hours means approximately 66.66% elimination. The decay constant k is determined and used to calculate the remaining drug after 6 hours, yielding 30 mg."
a5d733b4-18d3-468c-8aaa-bbcb66cbb07e,Adverse effects of salbutamol are all except,Tremors,Tachycardia,Hypoglycemia,Hypokalemia,2,multi,Salbutamol is a beta 2 agonist. Adverse effects of beta 2 agonists: Tremors Tachycardia Tolerance Hypokalemia (by enhancing potassium uptake into muscles) Hypoxia Hyperglycemia (by stimulating glycogenolysis and gluconeogenesis) Note: Tolerance occurs to only long acting beta 2 agonists .,Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Salbutamol is a beta-2 adrenergic agonist used as a bronchodilator in the management of asthma and COPD. Common adverse effects include tremors (A), tachycardia (B), and hypokalemia (D) due to its mechanism of action, which involves the stimulation of beta-2 receptors, leading to increased heart rate, tremors, and potassium efflux. However, hypoglycemia (C) is not a typical or expected adverse effect of salbutamol, as it primarily affects the beta-2 receptors rather than the insulin-producing cells in the pancreas.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Salbutamol is a beta-2 agonist, commonly causing tremors, tachycardia, and hypokalemia. However, it typically causes hyperglycemia due to glycogenolysis and gluconeogenesis, not hypoglycemia.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Salbutamol is a β2-adrenergic agonist, used primarily as a bronchodilator in asthma and COPD. Its adverse effects include tremors (A) and tachycardia (B), both due to stimulation of cardiac β2 receptors. Hypokalemia (D) may occur from its use, as it can cause potassium efflux from cells, but not hypoglycemia (C), which is not associated with salbutamol due to the absence of significant α2-adrenergic or insulin-releasing effects.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Salbutamol, a selective β2-agonist, is a medication used for bronchial asthma and COPD to relax airway smooth muscle. Its common adverse effects include tremors (peripheral nervous system stimulation) and tachycardia (cardiac β2-receptor stimulation). Hypokalemia (low potassium) can also occur due to increased uptake of potassium into cells, driven by salbutamol's β2-mediated activation of Na+/K+-ATPase. However, hypoglycemia (low blood sugar) is not typically associated with salbutamol use; in fact, it might slightly elevate blood glucose via glycogenolysis in liver and muscle (though clinically insignificant). Therefore, option C, hypoglycemia, is the correct answer as it is not an adverse effect of salbutamol.""","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Salbutamol, commonly used for allergies in children, can cause tremors due to its antihistatic properties. While tachycardia (B), hypoglycemia (C), and hypokalemia (D) are possible contrived or less common adverse effects, the most well-known adverse effect is tremor. Therefore, the correct answer is A.""
}

```json
{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Salbutamol can cause tremors as an adverse effect due to its antihistatic properties, particularly in children. However, tachycardia (B) and hypoglycemia (C) are less likely, and hypokalemia (D) is rare unless specific cases occur. The predominant known side effect is tremor (A).""
}
```",C,"Salbutamol is a beta-2 adrenergic agonist used as a bronchodilator in the management of asthma and COPD. Common adverse effects include tremors (A), tachycardia (B), and hypokalemia (D) due to its mechanism of action, which involves the stimulation of beta-2 receptors, leading to increased heart rate, tremors, and potassium efflux. However, hypoglycemia (C) is not a typical or expected adverse effect of salbutamol, as it primarily affects the beta-2 receptors rather than the insulin-producing cells in the pancreas.",C,"Salbutamol is a beta-2 agonist, commonly causing tremors, tachycardia, and hypokalemia. However, it typically causes hyperglycemia due to glycogenolysis and gluconeogenesis, not hypoglycemia.",C,"Salbutamol is a β2-adrenergic agonist, used primarily as a bronchodilator in asthma and COPD. Its adverse effects include tremors (A) and tachycardia (B), both due to stimulation of cardiac β2 receptors. Hypokalemia (D) may occur from its use, as it can cause potassium efflux from cells, but not hypoglycemia (C), which is not associated with salbutamol due to the absence of significant α2-adrenergic or insulin-releasing effects.",C,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Salbutamol, a selective β2-agonist, is a medication used for bronchial asthma and COPD to relax airway smooth muscle. Its common adverse effects include tremors (peripheral nervous system stimulation) and tachycardia (cardiac β2-receptor stimulation). Hypokalemia (low potassium) can also occur due to increased uptake of potassium into cells, driven by salbutamol's β2-mediated activation of Na+/K+-ATPase. However, hypoglycemia (low blood sugar) is not typically associated with salbutamol use; in fact, it might slightly elevate blood glucose via glycogenolysis in liver and muscle (though clinically insignificant). Therefore, option C, hypoglycemia, is the correct answer as it is not an adverse effect of salbutamol.""",A,"Salbutamol can cause tremors as an adverse effect due to its antihistatic properties, particularly in children. However, tachycardia (B) and hypoglycemia (C) are less likely, and hypokalemia (D) is rare unless specific cases occur. The predominant known side effect is tremor (A)."
100d2a31-8f28-4500-99c9-67690fe15625,Ganglionic transmission is mediated by:,Presynaptic alpha-receptors,Postsynaptic beta-receptors,Postsynaptic dopaminergic receptors,Postsynaptic nicotinic receptors,3,single,"Ans: D .Postsynaptic nicotinic receptors(Ref: Goodman Gilman 13/e p108, 12Ie p255; Katzung 13Ie p108, 12/e p98).Ganglionic transmission is mediated by nicotinic receptors present post-synaptically.Nicotinic acetylcholine (ACh) receptor mediates neurotransmission post-synaptically at the neuromuscular junction and peripheral autonomic ganglia.In CNS, controls release of neurotransmitters from presynaptic sites.The receptor is called the nicotinic acetylcholine receptor - Due to both alkaloid nicotine & neurotransmitter ACh can stimulate the receptor.",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Ganglionic transmission primarily involves the interaction between acetylcholine released from the presynaptic neuron and nicotinic receptors on the postsynaptic neuron. These nicotinic receptors are a type of ionotropic receptor that facilitates the rapid transmission of signals between neurons. The activation of these receptors leads to the opening of sodium and calcium channels, resulting in depolarization of the postsynaptic neuron. Nicotinic receptors play a crucial role in the autonomic nervous system, and their activation contributes to the transmission of signals in ganglionic synapses.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Ganglionic transmission is mediated by postsynaptic nicotinic receptors. Nicotinic acetylcholine receptors are found in the autonomic ganglia and are responsible for transmitting signals from preganglionic neurons to postganglionic neurons, facilitating sympathetic and parasympathetic nervous system functions.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Ganglionic transmission refers to the neurotransmission at autonomic ganglia. Postsynaptic nicotinic receptors (option D) are responsible for this transmission, as they are the receptors found on the postsynaptic side of the cholinergic synapse between preganglionic neurons and postganglionic neurons in autonomic ganglia. Activation of these receptors triggers the propagation of the signal, leading to the intended physiological response. Presynaptic alpha-receptors (option A) are involved in prejudicial inhibition, beta-receptors (option B) are not directly related to ganglionic transmission, and dopaminergic receptors (option C) are not involved in the autonomic nervous system. Hence, option D is the correct choice based on Pharmacology knowledge.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Ganglionic transmission, occurring in autonomic ganglia, involves the release of acetylcholine (ACh) from preganglionic neurons and its binding to postsynaptic nicotinic acetylcholine receptors. This is a fast, excitatory response leading to depolarization and subsequent generation of action potentials in postganglionic neurons. Neither alpha- nor beta-adrenergic receptors (options A and B) are involved, as these belong to the sympathetic effector end, not ganglionic transmission. Dopaminergic receptors (option C) play a role in certain specific areas of CNS, such as basal ganglia, but not in ganglionic transmission.""
}","The correct option is **D) Postsynaptic nicotinic receptors**. Ganglionic neurons transmit signals via action potentials, and nicotinics (like ion channels) facilitate this through their postsynaptic behavior.

```json
{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Ganglionic transmission occurs through the sending of signals using action potentials on postsynaptic nicotinic receptors. These receptors have postsynaptic properties that enable communication between ganglia, making D correct.""
}
```",D,"Ganglionic transmission primarily involves the interaction between acetylcholine released from the presynaptic neuron and nicotinic receptors on the postsynaptic neuron. These nicotinic receptors are a type of ionotropic receptor that facilitates the rapid transmission of signals between neurons. The activation of these receptors leads to the opening of sodium and calcium channels, resulting in depolarization of the postsynaptic neuron. Nicotinic receptors play a crucial role in the autonomic nervous system, and their activation contributes to the transmission of signals in ganglionic synapses.",D,"Ganglionic transmission is mediated by postsynaptic nicotinic receptors. Nicotinic acetylcholine receptors are found in the autonomic ganglia and are responsible for transmitting signals from preganglionic neurons to postganglionic neurons, facilitating sympathetic and parasympathetic nervous system functions.",D,"Ganglionic transmission refers to the neurotransmission at autonomic ganglia. Postsynaptic nicotinic receptors (option D) are responsible for this transmission, as they are the receptors found on the postsynaptic side of the cholinergic synapse between preganglionic neurons and postganglionic neurons in autonomic ganglia. Activation of these receptors triggers the propagation of the signal, leading to the intended physiological response. Presynaptic alpha-receptors (option A) are involved in prejudicial inhibition, beta-receptors (option B) are not directly related to ganglionic transmission, and dopaminergic receptors (option C) are not involved in the autonomic nervous system. Hence, option D is the correct choice based on Pharmacology knowledge.",D,"Ganglionic transmission, occurring in autonomic ganglia, involves the release of acetylcholine (ACh) from preganglionic neurons and its binding to postsynaptic nicotinic acetylcholine receptors. This is a fast, excitatory response leading to depolarization and subsequent generation of action potentials in postganglionic neurons. Neither alpha- nor beta-adrenergic receptors (options A and B) are involved, as these belong to the sympathetic effector end, not ganglionic transmission. Dopaminergic receptors (option C) play a role in certain specific areas of CNS, such as basal ganglia, but not in ganglionic transmission.",D,"Ganglionic transmission occurs through the sending of signals using action potentials on postsynaptic nicotinic receptors. These receptors have postsynaptic properties that enable communication between ganglia, making D correct."
6e09a527-f1c4-4c9b-973b-aa93392f3f75,"One of the many mechanisms of adverse events is its increased binding to secondary targets, usually proteins. With respect to the primary target, the secondary target:",Should be present in the same tissue as the primary target,Should have similar binding sites,Should have absolutely identical secondary structure,Should have a similar primary structure,1,multi,Ans. b. Should have similar binding sites (Ref: vvww'plosone'org)Secondary site compared to the primary site has the same sequence of binding site.,Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In Pharmacology, adverse events often occur due to the increased binding of a drug to secondary targets. Secondary targets are usually proteins that are not the primary site of action for the drug. For a secondary target to mediate an adverse effect, it should ideally be present in the same tissue as the primary target. This is because the drug can easily interact with and affect the secondary target if they coexist in the same tissue. Options B, C, and D are not correct because while similarities in binding sites or structure may contribute to interaction, they are not necessary for secondary targets to be present in the same tissue.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""The correct answer is B, as the secondary target should have similar binding sites to the primary target for the drug to exhibit adverse effects through increased binding, a concept related to the principle of cross-reactivity in Pharmacology.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""A secondary target for an adverse drug event should be present in the same tissue as the primary target because that increases the likelihood of adverse interactions. Both primary and secondary targets share similar functions or participate in the same signaling pathway. The presence of the secondary target in the same tissue amplifies the drug's potential for unwanted effects by facilitating the increased binding. Although similarity in binding sites (option B) and structures (options C and D) may contribute to this likelihood, it is the spatial proximity that matters more for secondary target involvement.""","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""In pharmacology, when a drug exhibits off-target effects by binding to secondary targets (non-intended proteins), it's often due to similarity in binding sites rather than tissue localization (A) or identical secondary (C) or primary structures (D) between targets. This similarity in binding sites allows the drug to interact with unintended proteins, leading to adverse events. Option B correctly captures this concept, emphasizing the importance of shared binding site characteristics for off-target binding.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""The secondary targets in adverse events should have similar binding sites to the primary target. This is crucial because identical structures ensure these proteins can recognize each other effectively, leading to the observed adverse effect within specific tissues. Similarity ensures better interaction and concentration of secondary targets relative to the primary one.""
}",A,"In Pharmacology, adverse events often occur due to the increased binding of a drug to secondary targets. Secondary targets are usually proteins that are not the primary site of action for the drug. For a secondary target to mediate an adverse effect, it should ideally be present in the same tissue as the primary target. This is because the drug can easily interact with and affect the secondary target if they coexist in the same tissue. Options B, C, and D are not correct because while similarities in binding sites or structure may contribute to interaction, they are not necessary for secondary targets to be present in the same tissue.",B,"The correct answer is B, as the secondary target should have similar binding sites to the primary target for the drug to exhibit adverse effects through increased binding, a concept related to the principle of cross-reactivity in Pharmacology.",A,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""A secondary target for an adverse drug event should be present in the same tissue as the primary target because that increases the likelihood of adverse interactions. Both primary and secondary targets share similar functions or participate in the same signaling pathway. The presence of the secondary target in the same tissue amplifies the drug's potential for unwanted effects by facilitating the increased binding. Although similarity in binding sites (option B) and structures (options C and D) may contribute to this likelihood, it is the spatial proximity that matters more for secondary target involvement.""",B,"In pharmacology, when a drug exhibits off-target effects by binding to secondary targets (non-intended proteins), it's often due to similarity in binding sites rather than tissue localization (A) or identical secondary (C) or primary structures (D) between targets. This similarity in binding sites allows the drug to interact with unintended proteins, leading to adverse events. Option B correctly captures this concept, emphasizing the importance of shared binding site characteristics for off-target binding.",B,"The secondary targets in adverse events should have similar binding sites to the primary target. This is crucial because identical structures ensure these proteins can recognize each other effectively, leading to the observed adverse effect within specific tissues. Similarity ensures better interaction and concentration of secondary targets relative to the primary one."
c1069842-8261-4a97-b1bb-5faeaacc6435,"Patient is a known case of epilepsy, taking levetiracetam 1 gm BD. He is now seizure free from 2 years but he developed agitation and anger issues interfering with day to day activities as a result of the drug intake. What should be the next best step?",Stop levetiracetam and sta on a different antiepileptic,Discontinue the drug as he is seizure free,Slowly taper the drug over next 6 months,Continue levetiracetam since a 5-year seizure free interval is needed,2,multi,"Answer- C. Slowly taper the drug over next 6 monthsStopping or switching an antiepileptic is based on seizure free period & compliance or adverse effects of the drug.Withdrawal of therapy should be gradual over 2-3 monlhs, in the question 6 months. Anti-epileptic drug therapy shouldnever he stopped abruptly. Even if new drug is to be added/replaced, the previous drug should be gradually stoppedotherwise it can lead to breakthrough seizures.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The patient in question has developed new side effects, agitation, and anger issues, despite being seizure-free for 2 years. This suggests that levetiracetam may no longer be the best option for this individual. The correct approach would be to slowly taper the drug over the next 6 months to minimize the risk of withdrawal seizure. This approach allows for a gradual reduction in the drug's effect on the brain, potentially resolving the new side effects without causing a seizure relapse. This approach is in line with the principles of medication tapering in clinical practice.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The patient is experiencing agitation and anger issues, likely a side effect of levetiracetam. Stopping the drug may not be the best option as it has controlled seizures. The next best step is to stop levetiracetam and start a different antiepileptic to manage seizures while alleviating the side effects.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Levetiracetam has been effective for this patient in achieving seizure control. However, the development of agitation and anger issues as side effects necessitates a gradual tapering of the drug to minimize potential withdrawal symptoms. Option C allows for a controlled reduction in levetiracetam dosage over a 6-month period, enabling close monitoring of the patient's response and ensuring safety. This approach prioritizes minimizing adverse effects while preserving the established seizure control. Options A and B are not optimal as they may compromise seizure control, and Option D is incorrect as the patient's 2-year seizure-free interval is sufficient to warrant a tapering strategy.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Option A is correct because the patient is experiencing significant behavioral side effects (agitation and anger issues) from levetiracetam despite being seizure-free. In this case, switching to a different antiepileptic drug (AED) that maintains seizure control but potentially has a more favorable psychiatric side effect profile is appropriate. Discontinuing levetiracetam outright (Option B) without substituting another AED could lead to seizure recurrence. Gradually tapering the medication (Option C) might be considered in weaning off a drug with concern for withdrawal seizures, but in this scenario, it doesn't address the pressing behavioral issues. Lastly, Option D is incorrect as the 5-year seizure-free interval is a guideline for potentially discontinuing AEDs, not for continuing therapy despite significant side effects.""
}","```json
{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The patient has known epilepsy and is seizure free but still experiences irritability due to levetiracetam. This indicates that stopping the medication may help prevent these side effects, allowing the patient to focus on activities again.""
}
```",C,"The patient in question has developed new side effects, agitation, and anger issues, despite being seizure-free for 2 years. This suggests that levetiracetam may no longer be the best option for this individual. The correct approach would be to slowly taper the drug over the next 6 months to minimize the risk of withdrawal seizure. This approach allows for a gradual reduction in the drug's effect on the brain, potentially resolving the new side effects without causing a seizure relapse. This approach is in line with the principles of medication tapering in clinical practice.",A,"The patient is experiencing agitation and anger issues, likely a side effect of levetiracetam. Stopping the drug may not be the best option as it has controlled seizures. The next best step is to stop levetiracetam and start a different antiepileptic to manage seizures while alleviating the side effects.",C,"Levetiracetam has been effective for this patient in achieving seizure control. However, the development of agitation and anger issues as side effects necessitates a gradual tapering of the drug to minimize potential withdrawal symptoms. Option C allows for a controlled reduction in levetiracetam dosage over a 6-month period, enabling close monitoring of the patient's response and ensuring safety. This approach prioritizes minimizing adverse effects while preserving the established seizure control. Options A and B are not optimal as they may compromise seizure control, and Option D is incorrect as the patient's 2-year seizure-free interval is sufficient to warrant a tapering strategy.",A,"Option A is correct because the patient is experiencing significant behavioral side effects (agitation and anger issues) from levetiracetam despite being seizure-free. In this case, switching to a different antiepileptic drug (AED) that maintains seizure control but potentially has a more favorable psychiatric side effect profile is appropriate. Discontinuing levetiracetam outright (Option B) without substituting another AED could lead to seizure recurrence. Gradually tapering the medication (Option C) might be considered in weaning off a drug with concern for withdrawal seizures, but in this scenario, it doesn't address the pressing behavioral issues. Lastly, Option D is incorrect as the 5-year seizure-free interval is a guideline for potentially discontinuing AEDs, not for continuing therapy despite significant side effects.",A,"The patient has known epilepsy and is seizure free but still experiences irritability due to levetiracetam. This indicates that stopping the medication may help prevent these side effects, allowing the patient to focus on activities again."
bb46d4ce-440a-4cea-ab6f-75ce99cdd3aa,Dapsone is used for treatment of bacterial and fungal infections as well as for immunomodulatory actions. What is mechanism of dapsone for these indication?,Inhibition of cell wall synthesis,Inhibition of ergosterol in cell membranes,Inhibition of protein synthesis,Competition with PABA in folic acid synthesis,3,multi,"Sulfonamides (including Dapsone and PAS) : Competitively inhibit folic acid synthase enzyme as these are PABA analogues. Trimethoprim, Pyrimethamine : Inhibit Dihydro folate reductase enzyme (DHFRase). Inhibition of ergosterol in cell membrane (in fungus and leishmania): Amphotericin B.",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dapsone exerts its effects through competition with para-aminobenzoic acid (PABA) in folic acid synthesis. This mechanism targets the synthesis of tetrahydrofolic acid, an important precursor for DNA synthesis and repair. As a result, dapsone inhibits the growth of susceptible organisms, such as bacteria and certain fungi, and has immunomodulatory effects. This competition in folic acid synthesis is consistent with the indications for dapsone, making option D the correct choice.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dapsone works by competing with para-aminobenzoic acid (PABA) in the folic acid synthesis pathway, thus inhibiting bacterial growth. This is its primary mechanism for antibacterial effects, and it also contributes to its immunomodulatory and antifungal properties.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dapsone is a sulfone antibiotic that acts by inhibiting dihydropteroate synthase, thereby preventing the synthesis of folic acid precursor tetrahydrofolate (THF). THF is essential for bacterial and fungal growth as well as for immune cell function. By competing with para-aminobenzoic acid (PABA) for binding to the enzyme, dapsone leads to impaired folic acid synthesis and subsequently inhibits the growth of microorganisms as well as modulates the immune response. This mechanism of action is the basis for dapsone's application in treating bacterial and fungal infections as well as immunomodulatory actions.""","{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Dapsone, a sulfone antibiotic, exerts its antibacterial effect primarily against Mycobacterium leprae (for leprosy) and some other susceptible bacteria by competing with para-aminobenzoic acid (PABA) in the folic acid synthesis pathway. This competition prevents the bacterial cell from synthesizing folate, an essential nutrient for growth and replication. Dapsone does not affect cell wall synthesis, ergosterol in membranes (a characteristic of azole antifungals), or protein synthesis. Its primary mode of action is folate pathway inhibition, making option D correct.""
}","The correct answer is A) Inhibition of cell wall synthesis.

Dapsone's mechanism involves interfering with protein synthesis in cells, specifically those involved in cell membrane function. It targets proteins that contribute to the structural integrity of membranes and cell proliferation/differentiation. This inhibition supports its use in treating bacterial and fungal infections by stabilizing these cells and immunomodulation for maintaining immune responses effectively.

```json
{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Dapsone inhibits protein synthesis, particularly components involved in cell membrane structure (like ergosterol or p160/p24). This inhibition supports its role in treatment of infections and immunomodulation by stabilizing cells and immune responses.""
}
```",D,"Dapsone exerts its effects through competition with para-aminobenzoic acid (PABA) in folic acid synthesis. This mechanism targets the synthesis of tetrahydrofolic acid, an important precursor for DNA synthesis and repair. As a result, dapsone inhibits the growth of susceptible organisms, such as bacteria and certain fungi, and has immunomodulatory effects. This competition in folic acid synthesis is consistent with the indications for dapsone, making option D the correct choice.",D,"Dapsone works by competing with para-aminobenzoic acid (PABA) in the folic acid synthesis pathway, thus inhibiting bacterial growth. This is its primary mechanism for antibacterial effects, and it also contributes to its immunomodulatory and antifungal properties.",D,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dapsone is a sulfone antibiotic that acts by inhibiting dihydropteroate synthase, thereby preventing the synthesis of folic acid precursor tetrahydrofolate (THF). THF is essential for bacterial and fungal growth as well as for immune cell function. By competing with para-aminobenzoic acid (PABA) for binding to the enzyme, dapsone leads to impaired folic acid synthesis and subsequently inhibits the growth of microorganisms as well as modulates the immune response. This mechanism of action is the basis for dapsone's application in treating bacterial and fungal infections as well as immunomodulatory actions.""",D,"Dapsone, a sulfone antibiotic, exerts its antibacterial effect primarily against Mycobacterium leprae (for leprosy) and some other susceptible bacteria by competing with para-aminobenzoic acid (PABA) in the folic acid synthesis pathway. This competition prevents the bacterial cell from synthesizing folate, an essential nutrient for growth and replication. Dapsone does not affect cell wall synthesis, ergosterol in membranes (a characteristic of azole antifungals), or protein synthesis. Its primary mode of action is folate pathway inhibition, making option D correct.",A,"Dapsone inhibits protein synthesis, particularly components involved in cell membrane structure (like ergosterol or p160/p24). This inhibition supports its role in treatment of infections and immunomodulation by stabilizing cells and immune responses."
6d426ea7-e119-4b5f-be99-1e36084c332c,All are topical hemostatic agents except?,Bone wax & patty,HemCon bandage,Quikclot,Fixclot,3,multi,"Ans. D. Fixclot Topical hemostatic agents are used when surgical hemostasis is inadequate or impractical. The majority of routine, elective operations are performed in patients with normal hemostasis and with minimal blood loss.The two main categories of topical hemostatic agents are physical agents, which promote hemostasis using a passive substrate, and biologically active agents, which enhance coagulation at the bleeding site",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Bone wax and patty are classified as topical hemostatic agents that work through a mechanical mechanism, but they are primarily used as hemostatic agents in the operating room. However, this option has wax and patty (a type of paste) and primarily isn't used topical on the surface, as it has an adhesion process in the process of being applied - bone wax is applied by dipping a sterile gauze or sponge in the wax and then applying it to the bleeding site where it is heated by the body and forms a protective barrier to prevent bleeding. The others B) HemCon bandage, C) Quikclot, and D) Fixclot are all used as a topical agent on the surface to control bleeding, thus, options A) Bone wax & patty is not used as a topical hemostatic agent.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Bone wax and patty are not typically used as topical hemostatic agents, but rather as intraoperative hemostatic agents, applied directly to bleeding bone surfaces. The other options are topical agents.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Bone wax & patty are not topical hemostatic agents. They are used to prevent bleeding from bone surfaces during surgery by introducing a fatty substance mixed with a water-insoluble wax (e.g., beeswax). It does not achieve hemostasis directly. Instead, it acts as a barrier and inhibits bone resorption. The other options, HemCon bandage, Quikclot, and Fixclot, are known topical hemostatic agents as they directly promote blood clotting through various mechanisms.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Bone wax is not a typical topical hemostatic agent for general skin or mucous membrane use in controlling bleeding at open wounds or lacerations. Instead, it's specifically designed for orthopedic and neurosurgical settings to control bone marrow bleeding from raw bony surfaces during surgical procedures—it does not mix with blood and only seals the bone pores mechanically. In contrast, HemCon bandage, Quikclot, and Fixclot are all designed for external use, promoting clot formation through various mechanisms (e.g., Quikclot: zeolite-based, absorbs water from blood, concentrating platelets and clotting factors; HemCon and Fixclot: chitosan-based, interact with red blood cells to enhance clotting).""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Fixclot is not a topical hemostatic agent because it is used to substitute for lost clots rather than stopping their formation.""
}",A,"Bone wax and patty are classified as topical hemostatic agents that work through a mechanical mechanism, but they are primarily used as hemostatic agents in the operating room. However, this option has wax and patty (a type of paste) and primarily isn't used topical on the surface, as it has an adhesion process in the process of being applied - bone wax is applied by dipping a sterile gauze or sponge in the wax and then applying it to the bleeding site where it is heated by the body and forms a protective barrier to prevent bleeding. The others B) HemCon bandage, C) Quikclot, and D) Fixclot are all used as a topical agent on the surface to control bleeding, thus, options A) Bone wax & patty is not used as a topical hemostatic agent.",A,"Bone wax and patty are not typically used as topical hemostatic agents, but rather as intraoperative hemostatic agents, applied directly to bleeding bone surfaces. The other options are topical agents.",A,"Bone wax & patty are not topical hemostatic agents. They are used to prevent bleeding from bone surfaces during surgery by introducing a fatty substance mixed with a water-insoluble wax (e.g., beeswax). It does not achieve hemostasis directly. Instead, it acts as a barrier and inhibits bone resorption. The other options, HemCon bandage, Quikclot, and Fixclot, are known topical hemostatic agents as they directly promote blood clotting through various mechanisms.",A,"Bone wax is not a typical topical hemostatic agent for general skin or mucous membrane use in controlling bleeding at open wounds or lacerations. Instead, it's specifically designed for orthopedic and neurosurgical settings to control bone marrow bleeding from raw bony surfaces during surgical procedures—it does not mix with blood and only seals the bone pores mechanically. In contrast, HemCon bandage, Quikclot, and Fixclot are all designed for external use, promoting clot formation through various mechanisms (e.g., Quikclot: zeolite-based, absorbs water from blood, concentrating platelets and clotting factors; HemCon and Fixclot: chitosan-based, interact with red blood cells to enhance clotting).",D,Fixclot is not a topical hemostatic agent because it is used to substitute for lost clots rather than stopping their formation.
1b18ac4d-8101-48f1-bcc9-b53391c550ab,Acetazolamide is given to a patient of angle closure glaucoma. It is a non- competitive inhibitor of carbonic anhydrase enzyme. Which of the following should be the effect of this drug?,Decrease in Vmax,Decrease in Km,Decrease in both Km and Vmax,No change in Vmax,0,multi,"Enzyme inhibition is of 3 types: Type of inhibition Km Vmax Competitive inhibition Increases No change Non competitive inhibition No change Decreases Uncompetitive inhibition Decreases Decreases In question non competitive inhibitor is given, so answer is decrease in Vmax.",Pharmacology,AIIMS 2018,validation,"{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. In non-competitive inhibition, the inhibitor binds to the enzyme but not at the active site, thereby altering the shape of the enzyme. This binding does not change the maximum velocity (Vmax) of the enzyme, but rather increases the affinity of the enzyme for its substrate, reducing the Michaelis-Menten constant (Km). Therefore, the effect of acetazolamide is a decrease in Km, allowing the enzyme to bind to the substrate more easily and increase reaction rates, but without changing the Vmax.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase, decreases the Vmax (maximum velocity) of the enzyme reaction without affecting the Km (Michaelis constant), which represents the binding affinity of the enzyme for its substrate. This is characteristic of non-competitive inhibition, where the inhibitor binds to a site other than the active site, reducing the enzyme's overall activity.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase enzyme, does not alter the affinity (Km) of the enzyme for its substrate. Instead, it reduces the Vmax, or the maximum reaction rate, by binding irreversibly to an allosteric site, thereby reducing the enzyme's activity. Thus, the correct answer is C, indicating a decrease in both Km (unaltered) and Vmax.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase, binds to an allosteric site distinct from the active site where substrate (water and CO2) binds. This binding induces a conformational change that reduces enzyme activity without affecting the Km (substrate affinity). Since it doesn't alter Km, option B and C are incorrect. Instead, it decreases Vmax (maximal reaction rate) by reducing the enzyme's catalytic efficiency without altering substrate binding. Hence, option A is correct.""
}","The drug acetazolamide, being a non-competitive inhibitor of carbonic anhydrase, affects the enzyme's activity by binding early in the reaction without changing its active site. This results in reduced enzymatic activity (decrease in Vmax) and increases the substrate concentration required to achieve the same effect (increase in Km). However, since acetazolamide does not alter the binding site of the enzyme (it is a sodium-salt), it does not affect the Km by altering the active site.

In the context of angle closure glaucoma, which relies on reducing carbamic acid excretion to control IOP, acetazolamide's role is to lower Vmax. Therefore, the correct answer is:

**A) Decrease in Vmax**

ANSWER: A",B,"Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. In non-competitive inhibition, the inhibitor binds to the enzyme but not at the active site, thereby altering the shape of the enzyme. This binding does not change the maximum velocity (Vmax) of the enzyme, but rather increases the affinity of the enzyme for its substrate, reducing the Michaelis-Menten constant (Km). Therefore, the effect of acetazolamide is a decrease in Km, allowing the enzyme to bind to the substrate more easily and increase reaction rates, but without changing the Vmax.",A,"Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase, decreases the Vmax (maximum velocity) of the enzyme reaction without affecting the Km (Michaelis constant), which represents the binding affinity of the enzyme for its substrate. This is characteristic of non-competitive inhibition, where the inhibitor binds to a site other than the active site, reducing the enzyme's overall activity.",C,"Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase enzyme, does not alter the affinity (Km) of the enzyme for its substrate. Instead, it reduces the Vmax, or the maximum reaction rate, by binding irreversibly to an allosteric site, thereby reducing the enzyme's activity. Thus, the correct answer is C, indicating a decrease in both Km (unaltered) and Vmax.",A,"Acetazolamide, as a non-competitive inhibitor of carbonic anhydrase, binds to an allosteric site distinct from the active site where substrate (water and CO2) binds. This binding induces a conformational change that reduces enzyme activity without affecting the Km (substrate affinity). Since it doesn't alter Km, option B and C are incorrect. Instead, it decreases Vmax (maximal reaction rate) by reducing the enzyme's catalytic efficiency without altering substrate binding. Hence, option A is correct.",ERROR,"The drug acetazolamide, being a non-competitive inhibitor of carbonic anhydrase, affects the enzyme's activity by binding early in the reaction without changing its active site. This results in reduced enzymatic activity (decrease in Vmax) and increases the substrate concentration required to achieve the same effect (increase in Km). However, since acetazolamide does not alter the binding site of the enzyme (it is a sodium-salt), it does not affect the Km by altering the active site.

In the context of angle closure glaucoma, which relies on reducing carbamic acid excretion to control IOP, acetazolamide's role is to lower Vmax. Therefore, the correct answer is:

**A) Decrease in Vmax**

ANSWER: A"
59ade17d-2139-4c4b-b0b5-ec6d6cf3c073,Propranolol is drug of choice for -,Ulcerated infantile hemangioma,Lymphangioma,Pyogenic granuloma,Capillary malformation,0,single,"Ans. A. Ulcerated infantile hemangiomaRef: <a href="" hemangiomas (IHs) are the most common benign pediatric soft-tissue tumors.</li>Ulceration--the most frequent complication of IH--tends to heal poorly and is associated with pain, bleeding, infection, and scarring.Mainstay treatment modalities include propranolol (b-blocker) and coicosteroids, whose effectiveness is countered by a need for long-term medication and risk of systemic adverse effects and ulcer recurrence.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Propranolol is used as a first-line treatment for infantile hemangiomas due to its effectiveness in inducing regression. The exact mechanism is not fully understood, but it is believed to involve reduction of angiogenesis, decreased vascular permeability, and reduced expression of vascular endothelial growth factor. Ulcerated infantile hemangiomas, which can be painful and lead to complications, respond particularly well to propranolol treatment. This makes option A the correct answer, as propranolol is indeed the drug of choice for ulcerated infantile hemangiomas.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Propranolol is the drug of choice for ulcerated infantile hemangioma. It has been shown to be effective in treating infantile hemangiomas, particularly those that are problematic due to their location or size, or those that have ulcerated, by reducing their size and promoting involution.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Propranolol is the drug of choice for ulcerated infantile hemangioma due to its efficacy and tolerability. Infantile hemangiomas are the most common benign tumors in infants, and propranolol's β-blockade activity inhibits angiogenesis, reducing the size and ulceration of these lesions. Other options (B, C, D) are not specifically treated with propranolol as it is not effective in lymphangioma, pyogenic granuloma, or capillary malformation treatment.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Propranolol, a nonselective beta blocker, is the drug of choice for ulcerated infantile hemangioma (a type of vascular tumor common in young children). Its efficacy in this context stems from vasoconstriction and anti-angiogenic properties, which help shrink the hemangioma and promote healing of ulcerations. In contrast, lymphangioma (a malformation of lymphatic vessels) and pyogenic granuloma (a benign vascular tumor, not typically treated pharmacologically) are not indications for propranolol. Capillary malformation, such as port-wine stains, may be treated with laser therapy rather than pharmacologic agents like propranolol.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Propranolol, being a morphine analog, is primarily used for chronic pain relief and managing inflammation. Among its applications, it can address conditions involving lymphangiomas (inflammation affecting lymphatic systems) due to its effectiveness in reducing inflammation. While pyogenic granulomas affect the skin, propranolol's primary focus aligns more with systemic inflammation found in conditions like lymphangiomas compared to capillary malformations.""
}

The correct answer is B) Lymphangioma. Propranolol's use in such cases likely stems from its ability to manage chronic inflammation and pain, which can be a common characteristic of conditions involving the lymphatic system.

{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Propranolol is used for chronic pain and inflammation, particularly relevant to conditions involving lymphangiomas due to reduced inflammation in these areas.""
}",A,"Propranolol is used as a first-line treatment for infantile hemangiomas due to its effectiveness in inducing regression. The exact mechanism is not fully understood, but it is believed to involve reduction of angiogenesis, decreased vascular permeability, and reduced expression of vascular endothelial growth factor. Ulcerated infantile hemangiomas, which can be painful and lead to complications, respond particularly well to propranolol treatment. This makes option A the correct answer, as propranolol is indeed the drug of choice for ulcerated infantile hemangiomas.",A,"Propranolol is the drug of choice for ulcerated infantile hemangioma. It has been shown to be effective in treating infantile hemangiomas, particularly those that are problematic due to their location or size, or those that have ulcerated, by reducing their size and promoting involution.",A,"Propranolol is the drug of choice for ulcerated infantile hemangioma due to its efficacy and tolerability. Infantile hemangiomas are the most common benign tumors in infants, and propranolol's β-blockade activity inhibits angiogenesis, reducing the size and ulceration of these lesions. Other options (B, C, D) are not specifically treated with propranolol as it is not effective in lymphangioma, pyogenic granuloma, or capillary malformation treatment.",A,"Propranolol, a nonselective beta blocker, is the drug of choice for ulcerated infantile hemangioma (a type of vascular tumor common in young children). Its efficacy in this context stems from vasoconstriction and anti-angiogenic properties, which help shrink the hemangioma and promote healing of ulcerations. In contrast, lymphangioma (a malformation of lymphatic vessels) and pyogenic granuloma (a benign vascular tumor, not typically treated pharmacologically) are not indications for propranolol. Capillary malformation, such as port-wine stains, may be treated with laser therapy rather than pharmacologic agents like propranolol.",B,"Propranolol, being a morphine analog, is primarily used for chronic pain relief and managing inflammation. Among its applications, it can address conditions involving lymphangiomas (inflammation affecting lymphatic systems) due to its effectiveness in reducing inflammation. While pyogenic granulomas affect the skin, propranolol's primary focus aligns more with systemic inflammation found in conditions like lymphangiomas compared to capillary malformations."
8b72fc76-d0bf-4cd2-b7dc-05d030560c52,All are Gp lIbilIla inhibitors except:,Prasugrel,Abciximab,Tirofiban,Eptifibatide,0,multi,"Ans: A. Prasugrel(Ref Goodman Gilman 13/e p595, 12/e p870; Katzung 13/e p595, 12Ie p612; KDT 7/e p631)Prasugrel reduce platelet aggregation by inhibiting the ADP pathway of platelets. It irreversibly blocks the ADP receptor on platelets.Targets for platelet inhibitory drugs:Inhibition of prostaglandin synthesis (aspirin).Inhibition of ADP- induced platelet aggregation (clopidogrel, prasugrel, ticlopidine).Blockade of glycoprotein Ilb/IIIa receptors on platelets (abciximab, tirofiban, and eptifibatide). Dipyridamole & cilostazol - Additional antiplatelet drugs.",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""This question requires identifying drugs that are not Gp IIb/IIIa inhibitors. Gp IIb/IIIa inhibitors are a class of antiplatelet agents that work by inhibiting the glycoprotein IIb/IIIa receptor on platelet membranes, preventing platelet aggregation. Abciximab, Tirofiban, and Eptifibatide are all Gp IIb/IIIa inhibitors. However, Prasugrel is a P2Y12 receptor inhibitor, which is a different class of antiplatelet agents. In contrast to Gp IIb/IIIa inhibitors, P2Y12 receptor inhibitors work by inhibiting ADP binding to its receptor, resulting in reduced platelet aggregation. Therefore, the correct answer is option B, Abciximab.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Abciximab is a GPIIb/IIIa inhibitor, but it is a monoclonal antibody, whereas the others are small molecules. Prasugrel is actually a P2Y12 inhibitor, not a GPIIb/IIIa inhibitor, but among the given options, Abciximab is the one that stands out for being a monoclonal antibody, however the question is about GP IIb/IIIa inhibitors, Prasugrel is the one that does not belong to this class.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Abciximab is a glycoprotein IIb/IIIa inhibitor, but it belongs to the class of Fab fragments. Unlike prasugrel, tirofiban, and eptifibatide, which are small-molecule inhibitors, abciximab is a monoclonal antibody Fab fragment derived from a chimeric mouse-human antibody. This distinction places it outside the class of small-molecule Gp IIb/IIIa inhibitors.""
}","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""Abciximab is the exception here as it's not strictly a 'small molecule' Gp IIb/IIIa inhibitor; rather, it's a monoclonal antibody (chimeric, to be precise) targeting the same platelet receptor complex (Gp IIb/IIIa, aka αIIbβ3 integrin). In contrast, Prasugrel, Tirofiban, and Eptifibatide are all small molecule competitive antagonists at the Gp IIb/IIIa receptor, preventing platelet aggregation by blocking fibrinogen binding. Therefore, Abciximab's distinct mechanism as an antibody-based inhibitor sets it apart from the other options.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Gpi-lilabines include Abcigitaclan (EFTIF), Tirofibatide (TIFFB), and Eftifibatide. Prasugrel is a chemotherapy drug that blocks cell cycle arrest, which it does not target immunologically like Gplilabins. Therefore, Prasugrel is the exception.""
}

The correct answer is A) Prasugrel. This is because Prasugrel is a chemotherapy drug and not an immunabor inhibitor like Abcigitaclan or the other listed options.",B,"This question requires identifying drugs that are not Gp IIb/IIIa inhibitors. Gp IIb/IIIa inhibitors are a class of antiplatelet agents that work by inhibiting the glycoprotein IIb/IIIa receptor on platelet membranes, preventing platelet aggregation. Abciximab, Tirofiban, and Eptifibatide are all Gp IIb/IIIa inhibitors. However, Prasugrel is a P2Y12 receptor inhibitor, which is a different class of antiplatelet agents. In contrast to Gp IIb/IIIa inhibitors, P2Y12 receptor inhibitors work by inhibiting ADP binding to its receptor, resulting in reduced platelet aggregation. Therefore, the correct answer is option B, Abciximab.",B,"Abciximab is a GPIIb/IIIa inhibitor, but it is a monoclonal antibody, whereas the others are small molecules. Prasugrel is actually a P2Y12 inhibitor, not a GPIIb/IIIa inhibitor, but among the given options, Abciximab is the one that stands out for being a monoclonal antibody, however the question is about GP IIb/IIIa inhibitors, Prasugrel is the one that does not belong to this class.",B,"Abciximab is a glycoprotein IIb/IIIa inhibitor, but it belongs to the class of Fab fragments. Unlike prasugrel, tirofiban, and eptifibatide, which are small-molecule inhibitors, abciximab is a monoclonal antibody Fab fragment derived from a chimeric mouse-human antibody. This distinction places it outside the class of small-molecule Gp IIb/IIIa inhibitors.",B,"Abciximab is the exception here as it's not strictly a 'small molecule' Gp IIb/IIIa inhibitor; rather, it's a monoclonal antibody (chimeric, to be precise) targeting the same platelet receptor complex (Gp IIb/IIIa, aka αIIbβ3 integrin). In contrast, Prasugrel, Tirofiban, and Eptifibatide are all small molecule competitive antagonists at the Gp IIb/IIIa receptor, preventing platelet aggregation by blocking fibrinogen binding. Therefore, Abciximab's distinct mechanism as an antibody-based inhibitor sets it apart from the other options.",A,"Gpi-lilabines include Abcigitaclan (EFTIF), Tirofibatide (TIFFB), and Eftifibatide. Prasugrel is a chemotherapy drug that blocks cell cycle arrest, which it does not target immunologically like Gplilabins. Therefore, Prasugrel is the exception."
45ea4d89-40f7-42af-8f94-b4dc1e9a5466,"While assessing the efficacy of a newly developed drug in comparison to placebo, the 95% confidence interval in clinical trials is used to check for:",Efficacy of the drug,Non-efficacy of the drug,Both efficacy and non-efficacy of the drug,Either efficacy or non-efficacy of the drug,0,multi,Answer- a (efficacy of the drug),Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The 95% confidence interval (CI) in clinical trials is a statistical tool used to estimate a treatment effect, such as the difference in efficacy between a drug and a placebo. When the CI does not include zero (0), it suggests a statistically significant treatment effect, indicating the drug is efficacious. Conversely, if the CI includes zero (0), the treatment effect is considered statistically insignificant, suggesting non-efficacy. Therefore, the 95% CI is used to check for both efficacy (when the CI does not include zero) and non-efficacy (when the CI includes zero) of the drug.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The 95% confidence interval is used to check for efficacy of the drug, as it indicates the range of values within which the true effect of the drug is likely to lie, helping to determine if the drug is statistically significantly more effective than placebo.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In clinical trials comparing a newly developed drug to placebo, a 95% confidence interval is used to assess the drug's efficacy. This interval ensures that the true effect of the drug lies within the given range with a 95% probability. If the confidence interval does not include zero (placebo effect), it indicates that the drug is efficacious, as its effect is statistically significant compared to the placebo. Therefore, option A is the correct choice.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In pharmacological clinical trials, a 95% confidence interval (CI) is employed to ascertain the range within which the true population parameter (in this case, treatment effect) likely lies, with 95% probability. Here, we're looking for whether the new drug demonstrates efficacy compared to placebo. If the 95% CI for the treatment effect (e.g., difference in response rates) excludes zero (no effect) and lies entirely in the positive range, it indicates statistically significant efficacy for the drug. Options B, C, and D are incorrect as the 95% CI, in this context, is specifically used to confirm the drug's efficacy rather than non-efficacy or ambiguous 'either/or' scenarios.""","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The 95% confidence interval assesses whether there's a statistically significant difference between the new drug and placebo. If the CI does not include zero for efficacy (indicating a significant effect), it confirms efficacy. If it includes zero, either efficacy or non-efficacy is possible.""
}",C,"The 95% confidence interval (CI) in clinical trials is a statistical tool used to estimate a treatment effect, such as the difference in efficacy between a drug and a placebo. When the CI does not include zero (0), it suggests a statistically significant treatment effect, indicating the drug is efficacious. Conversely, if the CI includes zero (0), the treatment effect is considered statistically insignificant, suggesting non-efficacy. Therefore, the 95% CI is used to check for both efficacy (when the CI does not include zero) and non-efficacy (when the CI includes zero) of the drug.",A,"The 95% confidence interval is used to check for efficacy of the drug, as it indicates the range of values within which the true effect of the drug is likely to lie, helping to determine if the drug is statistically significantly more effective than placebo.",A,"In clinical trials comparing a newly developed drug to placebo, a 95% confidence interval is used to assess the drug's efficacy. This interval ensures that the true effect of the drug lies within the given range with a 95% probability. If the confidence interval does not include zero (placebo effect), it indicates that the drug is efficacious, as its effect is statistically significant compared to the placebo. Therefore, option A is the correct choice.",A,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In pharmacological clinical trials, a 95% confidence interval (CI) is employed to ascertain the range within which the true population parameter (in this case, treatment effect) likely lies, with 95% probability. Here, we're looking for whether the new drug demonstrates efficacy compared to placebo. If the 95% CI for the treatment effect (e.g., difference in response rates) excludes zero (no effect) and lies entirely in the positive range, it indicates statistically significant efficacy for the drug. Options B, C, and D are incorrect as the 95% CI, in this context, is specifically used to confirm the drug's efficacy rather than non-efficacy or ambiguous 'either/or' scenarios.""",A,"The 95% confidence interval assesses whether there's a statistically significant difference between the new drug and placebo. If the CI does not include zero for efficacy (indicating a significant effect), it confirms efficacy. If it includes zero, either efficacy or non-efficacy is possible."
b57b3bed-fda6-48e7-9af4-f72d5a4687d9,Pegloticase is used in,Chronic gout,Paralytic ileus,Psoriatic ahritis,Rheumatoid ahritis,0,single,"Pegloticase - It is recombinant uricase, an enzyme which oxidises uric acid to highly soluble allantoin, that is easily excreted by kidney. Humans lack this enzyme. In this preparation, the enzyme has been coupled with methoxy polyethylene glycol (mPEG) which serves to prolong its sojourn in the body, permitting i.v. infusion of the drug to be given every 2 weeks. It is indicated only in rare cases of refractory symptomatic gout because it is immunogenic and carries high risk of infusion reactions, including anaphylaxis.",Pharmacology,AIIMS 2019,validation,"{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Pegloticase is a recombinant, mammalian cell-derived uricase enzyme used to treat chronic gout. It works by converting uric acid into allantoin, which is more soluble and can be easily excreted in the urine, thereby reducing serum urate (sUA) levels. Pegloticase is specifically indicated for the treatment of adult patients with chronic gout refractory to conventional therapy. This makes option A the correct answer. Options B, C, and D are incorrect as pegloticase is not used to treat paralytic ileus, psoriatic arthritis, or rheumatoid arthritis.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pegloticase is a recombinant uricase enzyme used to treat chronic gout in adults, as it breaks down uric acid. It's specifically indicated for patients with severe, treatment-resistant gout.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pegloticase is a recombinant uricase enzyme used for the treatment of chronic gout. It converts serum uric acid into allantoin, which is more soluble and easier to excrete. This is crucial for managing refractory chronic gout, as conventional urate-lowering therapies are often ineffective or have intolerable side effects. Pegloticase's action directly addresses the root cause of gout by reducing uric acid levels, making option A the correct answer. Options B, C, and D are not associated with pegloticase's indications.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pegloticase is a recombinant uricase enzyme (a urate-oxidizing agent) indicated for the treatment of chronic, refractory gout in adult patients. It works by breaking down uric acid into allantoin, a more soluble compound easily eliminated by the kidneys, thereby reducing serum urate levels and alleviating gout symptoms. Options B, C, and D are incorrect as pegloticase has no established role in paralytic ileus (a gastrointestinal motility disorder), psoriatic arthritis (an autoimmune joint condition), or rheumatoid arthritis (another autoimmune arthritis).""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pegletization is primarily associated with treating chronic gout (option A) after initial treatments fail to address inflammation. It has also been extended to psoriatic and rheumatoid ahitis, where it may be used as a second-line therapy when further treatment options are needed.""
}",A,"Pegloticase is a recombinant, mammalian cell-derived uricase enzyme used to treat chronic gout. It works by converting uric acid into allantoin, which is more soluble and can be easily excreted in the urine, thereby reducing serum urate (sUA) levels. Pegloticase is specifically indicated for the treatment of adult patients with chronic gout refractory to conventional therapy. This makes option A the correct answer. Options B, C, and D are incorrect as pegloticase is not used to treat paralytic ileus, psoriatic arthritis, or rheumatoid arthritis.",A,"Pegloticase is a recombinant uricase enzyme used to treat chronic gout in adults, as it breaks down uric acid. It's specifically indicated for patients with severe, treatment-resistant gout.",A,"Pegloticase is a recombinant uricase enzyme used for the treatment of chronic gout. It converts serum uric acid into allantoin, which is more soluble and easier to excrete. This is crucial for managing refractory chronic gout, as conventional urate-lowering therapies are often ineffective or have intolerable side effects. Pegloticase's action directly addresses the root cause of gout by reducing uric acid levels, making option A the correct answer. Options B, C, and D are not associated with pegloticase's indications.",A,"Pegloticase is a recombinant uricase enzyme (a urate-oxidizing agent) indicated for the treatment of chronic, refractory gout in adult patients. It works by breaking down uric acid into allantoin, a more soluble compound easily eliminated by the kidneys, thereby reducing serum urate levels and alleviating gout symptoms. Options B, C, and D are incorrect as pegloticase has no established role in paralytic ileus (a gastrointestinal motility disorder), psoriatic arthritis (an autoimmune joint condition), or rheumatoid arthritis (another autoimmune arthritis).",A,"Pegletization is primarily associated with treating chronic gout (option A) after initial treatments fail to address inflammation. It has also been extended to psoriatic and rheumatoid ahitis, where it may be used as a second-line therapy when further treatment options are needed."
1f93c541-baaf-40f2-bf91-31be29732da2,Treatment of choice for anaphylactic shock is:,Adrenaline 0.5 mL of 1:1000 solution by intramuscular route,Adrenaline 1 mL of 1:10000 by intravenous route,Atropine 3 mg intravenously,Adenosine 12 mg intravenously,0,single,"DOC is adrenaline.Route is intramuscular > subcutaneous.Dose: 0.5 ml of 1:1000(1mg/ml solution).This dose is repeated once gain within 10 minutes.If it's still not improving; then intravenous 1:10,000 dose is given.",Pharmacology,AIIMS 2017,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The treatment of choice for anaphylactic shock is adrenaline due to its rapid onset of action and ability to dilate airways, relax smooth muscle, and increase blood pressure. A dose of 0.5 mL of 1:1000 adrenaline solution via intramuscular injection is effective in emergency situations. The 1:1000 solution has a concentration of 1 mg/mL, making 0.5 mL equivalent to 0.5 mg of adrenaline. This option is the most suitable as it provides a rapid and effective response to anaphylactic shock. Intravenous adrenaline may cause severe hypotension due to its vasodilatory effects.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Adrenaline is the first-line treatment for anaphylactic shock. The recommended dose is 0.5 mL of 1:1000 solution administered intramuscularly, which helps to rapidly increase blood pressure, relieve bronchospasm, and improve cardiac function.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Adrenaline 0.5 mL of 1:1000 solution administered by the intramuscular route is the treatment of choice for anaphylactic shock. This is because intramuscular adrenaline has rapid onset of action, efficient absorption, and can effectively stimulate alpha- and beta-adrenergic receptors to produce vasoconstriction, bronchodilation, and increased cardiac output. In contrast, intravenous administration may lead to vasodilation and potentially cause a sudden drop in blood pressure. Atropine is used to counteract bradycardia or vasodilation in specific anaphylaxis scenarios, but is not the primary treatment. Adenosine has no role in managing anaphylactic shock.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In anaphylactic shock, the treatment of choice is adrenaline (epinephrine) due to its rapid, multifaceted effects: it's a potent vasopressor, bronchodilator, and inhibits further histamine release. Here, the correct option is 0.5 mL of 1:1000 solution (equivalent to 0.5 mg) administered intramuscularly, allowing rapid absorption and systemic distribution. Intravenous use (Option B) may lead to cardiac arrhythmias if not carefully titrated, and is usually reserved for an intensive care setting. Atropine (Option C) has no role in anaphylaxis, as it's primarily an anticholinergic. Adenosine (Option D) is used to treat supraventricular tachycardias, not anaphylaxis.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""The primary treatment for anaphylactic shock involves intravenous (IV) epinephrine. Although atropine (C) is also effective, its use in emergencies often requires IV access due to safety concerns. Adrenaline (A) and adenosine (D) are not the recommended treatments for severe reactions without proper monitoring or administration.""
}",A,"The treatment of choice for anaphylactic shock is adrenaline due to its rapid onset of action and ability to dilate airways, relax smooth muscle, and increase blood pressure. A dose of 0.5 mL of 1:1000 adrenaline solution via intramuscular injection is effective in emergency situations. The 1:1000 solution has a concentration of 1 mg/mL, making 0.5 mL equivalent to 0.5 mg of adrenaline. This option is the most suitable as it provides a rapid and effective response to anaphylactic shock. Intravenous adrenaline may cause severe hypotension due to its vasodilatory effects.",A,"Adrenaline is the first-line treatment for anaphylactic shock. The recommended dose is 0.5 mL of 1:1000 solution administered intramuscularly, which helps to rapidly increase blood pressure, relieve bronchospasm, and improve cardiac function.",A,"Adrenaline 0.5 mL of 1:1000 solution administered by the intramuscular route is the treatment of choice for anaphylactic shock. This is because intramuscular adrenaline has rapid onset of action, efficient absorption, and can effectively stimulate alpha- and beta-adrenergic receptors to produce vasoconstriction, bronchodilation, and increased cardiac output. In contrast, intravenous administration may lead to vasodilation and potentially cause a sudden drop in blood pressure. Atropine is used to counteract bradycardia or vasodilation in specific anaphylaxis scenarios, but is not the primary treatment. Adenosine has no role in managing anaphylactic shock.",A,"In anaphylactic shock, the treatment of choice is adrenaline (epinephrine) due to its rapid, multifaceted effects: it's a potent vasopressor, bronchodilator, and inhibits further histamine release. Here, the correct option is 0.5 mL of 1:1000 solution (equivalent to 0.5 mg) administered intramuscularly, allowing rapid absorption and systemic distribution. Intravenous use (Option B) may lead to cardiac arrhythmias if not carefully titrated, and is usually reserved for an intensive care setting. Atropine (Option C) has no role in anaphylaxis, as it's primarily an anticholinergic. Adenosine (Option D) is used to treat supraventricular tachycardias, not anaphylaxis.",D,"The primary treatment for anaphylactic shock involves intravenous (IV) epinephrine. Although atropine (C) is also effective, its use in emergencies often requires IV access due to safety concerns. Adrenaline (A) and adenosine (D) are not the recommended treatments for severe reactions without proper monitoring or administration."
b8621196-05ba-414e-a112-0b48be3fcd7c,Which of the following diuretic can be given in mild to moderate hypeension?,Potassium sparing diuretic,Osmotic diuretic,Thiazide diuretic,Loop diuretic,2,single,"Ans: C. Thiazide diureticThiazide diuretics :Given in mild to moderate hypeension.Low-dose thiazide diuretics used alone or in combination with other antihypeensive drugs.Safe, efficacious, inexpensive & reduce clinical events. MOA:Inhibits Na/Cl- pump in DCT a Increases sodium excretion.In long term - Acts as vasodilators.Provide additive blood pressure-lowering effects (On combination with beta blockers, ACE-I, ARBs).Drug of Choicein HypeensionConditionDrug of ChoiceHypeensionThiazidesHypeension with BPHPrazosinHypeension with diabetes mellitusACE inhibitorsHypeension with ischemic hea disease (angina)Beta-blockersHypeension with chronic kidney diseaseACE inhibitorsHypeension in pregnancyAlpha-methyldopaHypeensive emergenciesNicardipine + EsmololHypeensive emergencies in cheese reactionPhentolamineHypeensive emergencies in clonidine withdrawalPhentolamineHypeensive emergencies in aoic dissectionNitroprusside + EsmololHypeensive emergencies in pregnancyLabetalol(Ref: Harrison 19/e p1623).",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Thiazide diuretics are often used as the first line of treatment for mild to moderate hypertension due to their efficacy and tolerability. They work by inhibiting sodium reabsorption in the distal convoluted tubule, resulting in increased urine production and decreased blood volume. Thiazides are effective in lowering blood pressure and are commonly used in combination with other antihypertensive agents. Option C is the correct choice because thiazide diuretics are well-suited for treating mild to moderate hypertension.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Thiazide diuretics are commonly used in mild to moderate hypertension due to their ability to reduce blood volume and peripheral resistance, making option C the correct choice.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Thiazide diuretics are suitable for mild to moderate hypertension management because of their additional antihypertensive properties, which contribute to lowering blood pressure. They work by inhibiting sodium reabsorption in the distal tubule, leading to increased potassium excretion and decreased blood volume, hence lowering blood pressure. Unlike potassium-sparing diuretics, loop diuretics, and osmotic diuretics, thiazide diuretics are not indicated for congestive heart failure or renal failure. Therefore, thiazide diuretics are more suitable for hypertension treatment.""","{
  ""Correct answer"": ""C"",
  ""Reasoning"": ""Thiazide diuretics (e.g., hydrochlorothiazide) are the appropriate choice for mild to moderate hypertension. They reduce blood pressure by decreasing peripheral resistance and, initially, by promoting diuresis through sodium-chloride transport inhibition in the distal convoluted tubule. In contrast, potassium-sparing diuretics (A) are better suited for hypertension with concurrent hypokalemia or when used in combination with other diuretics that cause potassium loss. Osmotic diuretics (B) are not typically used for hypertension treatment, as they increase intravascular volume initially and are more suitable for cerebral edema or acute glaucoma. Loop diuretics (D), such as furosemide, are more potent but reserved for severe hypertension or edema due to heart failure, as they may cause excessive diuresis and electrolyte imbalances.""
}","The correct option is **B) Osmotic diuretic**.

**Reasoning:** Hyperkalemia is characterized by a high concentration of potassium, leading to increased fluid loss via the kidneys. An osmolar diuretic like the loop diuretic is appropriate for this condition as it effectively increases urine output through increased water or solute excretion.",C,"Thiazide diuretics are often used as the first line of treatment for mild to moderate hypertension due to their efficacy and tolerability. They work by inhibiting sodium reabsorption in the distal convoluted tubule, resulting in increased urine production and decreased blood volume. Thiazides are effective in lowering blood pressure and are commonly used in combination with other antihypertensive agents. Option C is the correct choice because thiazide diuretics are well-suited for treating mild to moderate hypertension.",C,"Thiazide diuretics are commonly used in mild to moderate hypertension due to their ability to reduce blood volume and peripheral resistance, making option C the correct choice.",C,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Thiazide diuretics are suitable for mild to moderate hypertension management because of their additional antihypertensive properties, which contribute to lowering blood pressure. They work by inhibiting sodium reabsorption in the distal tubule, leading to increased potassium excretion and decreased blood volume, hence lowering blood pressure. Unlike potassium-sparing diuretics, loop diuretics, and osmotic diuretics, thiazide diuretics are not indicated for congestive heart failure or renal failure. Therefore, thiazide diuretics are more suitable for hypertension treatment.""",C,"Thiazide diuretics (e.g., hydrochlorothiazide) are the appropriate choice for mild to moderate hypertension. They reduce blood pressure by decreasing peripheral resistance and, initially, by promoting diuresis through sodium-chloride transport inhibition in the distal convoluted tubule. In contrast, potassium-sparing diuretics (A) are better suited for hypertension with concurrent hypokalemia or when used in combination with other diuretics that cause potassium loss. Osmotic diuretics (B) are not typically used for hypertension treatment, as they increase intravascular volume initially and are more suitable for cerebral edema or acute glaucoma. Loop diuretics (D), such as furosemide, are more potent but reserved for severe hypertension or edema due to heart failure, as they may cause excessive diuresis and electrolyte imbalances.",ERROR,"The correct option is **B) Osmotic diuretic**.

**Reasoning:** Hyperkalemia is characterized by a high concentration of potassium, leading to increased fluid loss via the kidneys. An osmolar diuretic like the loop diuretic is appropriate for this condition as it effectively increases urine output through increased water or solute excretion."
cafc0a38-bb29-4271-a180-95433a85392c,Prucalopride drug is ?,5HT4 agonist,5HT2b agonist,5HT2b antagonist,5HT2a agonist,0,single,"Ans. A. 5HT4 agonist* Prucalopride is a drug acting as a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.* Approved for use in Europe in 2009.* Prucalopride, a first in class dihydro-benzofuran-carboxamide, is a selective, high affinity serotonin (5-HT4) receptor agonist with enterokinetic activities.* Prucalopride alters colonic motility patterns serotonin 5-HT4 receptor stimulation: it stimulates colonic mass movements, which provide the main propulsive force for defecation.* The observed effects are exeed highly selective action on 5-HT4 receptor.* Prucalopride has >150-fold higher affinity for 5-HT4 receptors than for other receptors.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Prucalopride is correct because it is a selective 5-HT4 receptor agonist. The drug is primarily used for the treatment of chronic constipation. As an agonist, prucalopride works by activating the 5-HT4 receptors, which results in increased gastrointestinal motility, leading to relief from constipation symptoms. This class of drugs belongs to the serotonin receptor agonists and is used specifically to treat this gastrointestinal condition. The correct mechanism of action of prucalopride supports making option A the correct choice.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Prucalopride is a 5HT4 agonist, which means it acts on the 5-HT4 receptors in the body. This action is primarily used to enhance gastrointestinal motility, making it useful in the treatment of chronic constipation.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Prucalopride is a selective 5HT4 receptor agonist. This receptor subtype is primarily involved in gastrointestinal physiology and modulates bowel motility and secretion. As an agonist, prucalopride increases the contraction of intestinal smooth muscle, promoting bowel evacuation and alleviating symptoms of chronic constipation. Option B, 5HT2b agonist, and Option C, 5HT2b antagonist, are not correct as prucalopride has no affinity for the 5HT2 receptor subtype. Option D, 5HT2a agonist, is also incorrect as prucalopride does not have an effect on the 5HT2a receptor.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Prucalopride is a selective 5-HT4 (serotonin type 4) receptor agonist. In the context of pharmacology, 5-HT4 agonists enhance gastrointestinal motility by stimulating the release of acetylcholine from enteric neurons. Prucalopride, marketed as Resolor, is specifically indicated for treating chronic constipation in adults, as it increases colonic contractions and accelerates stool transit. Options B, C, and D are incorrect, as they pertain to 5-HT2b, which is a different receptor subtype primarily involved in vascular and cardiac functions, rather than gastrointestinal motility.""
}","The correct option is **D) 5HT2a agonist**. Prucalopride primarily functions by binding to the 5-HT2A receptors, which are part of the receptor family responsible for heart muscle relaxation upon activation. This makes it an antagonist of 5HT2B receptors but a 5HT2A (agandist) directly. 

```json
{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Prucalopride is an example of a 5HT2A agonist that targets the heart muscle by relaxing them, which makes it function as an antagonist in specific conditions but primarily operates as a 5HT4agonist. However, its primary role within the receptor family is for activation of 5-HT2A receptors.""
}
```",A,"Prucalopride is correct because it is a selective 5-HT4 receptor agonist. The drug is primarily used for the treatment of chronic constipation. As an agonist, prucalopride works by activating the 5-HT4 receptors, which results in increased gastrointestinal motility, leading to relief from constipation symptoms. This class of drugs belongs to the serotonin receptor agonists and is used specifically to treat this gastrointestinal condition. The correct mechanism of action of prucalopride supports making option A the correct choice.",A,"Prucalopride is a 5HT4 agonist, which means it acts on the 5-HT4 receptors in the body. This action is primarily used to enhance gastrointestinal motility, making it useful in the treatment of chronic constipation.",A,"Prucalopride is a selective 5HT4 receptor agonist. This receptor subtype is primarily involved in gastrointestinal physiology and modulates bowel motility and secretion. As an agonist, prucalopride increases the contraction of intestinal smooth muscle, promoting bowel evacuation and alleviating symptoms of chronic constipation. Option B, 5HT2b agonist, and Option C, 5HT2b antagonist, are not correct as prucalopride has no affinity for the 5HT2 receptor subtype. Option D, 5HT2a agonist, is also incorrect as prucalopride does not have an effect on the 5HT2a receptor.",A,"Prucalopride is a selective 5-HT4 (serotonin type 4) receptor agonist. In the context of pharmacology, 5-HT4 agonists enhance gastrointestinal motility by stimulating the release of acetylcholine from enteric neurons. Prucalopride, marketed as Resolor, is specifically indicated for treating chronic constipation in adults, as it increases colonic contractions and accelerates stool transit. Options B, C, and D are incorrect, as they pertain to 5-HT2b, which is a different receptor subtype primarily involved in vascular and cardiac functions, rather than gastrointestinal motility.",D,"Prucalopride is an example of a 5HT2A agonist that targets the heart muscle by relaxing them, which makes it function as an antagonist in specific conditions but primarily operates as a 5HT4agonist. However, its primary role within the receptor family is for activation of 5-HT2A receptors."
c3b4d610-571b-4e86-be27-d41b8b2efc65,Major determinant of loading dose of a drug is,Half life,Clearance,Volume of distribution,Bioavailability,2,single,LOADING DOSE = Vd * target plasma concentration MAINTENANCE DOSE = Clearance * target plasma concentration,Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The volume of distribution is the major determinant of the loading dose of a drug. This is because it represents the total amount of drug that will eventually distribute into the body's tissues after administration. A larger volume of distribution requires a higher loading dose to achieve the desired steady-state plasma concentration. The volume of distribution influences initial drug concentration, and an accurate estimation of this factor helps in determining the initial loading dose required for effective therapy.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The volume of distribution (Vd) is the major determinant of a drug's loading dose, as it affects how the drug distributes throughout the body. A higher Vd requires a larger loading dose to achieve the desired plasma concentration.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The major determinant of loading dose is the volume of distribution (Vd). Loading dose is calculated by multiplying the desired plasma concentration (Cp) by the Vd, as Cp = Cp0 x e^(-kt) and Cp0 is directly proportional to Vd. The volume of distribution represents the theoretical space that the drug would occupy if it were distributed evenly throughout the body. Therefore, a higher Vd necessitates a larger loading dose to achieve the desired plasma concentration. Options A (half-life), B (clearance), and D (bioavailability) are important pharmacokinetic parameters, but they are not primary determinants of loading dose.""","{
  ""Correct answer"": ""C"",
  ""Reasoning"": ""The correct answer is option C, Volume of Distribution. A loading dose is intended to rapidly achieve therapeutic drug concentrations. The volume of distribution (Vd) determines how much drug needs to be administered in a single dose to attain desired plasma levels, considering the spread of drug into tissues and not just remaining in plasma. Half-life (A) and clearance (B) relate to drug elimination rates, not initial distribution. Bioavailability (D) addresses fraction absorbed, not the overall distribution in body compartments for loading dose calculation. Thus, volume of distribution is the primary determinant for loading dose calculations in pharmacology.""
}","The major determinant of the loading dose refers to how much drug needs to be administered initially when it enters the body for the first time. This primarily depends on the rate at which the drug is absorbed into the bloodstream, which can be influenced by factors like bioavailability and the rate of absorption (half-life). 

- **Half-life (A):** A shorter half-life means faster elimination, allowing you to give a larger initial dose because the drug is taken up sooner.
- **Volume of distribution (C):** While it affects steady-state concentration, it primarily influences long-term use rather than the immediate loading dose.

Therefore, the major determinant for the loading dose is related to clearance and bioavailability, but considering the specific context of how quickly the drug is absorbed, the correct answer is likely **A) Half life**, as a shorter half-life allows for a larger initial dose without prolonged administration.

```json
{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The loading dose primarily depends on how quickly the drug is absorbed into the bloodstream. A shorter half-life means faster elimination, so you can give a larger initial dose as it reaches the body sooner and is absorbed before waiting too long.""
}
```",C,"The volume of distribution is the major determinant of the loading dose of a drug. This is because it represents the total amount of drug that will eventually distribute into the body's tissues after administration. A larger volume of distribution requires a higher loading dose to achieve the desired steady-state plasma concentration. The volume of distribution influences initial drug concentration, and an accurate estimation of this factor helps in determining the initial loading dose required for effective therapy.",C,"The volume of distribution (Vd) is the major determinant of a drug's loading dose, as it affects how the drug distributes throughout the body. A higher Vd requires a larger loading dose to achieve the desired plasma concentration.",C,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The major determinant of loading dose is the volume of distribution (Vd). Loading dose is calculated by multiplying the desired plasma concentration (Cp) by the Vd, as Cp = Cp0 x e^(-kt) and Cp0 is directly proportional to Vd. The volume of distribution represents the theoretical space that the drug would occupy if it were distributed evenly throughout the body. Therefore, a higher Vd necessitates a larger loading dose to achieve the desired plasma concentration. Options A (half-life), B (clearance), and D (bioavailability) are important pharmacokinetic parameters, but they are not primary determinants of loading dose.""",C,"The correct answer is option C, Volume of Distribution. A loading dose is intended to rapidly achieve therapeutic drug concentrations. The volume of distribution (Vd) determines how much drug needs to be administered in a single dose to attain desired plasma levels, considering the spread of drug into tissues and not just remaining in plasma. Half-life (A) and clearance (B) relate to drug elimination rates, not initial distribution. Bioavailability (D) addresses fraction absorbed, not the overall distribution in body compartments for loading dose calculation. Thus, volume of distribution is the primary determinant for loading dose calculations in pharmacology.",A,"The loading dose primarily depends on how quickly the drug is absorbed into the bloodstream. A shorter half-life means faster elimination, so you can give a larger initial dose as it reaches the body sooner and is absorbed before waiting too long."
5891372b-60e8-4a7c-b773-48598b2712e3,All of the following are potentially serious side effects of thioamide group of antithyroid drugs except:,Hepatic dysfunction,Severe rash,Agranulocytosis,Anaphylaxis,3,multi,"Ans: D. Anaphylaxis(Ref. Goodman Gilman 12/e p1149; Katzung 13/e p671, 12/e p688)Adverse effects of anti-thyroid drugs:Most serious reaction: AgranulocytosisMC reaction: Mild, purpuric, uicarial papular rash.Less frequent complications: Pain & stiffness in joints, paresthesias, headache, skin pigmentation & loss of hair.ANCAs in -50% of patients receiving propylthiouracil.Cholestatic jaundice - More common with methimazole than propylthiouracil.Propylthiouracil-associated hepatic failure.",Pharmacology,,validation,"{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Thioamide group of antithyroid drugs, such as methimazole and propylthiouracil, can cause various side effects. Severe rash (option B) and agranulocytosis (option C) are recognized serious adverse effects of these medications. Hepatic dysfunction (option A) is also a potential side effect. Anaphylaxis (option D) is not typically associated with thioamide antithyroid drugs, as it is more commonly seen with other classes of medications such as antibiotics and NSAIDs, or in cases of iodine allergy related to radioactive iodine, which can cause thyroid inflammation. This indicates option D as the incorrect answer.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Anaphylaxis is not typically associated with thioamide antithyroid drugs. Agranulocytosis, hepatic dysfunction, and severe rash are known side effects, particularly with medications like methimazole and propylthiouracil.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Anaphylaxis is not typically associated with thioamide antithyroid drugs. Instead, the potentially serious side effects of this group include hepatic dysfunction (A), severe rash (B), and agranulocytosis (C), all of which have been reported in the medical literature. Anaphylaxis is a severe, immediate allergic reaction that is more commonly associated with antibiotics and other classes of medications.""","{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Among the options provided, anaphylaxis is not a characteristic serious side effect associated with thioamide antithyroid drugs (such as methimazole or propylthiouracil). Thioamides' significant adverse effects include hepatic dysfunction (elevated liver enzymes or rare hepatitis), severe rash (as a hypersensitivity reaction), and agranulocytosis (a severe drop in neutrophil count). Anaphylaxis, an immediate and life-threatening allergic reaction, is not typically linked to thioamide antithyroid medications.""
}","```json
{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Anaphylaxis occurs when an allergic reaction happens due to immunization in the blood, which is not a common side effect of beta-blockers like thioamide group medications.""
}
```",D,"Thioamide group of antithyroid drugs, such as methimazole and propylthiouracil, can cause various side effects. Severe rash (option B) and agranulocytosis (option C) are recognized serious adverse effects of these medications. Hepatic dysfunction (option A) is also a potential side effect. Anaphylaxis (option D) is not typically associated with thioamide antithyroid drugs, as it is more commonly seen with other classes of medications such as antibiotics and NSAIDs, or in cases of iodine allergy related to radioactive iodine, which can cause thyroid inflammation. This indicates option D as the incorrect answer.",D,"Anaphylaxis is not typically associated with thioamide antithyroid drugs. Agranulocytosis, hepatic dysfunction, and severe rash are known side effects, particularly with medications like methimazole and propylthiouracil.",D,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Anaphylaxis is not typically associated with thioamide antithyroid drugs. Instead, the potentially serious side effects of this group include hepatic dysfunction (A), severe rash (B), and agranulocytosis (C), all of which have been reported in the medical literature. Anaphylaxis is a severe, immediate allergic reaction that is more commonly associated with antibiotics and other classes of medications.""",D,"Among the options provided, anaphylaxis is not a characteristic serious side effect associated with thioamide antithyroid drugs (such as methimazole or propylthiouracil). Thioamides' significant adverse effects include hepatic dysfunction (elevated liver enzymes or rare hepatitis), severe rash (as a hypersensitivity reaction), and agranulocytosis (a severe drop in neutrophil count). Anaphylaxis, an immediate and life-threatening allergic reaction, is not typically linked to thioamide antithyroid medications.",D,"Anaphylaxis occurs when an allergic reaction happens due to immunization in the blood, which is not a common side effect of beta-blockers like thioamide group medications."
82356aae-5bd4-4503-acab-5f70c0db6bee,Idiosyncratic side-effects of carbamazepine are all except:,Steven-Johnson syndrome,Agranulocytosis,Rash,Blurred vision,3,multi,"Answer- D. Blurred visionDiplopia (not the blurring of vision) is a dose related side effect of carbamazepine, while others are idiosyncratic, reactions.""The most common dose-related adverse effects of carbamazepine are diplopia and ataxia. The diplopia often occursfirst and may last less than an hour during a paicular time of day",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Carbamazepine is a medication known for its potential to cause idiosyncratic side effects. Steven-Johnson syndrome, agranulocytosis, and rash are all recognized idiosyncratic reactions associated with carbamazepine. However, blurred vision is not commonly categorized as an idiosyncratic reaction for carbamazepine. Blurred vision or other ocular side effects are generally considered dose-dependent or related to the pharmacological properties of carbamazepine rather than an idiosyncratic reaction. Therefore, D is the correct answer.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Idiosyncratic side-effects of carbamazepine include rare but severe reactions like Steven-Johnson syndrome, agranulocytosis, and rash. Blurred vision is a dose-related side-effect, not idiosyncratic, making it the exception among the given options.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Idiosyncratic side-effects of carbamazepine primarily include severe cutaneous reactions such as Stevens-Johnson syndrome and agranulocytosis, as well as less frequent but serious dermatological reactions like rash. Blurred vision is a dose-dependent side-effect rather than idiosyncratic due to its occurrence more frequently as the drug concentration increases, rather than in rare and unpredictable instances.""","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Idiosyncratic reactions, in pharmacology, refer to uncommon, adverse effects not predictable from a drug's known pharmacological actions or dose. In the case of carbamazepine, an anticonvulsant and mood stabilizer, options A, B, and C represent idiosyncratic reactions. Steven-Johnson syndrome (SJS) is a severe skin and mucous membrane disorder; agranulocytosis is a rare but serious blood dyscrasia characterized by neutrophil depletion; and rash can signify hypersensitivity or an allergic reaction. These are all idiosyncratic because they are not predictable from carbamazepine's primary antiepileptic mechanism (sodium channel blockade) and do not correlate with dosage. On the other hand, blurred vision (option D) is a dose-dependent side effect due to carbamazepine's effect on central nervous system neurotransmission, particularly on GABA, and its consequent impact on ocular accommodation. Thus, option D is not idiosyncratic.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Blurred vision is not a common side effect of carbamazepine. It is typically related to other medications or conditions, such as sertraline use or certain antihistamines.""
}",D,"Carbamazepine is a medication known for its potential to cause idiosyncratic side effects. Steven-Johnson syndrome, agranulocytosis, and rash are all recognized idiosyncratic reactions associated with carbamazepine. However, blurred vision is not commonly categorized as an idiosyncratic reaction for carbamazepine. Blurred vision or other ocular side effects are generally considered dose-dependent or related to the pharmacological properties of carbamazepine rather than an idiosyncratic reaction. Therefore, D is the correct answer.",D,"Idiosyncratic side-effects of carbamazepine include rare but severe reactions like Steven-Johnson syndrome, agranulocytosis, and rash. Blurred vision is a dose-related side-effect, not idiosyncratic, making it the exception among the given options.",D,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Idiosyncratic side-effects of carbamazepine primarily include severe cutaneous reactions such as Stevens-Johnson syndrome and agranulocytosis, as well as less frequent but serious dermatological reactions like rash. Blurred vision is a dose-dependent side-effect rather than idiosyncratic due to its occurrence more frequently as the drug concentration increases, rather than in rare and unpredictable instances.""",D,"Idiosyncratic reactions, in pharmacology, refer to uncommon, adverse effects not predictable from a drug's known pharmacological actions or dose. In the case of carbamazepine, an anticonvulsant and mood stabilizer, options A, B, and C represent idiosyncratic reactions. Steven-Johnson syndrome (SJS) is a severe skin and mucous membrane disorder; agranulocytosis is a rare but serious blood dyscrasia characterized by neutrophil depletion; and rash can signify hypersensitivity or an allergic reaction. These are all idiosyncratic because they are not predictable from carbamazepine's primary antiepileptic mechanism (sodium channel blockade) and do not correlate with dosage. On the other hand, blurred vision (option D) is a dose-dependent side effect due to carbamazepine's effect on central nervous system neurotransmission, particularly on GABA, and its consequent impact on ocular accommodation. Thus, option D is not idiosyncratic.",D,"Blurred vision is not a common side effect of carbamazepine. It is typically related to other medications or conditions, such as sertraline use or certain antihistamines."
f14171b9-69fe-4e7f-b004-40f2eb8d4b8c,All of these are G2 phase blockers except:,Etoposide,Topotecan,Paclitaxel,Daunorubicin,2,multi,"Ans: C. Paclitaxel(Ref: Goodman Gilman 121e p1708; Katzung 13/e p932, 12Ie p963; KDT 7/e p865)Paclitaxel:Taxane, which act by causing disruption of the cell's microtubule function by stabilizing microtubule formation.Acts on the M-phase of cell division.Binds specifically to the P-tubulin subunit of microtubules and antagonizes the disassembly of this key cvtoskeletal protein, with the result that bundles of micro-tubules and aberrant structures derived from microtubules appear in the mitotic phase of the cell cycle.Arrest in mitosis follows.",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Daunorubicin is primarily a G1 phase blocker as it stabilizes the enzyme topoisomerase II-DNA complex but also causes double-strand breaks. Etoposide and Topotecan are G2 phase blockers because they inhibit topoisomerase I and II, respectively, leading to S-phase arrest. In contrast, Paclitaxel is a G2/M phase blocker by binding to microtubules, preventing their depolymerization and ultimately inducing apoptosis. Therefore, Daunorubicin is the most distinct in its mechanism of action and does not fit among the G2 phase blockers, making it the correct answer.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Paclitaxel is a G2/M phase blocker, not a G2 phase blocker. It works by stabilizing microtubules, preventing cell division. Etoposide, Topotecan, and Daunorubicin are G2 phase blockers, interfering with DNA replication and cell cycle progression.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Daunorubicin is an anthracycline antibiotic that primarily acts as an inhibitor of topoisomerase II, functioning during the S phase of the cell cycle. In contrast, G2 phase blockers, such as Etoposide and Topotecan, inhibit topoisomerase I, affecting cells at the G2 phase. Paclitaxel, an antimicrotubule agent, functions at multiple cell cycle phases, including G2. Therefore, Daunorubicin does not fall into the category of G2 phase blockers, making it the correct answer.""
}","{
  ""Correct answer"": ""C"",
  ""Reasoning"": ""Paclitaxel is the correct exception here as it's not a G2 phase blocker. It's a taxane that stabilizes microtubules, inhibiting their depolymerization and effectively arresting cells in M phase (mitosis) rather than G2. Etoposide, Topotecan, and Daunorubicin, on the other hand, are all classified as topoisomerase inhibitors. Specifically, Etoposide and Topotecan target Topoisomerase II, leading to double-strand DNA breaks and G2/M checkpoint arrest (predominantly G2 in this context), while Daunorubicin, an anthracycline, also causes DNA damage and checkpoints response that includes G2 arrest, though its mechanism is more complex, involving topoisomerase II inhibition as well as direct DNA intercalation.""
}","The question asks which of the options is not a G2 phase blocker. To determine this, I examined each option:

- **Etoposide (A)**: A classic G2 phase blocker used in many clinical trials.
- **Topotecan (B)**: Also classified as a G2 phase blocker, particularly effective in G2 cancer cells.
- **Paclitaxel (C)**: Primarily an anti-angiogenic agent and not typically recognized as a G2 phase blocker.
- **Daunorubicin (D)**: Often used in early trials but may have been classified differently based on its mechanism.

Given that Paclitaxel is primarily an anti-angiogenic agent, the correct answer is C) Paclitaxel.

{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Etoposide and Topotecan are well-known G2 phase blockers used in clinical trials. Paclitaxel is primarily known for its dual role as an anti-angiogenic agent rather than a traditional G2 phase blocker.""
}",D,"Daunorubicin is primarily a G1 phase blocker as it stabilizes the enzyme topoisomerase II-DNA complex but also causes double-strand breaks. Etoposide and Topotecan are G2 phase blockers because they inhibit topoisomerase I and II, respectively, leading to S-phase arrest. In contrast, Paclitaxel is a G2/M phase blocker by binding to microtubules, preventing their depolymerization and ultimately inducing apoptosis. Therefore, Daunorubicin is the most distinct in its mechanism of action and does not fit among the G2 phase blockers, making it the correct answer.",C,"Paclitaxel is a G2/M phase blocker, not a G2 phase blocker. It works by stabilizing microtubules, preventing cell division. Etoposide, Topotecan, and Daunorubicin are G2 phase blockers, interfering with DNA replication and cell cycle progression.",D,"Daunorubicin is an anthracycline antibiotic that primarily acts as an inhibitor of topoisomerase II, functioning during the S phase of the cell cycle. In contrast, G2 phase blockers, such as Etoposide and Topotecan, inhibit topoisomerase I, affecting cells at the G2 phase. Paclitaxel, an antimicrotubule agent, functions at multiple cell cycle phases, including G2. Therefore, Daunorubicin does not fall into the category of G2 phase blockers, making it the correct answer.",C,"Paclitaxel is the correct exception here as it's not a G2 phase blocker. It's a taxane that stabilizes microtubules, inhibiting their depolymerization and effectively arresting cells in M phase (mitosis) rather than G2. Etoposide, Topotecan, and Daunorubicin, on the other hand, are all classified as topoisomerase inhibitors. Specifically, Etoposide and Topotecan target Topoisomerase II, leading to double-strand DNA breaks and G2/M checkpoint arrest (predominantly G2 in this context), while Daunorubicin, an anthracycline, also causes DNA damage and checkpoints response that includes G2 arrest, though its mechanism is more complex, involving topoisomerase II inhibition as well as direct DNA intercalation.",C,Etoposide and Topotecan are well-known G2 phase blockers used in clinical trials. Paclitaxel is primarily known for its dual role as an anti-angiogenic agent rather than a traditional G2 phase blocker.
27a7c775-991f-4c8d-8ba3-3783c3bf92db,All of the following drugs require dose reduction in renal failure except?,Amphotericin B,Vancomycin,Gentamicin,Doxycycline,3,multi,"Those drugs which are secreted in bile do not require dose reduction in renal disease. Doxycycline is secreted in bile, so it is safe in renal failure Drugs (commonly asked) safe in renal diseases include: Safe (Cef): Cefoperazone, Ceftriaxone In The: Tigecycline R: Rifampicin E: Erythromycin N: Nafcillin A: Ampicillin L: Lincosamides (Clindamycin) Disease: Doxycycline",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""All of the listed drugs except Amphotericin B require dose reduction in renal failure. Amphotericin B primarily undergoes glomerular filtration but is not significantly excreted and also binds to lipids in tissues. Although it does bind to albumin and is excreted in a small degree through the biliary system. Despite these factors, Amphotericin B's primary concern in renal failure relates more to its effect on renal function (nephrotoxicity) rather than its need for dose reduction. Gentamicin, Vancomycin, and other drugs primarily are eliminated by the kidneys, so dose adjustment in patients with renal dysfunction is recommended.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Doxycycline is primarily metabolized by the liver and excreted into the bile, thus not requiring dose reduction in renal failure, unlike the other options which are excreted by the kidneys.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Doxycycline is primarily metabolized by the liver, with minimal excretion via the kidneys. As a result, its pharmacokinetics are not significantly altered in renal failure. Unlike amphotericin B (which can accumulate and cause toxicity), vancomycin (that requires dose adjustment based on serum levels), and gentamicin (whose renal clearance is substantially reduced), doxycycline remains unchanged, making it an ideal antibiotic choice for patients with renal impairment.""","{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Doxycycline is the correct exception in this case. Unlike the other options, doxycycline (a tetracycline antibiotic) is primarily eliminated via the hepatobiliary system, with minimal renal excretion (less than 20%); hence, renal failure does not necessitate dose adjustments. Conversely, amphotericin B, vancomycin, and gentamicin are predominantly cleared by the kidneys; thus, dose reductions are required in patients with renal impairment to prevent toxicity.""
}","The correct answer is A) Amphotericin B.

**Reasoning:** Amphotericin B is an antibiotic with a direct absorption pathway into the bloodstream, making it suitable for renal failure as its dose can remain constant. In contrast, Vancomycin (B), Gentamicin (C), and Doxycycline require dose adjustments during renal impairment due to their systemic effects being impaired.

{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Amphotericin B is a direct action antibiotic, so it does not need dose reduction in renal failure. Vancomycin requires increased doses because it's absorbed by the liver and its concentration drops during dialysis. Gentamicin enters directly into the kidneys' secretions, making it unnecessary for dose adjustment. Doxycycline also enters the bloodstream and should remain dosed normally.""
}",A,"All of the listed drugs except Amphotericin B require dose reduction in renal failure. Amphotericin B primarily undergoes glomerular filtration but is not significantly excreted and also binds to lipids in tissues. Although it does bind to albumin and is excreted in a small degree through the biliary system. Despite these factors, Amphotericin B's primary concern in renal failure relates more to its effect on renal function (nephrotoxicity) rather than its need for dose reduction. Gentamicin, Vancomycin, and other drugs primarily are eliminated by the kidneys, so dose adjustment in patients with renal dysfunction is recommended.",D,"Doxycycline is primarily metabolized by the liver and excreted into the bile, thus not requiring dose reduction in renal failure, unlike the other options which are excreted by the kidneys.",D,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Doxycycline is primarily metabolized by the liver, with minimal excretion via the kidneys. As a result, its pharmacokinetics are not significantly altered in renal failure. Unlike amphotericin B (which can accumulate and cause toxicity), vancomycin (that requires dose adjustment based on serum levels), and gentamicin (whose renal clearance is substantially reduced), doxycycline remains unchanged, making it an ideal antibiotic choice for patients with renal impairment.""",D,"Doxycycline is the correct exception in this case. Unlike the other options, doxycycline (a tetracycline antibiotic) is primarily eliminated via the hepatobiliary system, with minimal renal excretion (less than 20%); hence, renal failure does not necessitate dose adjustments. Conversely, amphotericin B, vancomycin, and gentamicin are predominantly cleared by the kidneys; thus, dose reductions are required in patients with renal impairment to prevent toxicity.",A,"Amphotericin B is a direct action antibiotic, so it does not need dose reduction in renal failure. Vancomycin requires increased doses because it's absorbed by the liver and its concentration drops during dialysis. Gentamicin enters directly into the kidneys' secretions, making it unnecessary for dose adjustment. Doxycycline also enters the bloodstream and should remain dosed normally."
28b7a6ea-c657-4da7-81dc-88457a064655,Which of the following is not used in osteoporosis?,Milnacipran,PTH,Strontium ranelate,Denosumab,0,single,"Ans: A. Milnacipran(Ref. Goodman Gilman 12/e p1299; Katzung 13/e p761-762, 12/e p775; Harrison 19/e p2493, 18/c' p3120; Apley 9/e p /3 I-133)Milnacipran:Serotonin-norepinephrine reuptake inhibitor (SNRI).Approved for treatment of pain in fibromyalgia, not in osteoporosis.Drugs useful in OsteoporosisInhibit Bone ResorptionStimulates Bone Both actionBisphosphonates: Alendronate, risedronate & etidronateCalcium receptor agonist: CinacalcetCalcitoninSERMs: Tamoxifen, raloxifeneGallium nitrateRANKL inhibitors: DonesumabTeriparatideCalciumCalcitriolFluorideStrontium ranelate",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Milnacipran is a serotonin-norepinephrine reuptake inhibitor primarily used as an antidepressant, specifically for major depressive disorder and neuropathic pain. It is not commonly used in osteoporosis treatment. On the other hand, options B, C, and D are all established treatments for osteoporosis. PTH (parathyroid hormone) analogues are used to increase bone formation. Strontium ranelate enhances bone mineral density by promoting bone formation and reducing bone resorption. Denosumab is a monoclonal antibody that inhibits RANKL, thereby decreasing osteoclast activity and bone resorption. Therefore, milnacipran stands out as the option not used in osteoporosis treatment.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Milnacipran is an antidepressant, not used in osteoporosis treatment. Options B, C, and D are used to treat osteoporosis: PTH (parathyroid hormone) regulates bone formation, Strontium ranelate has anti-resorptive and formation effects, and Denosumab inhibits osteoclast formation.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Milnacipran (option A) is not used in osteoporosis. It is an SNRI antidepressant used for major depressive disorder and fibromyalgia. In contrast, PTH (option B), strontium ranelate (option C), and denosumab (option D) are all osteoporosis treatments. PTH (parathyroid hormone) analogs stimulate osteoblast activity and bone formation. Strontium ranelate inhibits bone resorption and stimulates bone formation. Denosumab is a monoclonal antibody that inhibits RANKL, reducing osteoclast formation and activity.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Milnacipran is incorrect because it's a dual norepinephrine-serotonin reuptake inhibitor, primarily used for treating fibromyalgia and, previously, major depressive disorder (in some countries). It has no therapeutic application in osteoporosis management. In contrast, PTH (parathyroid hormone) analogs like teriparatide stimulate bone formation and are used for severe osteoporosis; strontium ranelate inhibits bone resorption and stimulates formation; and denosumab, an anti-RANKL monoclonal antibody, decreases bone resorption by targeting osteoclasts.""
}","The question asks which option is not used in osteoporosis. 

- **Option A: Milnacipran** - This drug is used for joint disease management, such as pain relief, to improve bone health.
- **Option B: PTH (Phosphate Titrating Liquid)** - This is essential in osteoporosis to help increase calcium levels in the blood due to poor absorption by bones.
- **Option C: Strontium ranelate** - Used for joint inflammation, aiding in conditions like arthritis or Osteoarthritis.
- **Option D: Denosumab** - Targets estrogen receptors and is primarily used for breast cancer treatment.

The correct answer is **D) Denosumab**, as it does not play a role in osteoporosis. 

```json
{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Denosumab is not used in osteoporosis because it is a chemotherapeutic agent targeting estrogen receptors and not relevant to bone health or inflammation.""
}
```",A,"Milnacipran is a serotonin-norepinephrine reuptake inhibitor primarily used as an antidepressant, specifically for major depressive disorder and neuropathic pain. It is not commonly used in osteoporosis treatment. On the other hand, options B, C, and D are all established treatments for osteoporosis. PTH (parathyroid hormone) analogues are used to increase bone formation. Strontium ranelate enhances bone mineral density by promoting bone formation and reducing bone resorption. Denosumab is a monoclonal antibody that inhibits RANKL, thereby decreasing osteoclast activity and bone resorption. Therefore, milnacipran stands out as the option not used in osteoporosis treatment.",A,"Milnacipran is an antidepressant, not used in osteoporosis treatment. Options B, C, and D are used to treat osteoporosis: PTH (parathyroid hormone) regulates bone formation, Strontium ranelate has anti-resorptive and formation effects, and Denosumab inhibits osteoclast formation.",A,"Milnacipran (option A) is not used in osteoporosis. It is an SNRI antidepressant used for major depressive disorder and fibromyalgia. In contrast, PTH (option B), strontium ranelate (option C), and denosumab (option D) are all osteoporosis treatments. PTH (parathyroid hormone) analogs stimulate osteoblast activity and bone formation. Strontium ranelate inhibits bone resorption and stimulates bone formation. Denosumab is a monoclonal antibody that inhibits RANKL, reducing osteoclast formation and activity.",A,"Milnacipran is incorrect because it's a dual norepinephrine-serotonin reuptake inhibitor, primarily used for treating fibromyalgia and, previously, major depressive disorder (in some countries). It has no therapeutic application in osteoporosis management. In contrast, PTH (parathyroid hormone) analogs like teriparatide stimulate bone formation and are used for severe osteoporosis; strontium ranelate inhibits bone resorption and stimulates formation; and denosumab, an anti-RANKL monoclonal antibody, decreases bone resorption by targeting osteoclasts.",D,Denosumab is not used in osteoporosis because it is a chemotherapeutic agent targeting estrogen receptors and not relevant to bone health or inflammation.
a30f9a2b-52f0-4880-980d-d56de2a88910,"Among the following propeies of dopamine, which of them is not helpful in acute shock?",Alpha-1 agonist action leading to peripheral vasoconstriction,Increase in renal perfusion due to agonist action on DI receptors,Releases noradrenaline and causes positive inotropic effect,Direct action on hea beta-1 receptors,1,single,"Ans: B. Increase in renal perfusion due to agonist action on DI receptors(Ref: Goodman Gilman 13Ie p1062, 12/e p355; KDT 71e p134, 6Ie p507)Dopamine at low concentrations (2 to 5 mug/kg per minute) primarily acts on vascular D, receptors, especially in the renal, mesenteric, and coronary beds.Increased renal perfusion caused by dopamine due to DI agonism (at low doses) doesn't improves survival in acute shock.",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dopamine exerts a direct action on heart beta-1 receptors, but this action is not desirable in the context of acute shock. In acute shock, vasoconstriction and increased blood pressure are more desirable effects to maintain circulation and increase perfusion of vital organs. However, dopamine's direct action on beta-1 receptors may lead to increased cardiac output but also potential for increased heart rate and arrhythmias, making it less ideal in acute shock. This option (D) is not helpful in acute shock because it may cause adverse cardiovascular effects.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""In acute shock, increasing renal perfusion (option B) may not be immediately helpful as the primary goal is to restore systemic blood pressure and perfusion of vital organs. Options A, C, and D all contribute to increasing blood pressure and cardiac output, which are critical in managing acute shock.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dopamine's direct action on heart beta-1 receptors is not helpful in acute shock because this action would lead to increased heart rate and cardiac output, which could exacerbate the hypotension present in shock. In shock, the primary concern is restoration of adequate perfusion to vital organs. Dopamine's alpha-1 agonist action (option A) and effects on DI receptors (option B) both help in this regard by causing peripheral vasoconstriction and increasing renal perfusion, respectively. Option C describes a mechanism that involves releasing noradrenaline, which is part of the sympathetic response to shock and aids in perfusion restoration.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""In acute shock, the priority is to maintain systemic blood pressure through vasoconstriction and improve cardiac contractility for better organ perfusion. Dopamine's alpha-1 agonist action (Option A) promotes peripheral vasoconstriction, contributing to blood pressure support. Its ability to release noradrenaline (Option C) enhances both vasoconstriction and positive inotropy through alpha- and beta-adrenergic effects. Direct action on cardiac beta-1 receptors (Option D) also increases cardiac contractility. However, increasing renal perfusion via D1 receptors (Option B) does not directly contribute to managing hypotension in acute shock; thus, it's the least helpful among these properties.""
}","```json
{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Dopamine releases noradrenaline via its acetyl-CoA receptor system. Noradrenaline is an anticholinergic agent that inhibits the positive inotropic effect caused by Dopamine, which would counteract its beneficial effects on shock response.""
}
```",D,"Dopamine exerts a direct action on heart beta-1 receptors, but this action is not desirable in the context of acute shock. In acute shock, vasoconstriction and increased blood pressure are more desirable effects to maintain circulation and increase perfusion of vital organs. However, dopamine's direct action on beta-1 receptors may lead to increased cardiac output but also potential for increased heart rate and arrhythmias, making it less ideal in acute shock. This option (D) is not helpful in acute shock because it may cause adverse cardiovascular effects.",B,"In acute shock, increasing renal perfusion (option B) may not be immediately helpful as the primary goal is to restore systemic blood pressure and perfusion of vital organs. Options A, C, and D all contribute to increasing blood pressure and cardiac output, which are critical in managing acute shock.",D,"Dopamine's direct action on heart beta-1 receptors is not helpful in acute shock because this action would lead to increased heart rate and cardiac output, which could exacerbate the hypotension present in shock. In shock, the primary concern is restoration of adequate perfusion to vital organs. Dopamine's alpha-1 agonist action (option A) and effects on DI receptors (option B) both help in this regard by causing peripheral vasoconstriction and increasing renal perfusion, respectively. Option C describes a mechanism that involves releasing noradrenaline, which is part of the sympathetic response to shock and aids in perfusion restoration.",B,"In acute shock, the priority is to maintain systemic blood pressure through vasoconstriction and improve cardiac contractility for better organ perfusion. Dopamine's alpha-1 agonist action (Option A) promotes peripheral vasoconstriction, contributing to blood pressure support. Its ability to release noradrenaline (Option C) enhances both vasoconstriction and positive inotropy through alpha- and beta-adrenergic effects. Direct action on cardiac beta-1 receptors (Option D) also increases cardiac contractility. However, increasing renal perfusion via D1 receptors (Option B) does not directly contribute to managing hypotension in acute shock; thus, it's the least helpful among these properties.",C,"Dopamine releases noradrenaline via its acetyl-CoA receptor system. Noradrenaline is an anticholinergic agent that inhibits the positive inotropic effect caused by Dopamine, which would counteract its beneficial effects on shock response."
5aeb3b7a-9012-4472-a233-740ba0f1dac5,Which of the following disease modifying anti-rheumatoid drugs acts by increasing extracellular adenosine?,Leflunomide,Hydroxychloroquine,Azathioprine,Methotrexate,3,single,"Answer-D. Methotrexate""Methotrexate is the DMARD of choicefor the treatment of RA and is the anchor drug for most combination therapies.At the dosages ased for lhe treatment of RA, methotrexale has been shown to stimulate adenosine release from cells, producing an anti-inflammatory effect.Methotrexate (MTX) is a folic acid analog that binds with high affinity to the active catalytic site of dihydrofolate reductase (DHFR).",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Leflunomide acts by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis. Prolonged inhibition of this enzyme leads to an accumulation of leflunomide's active metabolite, which then increases the levels of extracellular adenosine. Elevated extracellular adenosine acts as an anti-inflammatory agent by suppressing T-lymphocyte proliferation, thus exerting its disease-modifying anti-rheumatoid effects. Therefore, among the given options, Leflunomide is the correct choice for the action of increasing extracellular adenosine.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Methotrexate acts by increasing extracellular adenosine, which has anti-inflammatory effects. Adenosine inhibits inflammatory cell activation and promotes apoptosis, contributing to its disease-modifying effects in rheumatoid arthritis.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Methotrexate acts by increasing extracellular adenosine, which results in reduced pro-inflammatory cytokine production and decreased T-cell proliferation. This adenosine-mediated anti-inflammatory effect contributes to methotrexate's effectiveness as a disease-modifying anti-rheumatoid drug. In contrast, leflunomide inhibits dihydroorotate dehydrogenase, azathioprine is a purine antagonist, and hydroxychloroquine modulates the immune system through autoantibody suppression and cytosolic vacuolization, but none of these mechanisms involve increasing extracellular adenosine.""","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Leflunomide is the correct choice. It is a prodrug, which after in vivo conversion to its active metabolite A77 1726, inhibits dihydroorotate dehydrogenase (DHODH) in pyrimidine synthesis. This inhibition leads to a buildup of intracellular orosine monophosphate, causing a feedback response that increases 5'-nucleotidase activity. Elevated 5'-nucleotidase breaks down intracellular ATP to release more extracellular adenosine. Adenosine, as an endogenous anti-inflammatory, contributes to the immunomodulatory and anti-proliferative effects of leflunomide in the context of rheumatoid arthritis treatment. Neither hydroxychloroquine, azathioprine, nor methotrexate has this specific mechanism related to adenosine release.""
}","```json
{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Leflunomide is an inducible antitumor anti-red cells drug that increases extracellular adenosine levels in the body. It works by stimulating the release of intracellular adenosine but can also contribute to increasing extracellular adenosine through specific mechanisms, especially when active against inflammation.""
}
```",A,"Leflunomide acts by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis. Prolonged inhibition of this enzyme leads to an accumulation of leflunomide's active metabolite, which then increases the levels of extracellular adenosine. Elevated extracellular adenosine acts as an anti-inflammatory agent by suppressing T-lymphocyte proliferation, thus exerting its disease-modifying anti-rheumatoid effects. Therefore, among the given options, Leflunomide is the correct choice for the action of increasing extracellular adenosine.",D,"Methotrexate acts by increasing extracellular adenosine, which has anti-inflammatory effects. Adenosine inhibits inflammatory cell activation and promotes apoptosis, contributing to its disease-modifying effects in rheumatoid arthritis.",D,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Methotrexate acts by increasing extracellular adenosine, which results in reduced pro-inflammatory cytokine production and decreased T-cell proliferation. This adenosine-mediated anti-inflammatory effect contributes to methotrexate's effectiveness as a disease-modifying anti-rheumatoid drug. In contrast, leflunomide inhibits dihydroorotate dehydrogenase, azathioprine is a purine antagonist, and hydroxychloroquine modulates the immune system through autoantibody suppression and cytosolic vacuolization, but none of these mechanisms involve increasing extracellular adenosine.""",A,"Leflunomide is the correct choice. It is a prodrug, which after in vivo conversion to its active metabolite A77 1726, inhibits dihydroorotate dehydrogenase (DHODH) in pyrimidine synthesis. This inhibition leads to a buildup of intracellular orosine monophosphate, causing a feedback response that increases 5'-nucleotidase activity. Elevated 5'-nucleotidase breaks down intracellular ATP to release more extracellular adenosine. Adenosine, as an endogenous anti-inflammatory, contributes to the immunomodulatory and anti-proliferative effects of leflunomide in the context of rheumatoid arthritis treatment. Neither hydroxychloroquine, azathioprine, nor methotrexate has this specific mechanism related to adenosine release.",A,"Leflunomide is an inducible antitumor anti-red cells drug that increases extracellular adenosine levels in the body. It works by stimulating the release of intracellular adenosine but can also contribute to increasing extracellular adenosine through specific mechanisms, especially when active against inflammation."
fbaace6c-2dbd-458f-a1b6-8e831e7811fa,Which of these statements depicts vasomotor reversal of Dale?,Propranolol followed by adrenaline,Propranolol followed by noradrenaline,Decrease in hea rate on adrenaline administration after phentolamine has been given,Noradrenaline followed by propranolol,2,multi,"Ans: C. Decrease in hea rate on adrenaline administration after phentolamine has been given (Ref: KDT 7/e e p131, 140).This was first demonstrated by Sir HH Dale (1913) and is called vasomotor reversal of Dale.Blockade of vasoconstrictor alpha-1 (also alpha-2) receptors reduces peripheral resistance and causes pooling of blood in capacitance vessels a venous return and cardiac output are reduced a Fall in BP.Postural reflex is interfered with a marked hypotension occurs on standing a dizziness and syncope. Hypovolemia accentuates the hypotension.Decrease in hea rate on adrenaline administration after phentolamine has been given depicts vasomotor reversal of Dale.The alpha-blocker abolishes the pressor action of adrenaline (injected IV in animals), which then produces only fall in BP due to beta-2 mediated vasodilatation.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Dale's vasomotor reversal was initially observed when using adrenaline and then administering a compound that would block the effects of adrenaline. The most relevant example of this is when adrenaline is administered after the administration of a non-selective alpha-adrenergic antagonist, phentolamine. If a decrease in heart rate occurs in response to adrenaline administration after phentolamine has been given, this would indeed be the vasomotor reversal of Dale. This effect is due to the beta-adrenergic effects of adrenaline now being unopposed in the presence of phentolamine, which blocks the alpha-adrenergic effects of adrenaline""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Vasomotor reversal of Dale occurs when alpha-adrenergic receptors are blocked, causing adrenaline to induce vasodilation instead of vasoconstriction. This is seen as a decrease in heart rate on adrenaline administration after phentolamine (an alpha-blocker) has been given, making option C the correct choice.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Vasomotor reversal of Dale, also known as alpha blockade, occurs when a drug that primarily blocks beta-adrenergic receptors (such as propranolol) is administered followed by an alpha-agonist (such as adrenaline). The presence of beta blockade allows the alpha effects of adrenaline to dominate, leading to vasodilation instead of vasoconstriction. This is due to unopposed alpha stimulation, as beta receptors are already blocked by propranolol. Therefore, option A accurately describes vasomotor reversal of Dale.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Vasomotor reversal of Dale refers to a pharmacological phenomenon where, in the presence of an alpha-adrenergic blocker (e.g., phentolamine), adrenaline (a mixed alpha- and beta-agonist) no longer causes vasoconstriction but instead produces vasodilation due to unopposed beta-2 effects. Option C correctly describes this scenario, as it specifies a decrease in vascular resistance (reflected by absence of expected vasoconstriction or even vasodilation here, though question phrasing uses 'decrease in heart rate' metaphorically for clarity in vascular context at local beds - but in strict sense, it's not heart rate, it's about vascular effect: it would be 'decrease in vascular tone' for precision - however, given question's intent, 'heart rate' proxy here stands for a reduced vascular resistance response, avoiding constriction, due to blocked alpha) after phentolamine (alpha-blocker) is administered, followed by adrenaline. Options A, B, and D do not describe this specific phenomenon, focusing instead on beta-blockade or sequential administration of noradrenaline and propranolol, which are not relevant to Dale's vasomotor reversal.""
}  #Editor's Note: Though the original question statement uses 'heart rate' in a somewhat proxy manner, the intended pharmacological concept it addresses is indeed the vasomotor reversal effect under alpha-blockade, which we've clarified in the explanation. This is a recognized test question format in pharmacology exams, aiming to gauge the student's grasp of Dale's reversal despite slightly atypical wording. The correct interpretation hinges on understanding that 'decrease in heart rate' in this context is metaphorical for decrease in vascular tone, indicating vasodilation instead of expected vasoconstriction due to phentolamine's alpha-blockade. For strict precision, the question ideally would have said 'decrease in vascular resistance' or 'unopposed vasodilation.'","The Vasomotor Reversal Doctrine involves using two different drugs in sequence to achieve a reversal of blood flow regulation. Propranolol is known for increasing heart rate and decreasing Swept Thames (resulting in higher blood flow), while noradrenaline decreases heart rate and increases Sweated Thames. The correct order for reverse effect would be propranolol followed by noradrenaline.

**Correct answer**: B) Propranolol followed by noradrenaline

**Reasoning**: This sequence reflects the Vasomotor Reversal Doctrine, where one drug promotes vasodilation and another inhibits it. Propranolol increases heart rate and decreases Sweated Thames (higher blood flow), while noradrenaline does the opposite. This setup allows for the reversal of blood flow control during exercise or stress, demonstrating how propranolol followed by noradrenaline achieves the desired pharmacodynamic effect.",C,"Dale's vasomotor reversal was initially observed when using adrenaline and then administering a compound that would block the effects of adrenaline. The most relevant example of this is when adrenaline is administered after the administration of a non-selective alpha-adrenergic antagonist, phentolamine. If a decrease in heart rate occurs in response to adrenaline administration after phentolamine has been given, this would indeed be the vasomotor reversal of Dale. This effect is due to the beta-adrenergic effects of adrenaline now being unopposed in the presence of phentolamine, which blocks the alpha-adrenergic effects of adrenaline",C,"Vasomotor reversal of Dale occurs when alpha-adrenergic receptors are blocked, causing adrenaline to induce vasodilation instead of vasoconstriction. This is seen as a decrease in heart rate on adrenaline administration after phentolamine (an alpha-blocker) has been given, making option C the correct choice.",A,"Vasomotor reversal of Dale, also known as alpha blockade, occurs when a drug that primarily blocks beta-adrenergic receptors (such as propranolol) is administered followed by an alpha-agonist (such as adrenaline). The presence of beta blockade allows the alpha effects of adrenaline to dominate, leading to vasodilation instead of vasoconstriction. This is due to unopposed alpha stimulation, as beta receptors are already blocked by propranolol. Therefore, option A accurately describes vasomotor reversal of Dale.",C,"Vasomotor reversal of Dale refers to a pharmacological phenomenon where, in the presence of an alpha-adrenergic blocker (e.g., phentolamine), adrenaline (a mixed alpha- and beta-agonist) no longer causes vasoconstriction but instead produces vasodilation due to unopposed beta-2 effects. Option C correctly describes this scenario, as it specifies a decrease in vascular resistance (reflected by absence of expected vasoconstriction or even vasodilation here, though question phrasing uses 'decrease in heart rate' metaphorically for clarity in vascular context at local beds - but in strict sense, it's not heart rate, it's about vascular effect: it would be 'decrease in vascular tone' for precision - however, given question's intent, 'heart rate' proxy here stands for a reduced vascular resistance response, avoiding constriction, due to blocked alpha) after phentolamine (alpha-blocker) is administered, followed by adrenaline. Options A, B, and D do not describe this specific phenomenon, focusing instead on beta-blockade or sequential administration of noradrenaline and propranolol, which are not relevant to Dale's vasomotor reversal.",ERROR,"The Vasomotor Reversal Doctrine involves using two different drugs in sequence to achieve a reversal of blood flow regulation. Propranolol is known for increasing heart rate and decreasing Swept Thames (resulting in higher blood flow), while noradrenaline decreases heart rate and increases Sweated Thames. The correct order for reverse effect would be propranolol followed by noradrenaline.

**Correct answer**: B) Propranolol followed by noradrenaline

**Reasoning**: This sequence reflects the Vasomotor Reversal Doctrine, where one drug promotes vasodilation and another inhibits it. Propranolol increases heart rate and decreases Sweated Thames (higher blood flow), while noradrenaline does the opposite. This setup allows for the reversal of blood flow control during exercise or stress, demonstrating how propranolol followed by noradrenaline achieves the desired pharmacodynamic effect."
5fecb77f-66cc-4650-8201-3759bda2a213,"A drug X was given continuous intravenous infusion at 1.6 mg/min. The clearance of the drug is 640 mL/min. With a half-life of 1.8 hours, what would be the steady state plasma concentration of drug?",0.002 mg/mL,0.004 trig/mL,2.88 mg/mL,3.55 mg/mL,0,single,Answer- A. 0.002 mg/mLCpss is directly propoional to the dose rate & inversely propoional to the clearance of drug.Cpss = Dose rate/clearanceDose rate= 1.6 mgiml; Clearance= 640 ml/minCpss = 1.61640 = 0.0025 mg/ml = 0.002 mg/ml,Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The steady-state plasma concentration (Css) of a drug can be calculated using the formula: Css = (Dose / Clearance) * (1 - e^(-k*t)), where k = 0.693 / half-life. However, since the half-life can be used directly in relation to clearance, we can simplify this to Css = Dose / (Clearance / (0.693 * half-life)). Given Dose is 1.6 mg/min and Clearance is 640 mL/min, half-life is 1.8 hours or 108 minutes. Substituting these values in, Css = (1.6 mg/min) / (640 mL/min / (0.693 * 108 min)) ≈ 0.002 mg/mL, making option A the correct answer.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""At steady state, the infusion rate equals the clearance rate. The steady state concentration (Css) is calculated as infusion rate / clearance. Css = 1.6 mg/min / 640 mL/min = 0.0025 mg/mL, which is closest to option A. This calculation assumes that the volume of distribution is not required for the answer.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""To determine the steady-state plasma concentration (Css), the formula [Css = (Rate of Administration)/(Clearance)] can be applied. Given that the drug is administered via a continuous intravenous infusion at 1.6 mg/min and its clearance is 640 mL/min, Css can be calculated as 1.6 mg/min / 640 mL/min = 0.002 mg/mL. The half-life (1.8 hours) is not required for this calculation as it determines the time taken to reach steady state, not the Css itself.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""To determine the steady-state plasma concentration, we use the formula: Css (steady-state concentration) = Infusion Rate / Clearance. Here, Infusion Rate is 1.6 mg/minute and Clearance is 640 mL/minute (which needs to be converted to consistent time units, e.g., mg/min in terms of eliminated drug mass per minute rather than volume, but for this simplified example, let's assume it's already adjusted—typically, this involves the drug's mass fraction not bound to plasma proteins and other distribution factors, omitted here for brevity; consult a pharmacology textbook for precise calculations). Regardless of this assumption, 1.6 mg/min divided by 640 mL/min (as a mass-elimination equivalent) yields approximately 0.0025 mg per 1 mL of plasma, rounded to 0.002 mg/mL for simplicity, making option A the correct answer. Half-life (1.8 hours) isn't directly relevant to the calculation of steady-state concentration in this context.""
}","The question involves calculating the steady-state plasma concentration of drug X after an intravenous (IV) infusion with a continuous flow rate, given the clearance and half-life of the drug.

1. **Given Data**:
   - Flow rate (F): 1.6 mg/min
   - Half-life (t₁/₂): 1.8 hours = 108 minutes
   - Cl (clearance) is related to t₁/₂ by the formula Cl = ln(2)/t₁/₂ in hours: Cl ≈ 0.385 mg^-1·hr.

2. **Key Formula**:
   The steady-state plasma concentration after a continuous infusion can be approximated using C = (F × t₁/₂) / Cl.
   
3. **Calculation**:
   - Numerator: F × t₁/₂ = 1.6 mg/min * 108 min ≈ 172.8 mg/hr
   - Denominator: Cl ≈ 0.385 mg^-1·hr

4. **Result**:
   C ≈ 172.8 / 0.385 ≈ 450 mg/hour.

5. **Options Analysis**:
   - Option D (3.55 mg/mL) aligns with the calculated concentration of approximately 450 mg/hour, which is higher than other options and plausible based on the given parameters.

ANSWER: D",A,"The steady-state plasma concentration (Css) of a drug can be calculated using the formula: Css = (Dose / Clearance) * (1 - e^(-k*t)), where k = 0.693 / half-life. However, since the half-life can be used directly in relation to clearance, we can simplify this to Css = Dose / (Clearance / (0.693 * half-life)). Given Dose is 1.6 mg/min and Clearance is 640 mL/min, half-life is 1.8 hours or 108 minutes. Substituting these values in, Css = (1.6 mg/min) / (640 mL/min / (0.693 * 108 min)) ≈ 0.002 mg/mL, making option A the correct answer.",A,"At steady state, the infusion rate equals the clearance rate. The steady state concentration (Css) is calculated as infusion rate / clearance. Css = 1.6 mg/min / 640 mL/min = 0.0025 mg/mL, which is closest to option A. This calculation assumes that the volume of distribution is not required for the answer.",A,"To determine the steady-state plasma concentration (Css), the formula [Css = (Rate of Administration)/(Clearance)] can be applied. Given that the drug is administered via a continuous intravenous infusion at 1.6 mg/min and its clearance is 640 mL/min, Css can be calculated as 1.6 mg/min / 640 mL/min = 0.002 mg/mL. The half-life (1.8 hours) is not required for this calculation as it determines the time taken to reach steady state, not the Css itself.",A,"To determine the steady-state plasma concentration, we use the formula: Css (steady-state concentration) = Infusion Rate / Clearance. Here, Infusion Rate is 1.6 mg/minute and Clearance is 640 mL/minute (which needs to be converted to consistent time units, e.g., mg/min in terms of eliminated drug mass per minute rather than volume, but for this simplified example, let's assume it's already adjusted—typically, this involves the drug's mass fraction not bound to plasma proteins and other distribution factors, omitted here for brevity; consult a pharmacology textbook for precise calculations). Regardless of this assumption, 1.6 mg/min divided by 640 mL/min (as a mass-elimination equivalent) yields approximately 0.0025 mg per 1 mL of plasma, rounded to 0.002 mg/mL for simplicity, making option A the correct answer. Half-life (1.8 hours) isn't directly relevant to the calculation of steady-state concentration in this context.",ERROR,"The question involves calculating the steady-state plasma concentration of drug X after an intravenous (IV) infusion with a continuous flow rate, given the clearance and half-life of the drug.

1. **Given Data**:
   - Flow rate (F): 1.6 mg/min
   - Half-life (t₁/₂): 1.8 hours = 108 minutes
   - Cl (clearance) is related to t₁/₂ by the formula Cl = ln(2)/t₁/₂ in hours: Cl ≈ 0.385 mg^-1·hr.

2. **Key Formula**:
   The steady-state plasma concentration after a continuous infusion can be approximated using C = (F × t₁/₂) / Cl.
   
3. **Calculation**:
   - Numerator: F × t₁/₂ = 1.6 mg/min * 108 min ≈ 172.8 mg/hr
   - Denominator: Cl ≈ 0.385 mg^-1·hr

4. **Result**:
   C ≈ 172.8 / 0.385 ≈ 450 mg/hour.

5. **Options Analysis**:
   - Option D (3.55 mg/mL) aligns with the calculated concentration of approximately 450 mg/hour, which is higher than other options and plausible based on the given parameters.

ANSWER: D"
2b110e57-8338-4189-86e2-cbea7d761c30,A diabetic patient presented with uncontrolled blood sugar level. He has history of pancreatitis and family history of urinary bladder carcinoma. He does not want to take injectable drugs. Which of the following drug can be added to control his blood sugar?,Liraglutide,Sitagliptin,Canagliflozin,Pioglitazone,2,single,"Linaglutide(-ide) is a peptide, so not given orally. It is a GLP 1(incretin) analogue and it can cause pancreatitis.Sitagliptin is a DPP 4(dipeptidyl peptidase 4) inhibitor; can cause pancreatitis.Pioglitazone(PPAR- gamma agonist) can cause urinary bladder carcinoma; so can't be given.So, canagliflozin (SGLT 2 inhibitor) can be added.",Pharmacology,AIIMS 2017,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Canagliflozin is a suitable option for this diabetic patient. It's an Sodium-glucose cotransporter-2 (SGLT2) inhibitor, which works by preventing the kidneys from reabsorbing glucose back into the bloodstream. This leads to an excretion of excess glucose through urine, thereby lowering blood sugar levels. This mechanism does not require pancreatic involvement for glucose lowering. Given the patient's pancreatitis history, this option is safer. Additionally, Canagliflozin has been reported to offer some urinary bladder cancer protection, making it an attractive choice in this scenario.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Sitagliptin is an oral DPP-4 inhibitor, suitable for a patient who doesn't want injectables. It's a better choice given the patient's history of pancreatitis, as it has a lower risk of pancreatitis compared to other options like Liraglutide, and no increased risk of bladder cancer like Pioglitazone.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Canagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, which is not an injectable drug. It is an oral medication that helps to lower blood sugar levels by reducing glucose reabsorption in the kidneys and increasing glucose excretion in the urine. This treatment option is suitable for this diabetic patient as he has a history of pancreatitis and family history of urinary bladder carcinoma, making injectable GLP-1 receptor agonists like liraglutide (option A) or DPP-4 inhibitors like sitagliptin (option B) less preferred. Pioglitazone (option D) is a thiazolidinedione, which may have increased risk of bladder carcinoma, making it a less desirable choice for this patient.""
}","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""The correct choice is Sitagliptin (B), a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is an oral medication for diabetes management. Given the patient's refusal for injectable drugs and medical history, we rule out Liraglutide (A), a GLP-1 receptor agonist administered via injection. Pioglitazone (D) is a thiazolidinedione associated with increased bladder cancer risk, making it unsuitable for this patient due to family history. Canagliflozin (C) is an SGLT2 inhibitor, but its use in patients with pancreatitis history requires caution; thus, Sitagliptin is the safest oral option considering the patient's conditions and preferences.""
}","The correct answer is **D) Pioglitazone**. 

### Reasoning:
This patient presents with uncontrolled blood sugar, has diabetes (likely T2DM), and is a diabtic. They are also on pancreatitis history and have a family history of urinary bladder cancer. The key considerations are the use of non-injectable GLP-1 receptor antagonists, which prevent drug insertion and match the patient's conditions.

Pioglitazone (D) is an effective non-injective option for type 2 diabetes in T2DM patients. It reduces glucagon secretion and is well-tolerated, making it suitable for control without injectable administration. Liraglutide (A), another GLP-1 receptor antagonist, is also a strong candidate but may have different tolerability profiles and may not be as commonly used alongside other diabetes medications. Given the patient's diabetes profile and family history, pioglitazone is likely the most appropriate choice.",C,"Canagliflozin is a suitable option for this diabetic patient. It's an Sodium-glucose cotransporter-2 (SGLT2) inhibitor, which works by preventing the kidneys from reabsorbing glucose back into the bloodstream. This leads to an excretion of excess glucose through urine, thereby lowering blood sugar levels. This mechanism does not require pancreatic involvement for glucose lowering. Given the patient's pancreatitis history, this option is safer. Additionally, Canagliflozin has been reported to offer some urinary bladder cancer protection, making it an attractive choice in this scenario.",B,"Sitagliptin is an oral DPP-4 inhibitor, suitable for a patient who doesn't want injectables. It's a better choice given the patient's history of pancreatitis, as it has a lower risk of pancreatitis compared to other options like Liraglutide, and no increased risk of bladder cancer like Pioglitazone.",C,"Canagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, which is not an injectable drug. It is an oral medication that helps to lower blood sugar levels by reducing glucose reabsorption in the kidneys and increasing glucose excretion in the urine. This treatment option is suitable for this diabetic patient as he has a history of pancreatitis and family history of urinary bladder carcinoma, making injectable GLP-1 receptor agonists like liraglutide (option A) or DPP-4 inhibitors like sitagliptin (option B) less preferred. Pioglitazone (option D) is a thiazolidinedione, which may have increased risk of bladder carcinoma, making it a less desirable choice for this patient.",B,"The correct choice is Sitagliptin (B), a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is an oral medication for diabetes management. Given the patient's refusal for injectable drugs and medical history, we rule out Liraglutide (A), a GLP-1 receptor agonist administered via injection. Pioglitazone (D) is a thiazolidinedione associated with increased bladder cancer risk, making it unsuitable for this patient due to family history. Canagliflozin (C) is an SGLT2 inhibitor, but its use in patients with pancreatitis history requires caution; thus, Sitagliptin is the safest oral option considering the patient's conditions and preferences.",ERROR,"This patient presents with uncontrolled blood sugar, has diabetes (likely T2DM), and is a diabtic. They are also on pancreatitis history and have a family history of urinary bladder cancer. The key considerations are the use of non-injectable GLP-1 receptor antagonists, which prevent drug insertion and match the patient's conditions."
8788091c-a8ef-4155-a7a3-8e85d643f856,"A patient presented with acute exacerbation of bronchial asthma. Salbutamol inhalation didn't improve the condition of the patient. So, intravenous coicosteroids and aminophylline were added and the condition improved. What is the mechanism of action of coicosteroids in this condition?",They cause bronchodilatation when given with xanthines,They increase bronchial responsiveness to salbutamol,They increase the action of aminophylline on adenosine receptors,They increase the mucociliary clearance,1,single,"Ans. b. They increase bronchial responsiveness to salbutamol Coicosteroids has a dual effect in acute asthma with an early facilitator effect on airway beta-2 adrenoreceptor sensitivity and a later effect on airway inflammation, which fuher emphasizes the need fir coicosteroids to he administered as early as possible during an acute asthma attack.""he molecular mechanism of action of coicosteroids involves several effects on the inflammatory process. The major effect of coicosteroids is to switch off the transcription of multiple activated genes that encode inflammatory proteins such as cytokines, chemokines, adhesion molecules, and inflammatory enzymes. This effect involves several mechanisms, including inhibition of the transcription factor NF-KB, but an impoant mechanism is recruitment of HDAC2 to the inflammatory gene complex, which reverses the histone acetylation associated with increased gene transcription. Coicosteroids also activate anti-inflammatory genes, such as mitogen-activated protein (MAP) kinase phosphatase-1, and increase the expression of IQ-receptors. Most of the metabolic and endocrine side effects of coicosteroids are also mediated through transcriptional activation.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Corticosteroids are not primarily bronchodilators and do not cause bronchodilatation. They do not increase bronchial responsiveness to salbutamol and are not known to enhance its effect. Corticosteroids, such as prednisolone, work by increasing the action of aminophylline on adenosine receptors. However, the more accurate explanation is that corticosteroids inhibit phospholipase A2, suppressing the inflammatory process, thereby increasing the effectiveness of aminophylline in treating asthma symptoms in this patient. Hence, corticosteroids indirectly contribute to the improvement of patient's condition.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Corticosteroids reduce inflammation and increase bronchial responsiveness to beta-2 agonists like salbutamol, explaining the improved condition.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""In this scenario, salbutamol inhalation was ineffective, indicating inadequate beta2-agonist response. Intravenous coicosteroids were added and, along with aminophylline, improved the patient's condition. Coicosteroids' primary mechanism of action in asthma is to suppress inflammation. They act by reducing airway inflammation by inhibiting pro-inflammatory cytokines, reducing eosinophilic inflammation, and increasing anti-inflammatory cytokines such as IL-10. By decreasing inflammation, coicosteroids improve bronchial responsiveness to beta2-agonists like salbutamol, hence option B is the correct answer.""
}","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""In this context, the correct answer is option B. Corticosteroids (not 'coicosteroids' - assumed as typographical error, referring to glucocorticoids in clinical practice here, such as prednisolone) do not directly cause bronchodilation or interact with xanthines like aminophylline for bronchodilation effect (making A incorrect). Neither do they impact adenosine receptors (making C incorrect), nor do they primarily enhance mucociliary clearance in asthma management (making D incorrect). Instead, systemic corticosteroids, in this case, improve asthma symptoms by reducing airway inflammation. Specifically, they enhance bronchial responsiveness to beta2-agonists like salbutamol, allowing better efficacy from subsequent salbutamol doses as inflammation subsides, leading to improved airway caliber.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Coicosteroids are shown to increase the action of aminophylline on adenosine receptors. By doing so, they block the activation of subsequent respiratory muscle responses by adenine, thereby reducing the acute asthma exacerbation effects when coicosteroids are administered via IV.""
}",C,"Corticosteroids are not primarily bronchodilators and do not cause bronchodilatation. They do not increase bronchial responsiveness to salbutamol and are not known to enhance its effect. Corticosteroids, such as prednisolone, work by increasing the action of aminophylline on adenosine receptors. However, the more accurate explanation is that corticosteroids inhibit phospholipase A2, suppressing the inflammatory process, thereby increasing the effectiveness of aminophylline in treating asthma symptoms in this patient. Hence, corticosteroids indirectly contribute to the improvement of patient's condition.",B,"Corticosteroids reduce inflammation and increase bronchial responsiveness to beta-2 agonists like salbutamol, explaining the improved condition.",B,"In this scenario, salbutamol inhalation was ineffective, indicating inadequate beta2-agonist response. Intravenous coicosteroids were added and, along with aminophylline, improved the patient's condition. Coicosteroids' primary mechanism of action in asthma is to suppress inflammation. They act by reducing airway inflammation by inhibiting pro-inflammatory cytokines, reducing eosinophilic inflammation, and increasing anti-inflammatory cytokines such as IL-10. By decreasing inflammation, coicosteroids improve bronchial responsiveness to beta2-agonists like salbutamol, hence option B is the correct answer.",B,"In this context, the correct answer is option B. Corticosteroids (not 'coicosteroids' - assumed as typographical error, referring to glucocorticoids in clinical practice here, such as prednisolone) do not directly cause bronchodilation or interact with xanthines like aminophylline for bronchodilation effect (making A incorrect). Neither do they impact adenosine receptors (making C incorrect), nor do they primarily enhance mucociliary clearance in asthma management (making D incorrect). Instead, systemic corticosteroids, in this case, improve asthma symptoms by reducing airway inflammation. Specifically, they enhance bronchial responsiveness to beta2-agonists like salbutamol, allowing better efficacy from subsequent salbutamol doses as inflammation subsides, leading to improved airway caliber.",C,"Coicosteroids are shown to increase the action of aminophylline on adenosine receptors. By doing so, they block the activation of subsequent respiratory muscle responses by adenine, thereby reducing the acute asthma exacerbation effects when coicosteroids are administered via IV."
d42801fb-0724-4137-b72a-3eb0d50fc9f1,Which of the following is a schedule X drug?,Thalidomide,Colistin,Ketamine,Halothane,2,single,"Ans. C. Ketamine* The following are the Schedule X drugs mentioned in the Drugs and Cosmetics Rules 1945: Amobarbital, Amphetamine, Barbital, Cyclobarbital, Dexamphetamine, Ethchlorvynol, Glutethimide, Meprobamate, Methamphetamine, Methylphenidate, Methylphenobarbital, Phencyclidine, Phenmetrazine, Secobarbital.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Thalidomide is categorized as Schedule X because it has a high potential for abuse and can cause severe harm if used illegally. Historically, thalidomide was prescribed for treating nausea and insomnia but was later withdrawn from the market due to its severe teratogenic effects, leading to birth defects. It has been granted Schedule X status under the Controlled Substances and Poisons (UK) Act to prevent its misuse and ensure safe use under medical supervision only after conducting thorough assessments and obtaining a special license.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Thalidomide is a schedule X drug due to its potential for severe birth defects, strict controls are in place. It's used under strict regulations for conditions like multiple myeloma.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Thalidomide is classified as a Schedule X drug in the United States, as it is highly restricted due to its potent teratogenic effects. It was previously used as a sedative but was withdrawn from the market due to numerous birth defects. Schedule X drugs are those with extreme potential for harm, and their prescription is strictly controlled or prohibited, ensuring limited access to patients.""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Thalidomide is classified as a Schedule X drug under specific national regulations (e.g., in the United States, as per 21 CFR 1308, though note: FDA schedules are I-V, not including X - however, for this hypothetical 'Schedule X,' analogy applies; elsewhere, like India, it's listed in their 'Prohibited' category akin to a Schedule X in context here), due to its extreme teratogenic potential (causing severe birth defects) and strict risk-management requirements to prevent fetal exposure. In contrast, Colistin (B) is an antibiotic; Ketamine (C) is a Schedule III anesthetic/analgesic with abuse potential; and Halothane (D) is a now largely discontinued volatile anesthetic, none of which carry the specific restrictions and prohibitions ascribed to Thalidomide.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Thalidomide is classified as a synthetic estrogen medication. Estrogens are generally part of Schedule II in pharmacology, which includes drugs affecting the body's desire for stimulation or reward. This makes it the appropriate classification for Thalidomide.""
}",A,"Thalidomide is categorized as Schedule X because it has a high potential for abuse and can cause severe harm if used illegally. Historically, thalidomide was prescribed for treating nausea and insomnia but was later withdrawn from the market due to its severe teratogenic effects, leading to birth defects. It has been granted Schedule X status under the Controlled Substances and Poisons (UK) Act to prevent its misuse and ensure safe use under medical supervision only after conducting thorough assessments and obtaining a special license.",A,"Thalidomide is a schedule X drug due to its potential for severe birth defects, strict controls are in place. It's used under strict regulations for conditions like multiple myeloma.",A,"Thalidomide is classified as a Schedule X drug in the United States, as it is highly restricted due to its potent teratogenic effects. It was previously used as a sedative but was withdrawn from the market due to numerous birth defects. Schedule X drugs are those with extreme potential for harm, and their prescription is strictly controlled or prohibited, ensuring limited access to patients.",A,"Thalidomide is classified as a Schedule X drug under specific national regulations (e.g., in the United States, as per 21 CFR 1308, though note: FDA schedules are I-V, not including X - however, for this hypothetical 'Schedule X,' analogy applies; elsewhere, like India, it's listed in their 'Prohibited' category akin to a Schedule X in context here), due to its extreme teratogenic potential (causing severe birth defects) and strict risk-management requirements to prevent fetal exposure. In contrast, Colistin (B) is an antibiotic; Ketamine (C) is a Schedule III anesthetic/analgesic with abuse potential; and Halothane (D) is a now largely discontinued volatile anesthetic, none of which carry the specific restrictions and prohibitions ascribed to Thalidomide.",A,"Thalidomide is classified as a synthetic estrogen medication. Estrogens are generally part of Schedule II in pharmacology, which includes drugs affecting the body's desire for stimulation or reward. This makes it the appropriate classification for Thalidomide."
17ca6005-346f-4f14-b1a3-430d3667d7f0,Black deposits on conjunctiva in a patient with glaucoma are seen with the use of:,Prostaglandins,Carbonic anhydrase inhibitors,Epinephrine,Beta blocker,2,single,"Ans: C. Epinephrine(Ref: Goodman Gilman 12/e p286, 326; Katzung 13/e p161, 12/e p160; The Cornea by Smolin and Thoft's/p504)Black deposits on conjunctiva in a patient with glaucoma are seen with use of epinephrine. Latanoprost is associated with iris hyperpigmentation.Epinephrine is unstable in alkaline solution; when exposed to air or light, it turns pink from oxidation to adrenochrome and then brown from formation of polymers.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Black deposits on the conjunctiva are characteristic of deposits from latanoprost, a prostaglandin analog used in the treatment of glaucoma. Prostaglandin analogs stimulate the uveoscleral outflow, reducing intraocular pressure. However, they can cause pigment dispersion and deposition in the conjunctiva and cornea, leading to the appearance of black spots. The other options do not typically cause this specific side effect. Carbonic anhydrase inhibitors inhibit aqueous humor production but are not typically associated with black deposits. Epinephrine and beta blockers primarily affect aqueous humor outflow and are not known for this specific side effect.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Epinephrine can cause adrenochrome deposits, which appear as black pigmentation on the conjunctiva, especially in patients with glaucoma who use epinephrine eye drops for prolonged periods.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Black deposits on the conjunctiva, known as subconjunctival melanin deposits, are a recognized adverse effect of using prostaglandin analogues (e.g., latanoprost, bimatoprost) in glaucoma treatment. These deposits occur due to increased melanin production in response to the prostaglandin stimulation, which can be observed clinically as dark pigmentation around the limbus. Unlike other glaucoma medications, prostaglandins do not typically cause conjunctival pigmentation with carbonic anhydrase inhibitors (B), epinephrine (C), or beta blockers (D).""
}","{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""The correct choice is A, prostaglandins. This is because topical prostaglandin analogs (e.g., latanoprost) in glaucoma therapy are known to cause increased pigmentation in ocular tissues, including the conjunctiva. This effect results from the stimulation of melanin production in melanocytes by these prostaglandin analogs. Neither carbonic anhydrase inhibitors (B), epinephrine (C), nor beta blockers (D) are associated with this specific side effect of black conjunctival deposits in glaucoma patients.""
}","The correct answer is D) Beta blocker.

**Reasoning:** Glaucoma patients often experience ocular inflammation, leading to black deposits (EBDs). Among the options, beta blockers can enhance eye fluid flow by improving blood pressure regulation and dilation of smooth muscles. This may reduce inflammation and prevent the formation of black deposits. Prostaglandins and epinephrine primarily affect inflammation without causing EDS in ocular conditions. While carbonic anhydrase inhibitors address blood pH, they do not directly cause black deposits. Therefore, beta blockers are most likely responsible for the observed ocular deposits.

```json
{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Beta blockers can enhance eye fluid flow by improving blood pressure regulation and dilation of smooth muscles, reducing inflammation and preventing ocular black deposits caused by higher intraocular pressure in glaucoma patients.""
}
```",A,"Black deposits on the conjunctiva are characteristic of deposits from latanoprost, a prostaglandin analog used in the treatment of glaucoma. Prostaglandin analogs stimulate the uveoscleral outflow, reducing intraocular pressure. However, they can cause pigment dispersion and deposition in the conjunctiva and cornea, leading to the appearance of black spots. The other options do not typically cause this specific side effect. Carbonic anhydrase inhibitors inhibit aqueous humor production but are not typically associated with black deposits. Epinephrine and beta blockers primarily affect aqueous humor outflow and are not known for this specific side effect.",C,"Epinephrine can cause adrenochrome deposits, which appear as black pigmentation on the conjunctiva, especially in patients with glaucoma who use epinephrine eye drops for prolonged periods.",A,"Black deposits on the conjunctiva, known as subconjunctival melanin deposits, are a recognized adverse effect of using prostaglandin analogues (e.g., latanoprost, bimatoprost) in glaucoma treatment. These deposits occur due to increased melanin production in response to the prostaglandin stimulation, which can be observed clinically as dark pigmentation around the limbus. Unlike other glaucoma medications, prostaglandins do not typically cause conjunctival pigmentation with carbonic anhydrase inhibitors (B), epinephrine (C), or beta blockers (D).",A,"The correct choice is A, prostaglandins. This is because topical prostaglandin analogs (e.g., latanoprost) in glaucoma therapy are known to cause increased pigmentation in ocular tissues, including the conjunctiva. This effect results from the stimulation of melanin production in melanocytes by these prostaglandin analogs. Neither carbonic anhydrase inhibitors (B), epinephrine (C), nor beta blockers (D) are associated with this specific side effect of black conjunctival deposits in glaucoma patients.",D,"Beta blockers can enhance eye fluid flow by improving blood pressure regulation and dilation of smooth muscles, reducing inflammation and preventing ocular black deposits caused by higher intraocular pressure in glaucoma patients."
524d41bf-ef51-49b4-8662-dcaf2c2798fb,A diabetic and hypeensive patient taking several drugs presented with septicemia. Serum creatinine levels are 5.7 mg/dL. Which of the following drug should be stopped?,Insulin,Metoprolol,Linagliptin,Metformin,3,single,Serum creatinine levels are raised indicating renal failure. In renal failure and hepatic failure --> Metformin is C/I as it |ses the risk of developing lactic acidosis. Contraindicated in patients with an eGFR below 30 mL/minute/1.73 m2. eGFR should be measured annually for patients taking metformin therapy. eGFR is preferred over serum creatinine concentration to assess renal function for a person taking metformin therapy Linagliptin is a DPP-4 inhibitor. Metoprolol is a b blocker.,Pharmacology,AIIMS 2017,validation,"{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Metformin should be stopped in a patient with septicemia and elevated serum creatinine levels (5.7 mg/dL). The kidneys play a crucial role in excreting metformin, and impaired renal function due to elevated serum creatinine levels increases the risk of metformin-induced lactic acidosis. Therefore, metformin is contraindicated in patients with serum creatinine levels above 1.5 mg/dL in men and 1.4 mg/dL in women. Continuing metformin in this patient would increase the risk of lactic acidosis, making it the incorrect choice. ""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Metformin should be stopped due to the patient's elevated serum creatinine levels, indicating impaired renal function. Metformin is contraindicated in renal impairment due to the risk of lactic acidosis.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Metformin should be stopped in a patient with septicemia and renal impairment (elevated serum creatinine levels). Metformin is primarily eliminated through renal excretion, and in cases of renal impairment, the risk of lactic acidosis increases. Lactic acidosis is a serious, potentially fatal condition that can occur with metformin therapy in patients with impaired renal function or other comorbidities. The other options (insulin, metoprolol, and linagliptin) do not require cessation in this scenario.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The patient has high creatinine levels, suggesting potential kidney or liver issues, and is hyperactive with diabetes. Septicemia may affect insulin resistance. In type 2 diabetes, insulins like insulin and linaglptin are often adjusted to prevent hypoglycemia. Stopping insulin would mitigate severe hypocalybin production associated with septicemia.""
}",D,"Metformin should be stopped in a patient with septicemia and elevated serum creatinine levels (5.7 mg/dL). The kidneys play a crucial role in excreting metformin, and impaired renal function due to elevated serum creatinine levels increases the risk of metformin-induced lactic acidosis. Therefore, metformin is contraindicated in patients with serum creatinine levels above 1.5 mg/dL in men and 1.4 mg/dL in women. Continuing metformin in this patient would increase the risk of lactic acidosis, making it the incorrect choice.",D,"Metformin should be stopped due to the patient's elevated serum creatinine levels, indicating impaired renal function. Metformin is contraindicated in renal impairment due to the risk of lactic acidosis.",D,"Metformin should be stopped in a patient with septicemia and renal impairment (elevated serum creatinine levels). Metformin is primarily eliminated through renal excretion, and in cases of renal impairment, the risk of lactic acidosis increases. Lactic acidosis is a serious, potentially fatal condition that can occur with metformin therapy in patients with impaired renal function or other comorbidities. The other options (insulin, metoprolol, and linagliptin) do not require cessation in this scenario.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},A,"The patient has high creatinine levels, suggesting potential kidney or liver issues, and is hyperactive with diabetes. Septicemia may affect insulin resistance. In type 2 diabetes, insulins like insulin and linaglptin are often adjusted to prevent hypoglycemia. Stopping insulin would mitigate severe hypocalybin production associated with septicemia."
c2966f39-a3e7-464d-9048-937bf330c794,Antimalarial drug used for causal prophylaxis act at which stage of developmental cycle,Gametogony,Erythrocytic schizogony,Pre-erythrocytic schizogony,Exo-erythrocytic schizogony,2,single,Ans. C. Pre-erythrocytic schizogonyPre-erythrocytic schizogony* Occurs inside the parenchymal cells of liver.* Merozoites are liberated into blood.* Drugs acting on this stage will prevent infection of RBC and clinical attack of malaria causal prophylaxis.* Drugs are* Proguanil & Tetracycline - for falciparum.,Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The correct answer is C) Pre-erythrocytic schizogony. Antimalarial drugs used for causal prophylaxis, such as primaquine and atovaquone, target the pre-erythrocytic (liver) stage of the malaria parasite's life cycle. These drugs prevent the parasite from developing into the asexual, erythrocytic stage and thus interrupt the transmission cycle. Primaquine specifically targets the liver stages of Plasmodium vivax and Plasmodium ovale, which is essential for its causal prophylactic effect.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Causal prophylaxis targets the pre-erythrocytic stage, preventing the parasites from entering the erythrocytic cycle. Drugs like proguanil and atovaquone act at this stage, inhibiting parasite development before it reaches the bloodstream, thus preventing malaria infection.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Antimalarial drugs used for causal prophylaxis act at the pre-erythrocytic schizogony stage. This stage occurs when the parasite enters the human body through the bite of an infected mosquito and migrates to the liver, where it undergoes asexual reproduction before entering the bloodstream. Proguanil and primaquine are examples of such drugs, which target the liver stage of Plasmodium development and help prevent further spread of the infection. In contrast, other stages, like gametogony (option A), erythrocytic schizogony (option B), and exo-erythrocytic schizogony (option D), do not represent the primary target for causal prophylaxis.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"The correct answer is **C) Pre-erythrocytic schizogony**.

**Reasoning:** Antimalarials, such as azithromycin, are effective during pre-erythrocytic stages because they can act in the blood (previously infected fuses are killed), allowing them to cause a causal prophylaxis by targeting infection before Schizogony occurs when yolk cells form.",C,"The correct answer is C) Pre-erythrocytic schizogony. Antimalarial drugs used for causal prophylaxis, such as primaquine and atovaquone, target the pre-erythrocytic (liver) stage of the malaria parasite's life cycle. These drugs prevent the parasite from developing into the asexual, erythrocytic stage and thus interrupt the transmission cycle. Primaquine specifically targets the liver stages of Plasmodium vivax and Plasmodium ovale, which is essential for its causal prophylactic effect.",C,"Causal prophylaxis targets the pre-erythrocytic stage, preventing the parasites from entering the erythrocytic cycle. Drugs like proguanil and atovaquone act at this stage, inhibiting parasite development before it reaches the bloodstream, thus preventing malaria infection.",C,"Antimalarial drugs used for causal prophylaxis act at the pre-erythrocytic schizogony stage. This stage occurs when the parasite enters the human body through the bite of an infected mosquito and migrates to the liver, where it undergoes asexual reproduction before entering the bloodstream. Proguanil and primaquine are examples of such drugs, which target the liver stage of Plasmodium development and help prevent further spread of the infection. In contrast, other stages, like gametogony (option A), erythrocytic schizogony (option B), and exo-erythrocytic schizogony (option D), do not represent the primary target for causal prophylaxis.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},ERROR,"The correct answer is **C) Pre-erythrocytic schizogony**.

**Reasoning:** Antimalarials, such as azithromycin, are effective during pre-erythrocytic stages because they can act in the blood (previously infected fuses are killed), allowing them to cause a causal prophylaxis by targeting infection before Schizogony occurs when yolk cells form."
407d4eec-cf0b-460c-bcdb-cf0081ec8c5d,Methacholine acts at which receptor?,M1,M2,M3,M4,1,single,"Ans: B. M2Methacholine is an M2 receptor agonist.ParameterM1M2M3Agonists (Relatively selective)Oxotremorine, MCN-343AMethacholineBethanecholAntagonists (Relatively selective)Pirenzepine, TelenzepineMethoctramine, TripitramineDarifenacin, Solifenacin",Pharmacology,,validation,"{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""Methacholine is a muscarinic agonist that acts at the M2 subtype of muscarinic receptors. It primarily affects the heart, where it stimulates the M2 receptors, resulting in a decrease in heart rate. Methacholine's action on M2 receptors is responsible for its role in diagnosing and assessing the severity of obstructive airway diseases. This occurs mainly because the parasympathomimetic effects are mediated through these receptors. The other options (M1, M3, and M4) are not primarily associated with methacholine's actions, making option B the correct choice.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Methacholine acts at M2 muscarinic receptors, found in the heart, causing a decrease in heart rate. It is a non-selective muscarinic agonist but has a preference for M2 receptors.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Methacholine is a non-selective muscarinic receptor agonist that primarily acts at the M2 subtype. M2 receptors are predominantly found in the heart, where they mediate negative chronotropy and negative dromotropy by decreasing heart rate and contractility, respectively. The other options (M1, M3, and M4) have different distribution patterns and functional effects, making option B (M2) the correct choice based on methacholine's pharmacological characteristics.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"The correct answer is A) M1. Methacholine acts on the M2 receptor, which is one of the primary types involved in opioid signaling.

```json
{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Methacolines are a class of drugs that function as M2 receptors. They are used for pain relief and are antagonists that bind directly to the M4 receptor, helping to reduce pain by dissociating the ligand-receptor interaction.""
}
```",B,"Methacholine is a muscarinic agonist that acts at the M2 subtype of muscarinic receptors. It primarily affects the heart, where it stimulates the M2 receptors, resulting in a decrease in heart rate. Methacholine's action on M2 receptors is responsible for its role in diagnosing and assessing the severity of obstructive airway diseases. This occurs mainly because the parasympathomimetic effects are mediated through these receptors. The other options (M1, M3, and M4) are not primarily associated with methacholine's actions, making option B the correct choice.",B,"Methacholine acts at M2 muscarinic receptors, found in the heart, causing a decrease in heart rate. It is a non-selective muscarinic agonist but has a preference for M2 receptors.",B,"Methacholine is a non-selective muscarinic receptor agonist that primarily acts at the M2 subtype. M2 receptors are predominantly found in the heart, where they mediate negative chronotropy and negative dromotropy by decreasing heart rate and contractility, respectively. The other options (M1, M3, and M4) have different distribution patterns and functional effects, making option B (M2) the correct choice based on methacholine's pharmacological characteristics.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},A,"Methacolines are a class of drugs that function as M2 receptors. They are used for pain relief and are antagonists that bind directly to the M4 receptor, helping to reduce pain by dissociating the ligand-receptor interaction."
0ba46472-54a7-4bb9-9802-a0546e24cede,A bank employee felt depressed with no interest in activities came to AIIMS OPD. He was staed on Escitalopram. Which of these adverse effects cannot be explained with escitalopram?,Vivid dreaming,Anorgasmia,Sialorrhea,Nausea,2,single,"Ans. C. SialorrheaEscitalopram belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRI).Improves your energy levels and feelings of well-being and decrease nervousness.Used to treat depression and anxiety.MOA: Works by helping to restore the serotonin balance in the brain.S/E:Headache, Nausea, Ejaculation disorder, Somnolence, Insomnia, Dry mouth, Constipation, Fatigue, Libido decreased, Inability to achieve orgasm, Gas (flatulence), Toothache, Weight gain, Menstrual disorder, Neck/shoulder pain, Runny nose & Flu-like syndrome.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and other mood disorders. Common adverse effects of SSRIs include nausea, vivid dreaming, and anorgasmia. Sialorrhea, excessive salivation, is not a typical side effect of SSRIs like escitalopram. SSRIs primarily affect the brain's neurotransmitters, such as serotonin, rather than saliva production. Therefore, sialorrhea cannot be explained as a direct adverse effect of escitalopram, making option C the correct answer.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Escitalopram is an SSRI, known for side effects like vivid dreaming, anorgasmia, and nausea. However, sialorrhea (excessive salivation) is not a common or expected side effect of escitalopram, making it the option that cannot be explained by escitalopram use.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Vivid dreaming is not a known adverse effect of Escitalopram. Escitalopram is a selective serotonin reuptake inhibitor (SSRI), commonly used for treating depression. Its adverse effects include nausea (D), anorgasmia (B), and sialorrhea (C), which can be explained by its pharmacological action on serotonin reuptake inhibition and potential modulation of other neurotransmitters. Vivid dreaming is more commonly associated with serotonin-norepinephrine reuptake inhibitors (SNRIs) and is not reported with SSRI escitalopram.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Escitalopram, as a selective serotonin reuptake inhibitor (SSRI), is known to cause vivid dreaming and anorgasmia. However, sialorrhea is not typically associated with Escitalopram's effects, as its mechanisms are more aligned with other conditions like β-agonists or certain antidepressants.""
}",C,"Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and other mood disorders. Common adverse effects of SSRIs include nausea, vivid dreaming, and anorgasmia. Sialorrhea, excessive salivation, is not a typical side effect of SSRIs like escitalopram. SSRIs primarily affect the brain's neurotransmitters, such as serotonin, rather than saliva production. Therefore, sialorrhea cannot be explained as a direct adverse effect of escitalopram, making option C the correct answer.",C,"Escitalopram is an SSRI, known for side effects like vivid dreaming, anorgasmia, and nausea. However, sialorrhea (excessive salivation) is not a common or expected side effect of escitalopram, making it the option that cannot be explained by escitalopram use.",A,"Vivid dreaming is not a known adverse effect of Escitalopram. Escitalopram is a selective serotonin reuptake inhibitor (SSRI), commonly used for treating depression. Its adverse effects include nausea (D), anorgasmia (B), and sialorrhea (C), which can be explained by its pharmacological action on serotonin reuptake inhibition and potential modulation of other neurotransmitters. Vivid dreaming is more commonly associated with serotonin-norepinephrine reuptake inhibitors (SNRIs) and is not reported with SSRI escitalopram.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},C,"Escitalopram, as a selective serotonin reuptake inhibitor (SSRI), is known to cause vivid dreaming and anorgasmia. However, sialorrhea is not typically associated with Escitalopram's effects, as its mechanisms are more aligned with other conditions like β-agonists or certain antidepressants."
fc3d5863-8850-4136-8bf9-8f7bb80ca2cb,Which of the following is not true for rifabutin as compared to rifampicin?,Rifabutin has the longer half-life than rifampicin,Rifabutin has lesser incidence of drug-interactions,Rifabutin is more efficacious against MAC as compared to rifampicin,Rifabutin is more efficacious for pulmonary TB as compared to rifampicin,3,multi,"Ans: D. Rifabutin is more efficacious for pulmonary TB as compared to rifampicin(Ref Goodman Gilman 12/e p1550, 1552, 1554, 1568; Katzung 12/e p845)Rifabutin:Stronger activity against Mycobacterium avium complex (compared to rifampicin).Ineffective against Mycobacterium tuberculosis. RifabutinRifampicin (Rifampin)RifapentineProtein binding 718597Oral 2068deg-tmax (hours)2.5-4.01.5-2.05.0-6.0degHalf-life (hours)32-67deg2-5deg14-18Intracellular/extracellular9524-60degAutoinduction40%deg38%20%CYP3A inductionWeakPronouncedModerateCYP3A substrateYesdegNoNo",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Rifabutin is generally used as an alternative to rifampicin in cases of drug interactions, especially when concomitant use with antiretroviral agents and protease inhibitors is necessary, due to its lower propensity for inducing the cytochrome P450 liver enzyme. However, in terms of efficacy for pulmonary tuberculosis (TB), rifampicin remains a preferred choice and the primary rifampicin derivative used in this context. While rifabutin has shown activity against Mycobacterium avium complex (MAC), its advantage over rifampicin specifically for pulmonary TB treatment is not established. Thus, option D is not true for rifabutin compared to rifampicin.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Rifabutin is not more efficacious for pulmonary TB than rifampicin. Rifampicin is a key drug in TB treatment due to its potent bactericidal activity. Rifabutin is used as an alternative, especially in HIV patients, due to its lesser enzyme-inducing potential and efficacy against Mycobacterium avium complex (MAC).""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Rifabutin is not more efficacious for pulmonary tuberculosis (TB) as compared to rifampicin. Both rifabutin and rifampicin are primary components of anti-TB treatment regimens. Rifabutin has better activity against mycobacterium avium complex (MAC) infections and is used in prophylaxis and treatment of disseminated MAC in HIV-positive individuals. However, in terms of efficacy against pulmonary TB, there is no difference between the two agents. Rifabutin's reduced bioavailability and lower potency in TB treatment compared to rifampicin are due to lower metabolic activation and decreased protein binding.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Rifabutin typically has a shorter half-life than rifampicin due to differences in substrate specificity and mechanism of action. Both drugs are β-lactams but target different organisms, so their pharmacokinetic profiles might not show significant variation in half-life when used together.""
}",D,"Rifabutin is generally used as an alternative to rifampicin in cases of drug interactions, especially when concomitant use with antiretroviral agents and protease inhibitors is necessary, due to its lower propensity for inducing the cytochrome P450 liver enzyme. However, in terms of efficacy for pulmonary tuberculosis (TB), rifampicin remains a preferred choice and the primary rifampicin derivative used in this context. While rifabutin has shown activity against Mycobacterium avium complex (MAC), its advantage over rifampicin specifically for pulmonary TB treatment is not established. Thus, option D is not true for rifabutin compared to rifampicin.",D,"Rifabutin is not more efficacious for pulmonary TB than rifampicin. Rifampicin is a key drug in TB treatment due to its potent bactericidal activity. Rifabutin is used as an alternative, especially in HIV patients, due to its lesser enzyme-inducing potential and efficacy against Mycobacterium avium complex (MAC).",D,"Rifabutin is not more efficacious for pulmonary tuberculosis (TB) as compared to rifampicin. Both rifabutin and rifampicin are primary components of anti-TB treatment regimens. Rifabutin has better activity against mycobacterium avium complex (MAC) infections and is used in prophylaxis and treatment of disseminated MAC in HIV-positive individuals. However, in terms of efficacy against pulmonary TB, there is no difference between the two agents. Rifabutin's reduced bioavailability and lower potency in TB treatment compared to rifampicin are due to lower metabolic activation and decreased protein binding.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},A,"Rifabutin typically has a shorter half-life than rifampicin due to differences in substrate specificity and mechanism of action. Both drugs are β-lactams but target different organisms, so their pharmacokinetic profiles might not show significant variation in half-life when used together."
4127528f-2cc3-44bc-b07e-446577f5018c,What is the dose of adrenaline in anaphylactic shock?,0.5 ml in 1:1000,0.5 ml in 1:10000,1 ml in 1:1000,1.5 ml in 1:1000,0,single,"Ans. A. 0.5 ml in 1:1000Severe hypersensitivity reactions, anaphylactic shockIM Injection:* Adults: The usual dose is 500 micrograms (0.5ml of adrenaline 1/1000). If necessary, this dose may be repeated several times at 5-minute intervals according to blood pressure, pulse and respiratory function.* Half doses of adrenaline may be safer for patients who are taking amitriptyline, imipramine or a beta blocker.Paediatric population:* The following doses of adrenaline 1/1,000 are recommended:AgeDoseOver 12 years0.5 mg IM (0.5ml 1:1000 solution)6 - 12 years0.3 mg IM (0.3ml 1:1000 solution)6 months - 6 years0.15 mg IM (0.15ml 1:1000 solution)Under 6 months0.01mg/kg IM (0.01ml/kg 1:1000 solution)* If necessary, these doses may be repeated at 5-15 -minute intervals according to blood pressure, pulse and respiratory function.",Pharmacology,,validation,"{
  ""Correct answer"": ""A) 0.5 ml in 1:1000"",
  ""Reasoning"": ""The correct dose of adrenaline in anaphylactic shock is 0.5 ml of 1 in 1000 solution, which is equivalent to 0.5 mg of adrenaline. This dose is administered intramuscularly to help alleviate symptoms such as bronchospasm, hypotension, and cardiac arrest. This is a standard first-line treatment for anaphylaxis in many clinical guidelines, including those from the American Heart Association and the European Resuscitation Council.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Adrenaline for anaphylactic shock is typically given as 0.5 ml of a 1:1000 solution intramuscularly, making option A the correct choice, based on standard emergency treatment protocols for anaphylaxis.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In anaphylactic shock, adrenaline is administered as an intramuscular injection using an auto-injector or prefilled syringe. The recommended dose is 0.5 ml of 1:1000 concentration, which corresponds to 0.5 mg of adrenaline. This concentration provides an adequate dose for immediate treatment while minimizing the risk of vasoconstriction and tachycardia.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In anaphylactic shock, rapid administration of adrenaline is crucial to minimize severe adverse reactions. A dose of 0.5 ml given as a rapid intravenous drip at a 1:1000 ratio ensures controlled concentration in the bloodstream, preventing complications like hypotheric effects and toxic interference from too much adrenaline. This approach helps maintain blood pressure stability while managing heart rate upswing.""
}",A,"The correct dose of adrenaline in anaphylactic shock is 0.5 ml of 1 in 1000 solution, which is equivalent to 0.5 mg of adrenaline. This dose is administered intramuscularly to help alleviate symptoms such as bronchospasm, hypotension, and cardiac arrest. This is a standard first-line treatment for anaphylaxis in many clinical guidelines, including those from the American Heart Association and the European Resuscitation Council.",A,"Adrenaline for anaphylactic shock is typically given as 0.5 ml of a 1:1000 solution intramuscularly, making option A the correct choice, based on standard emergency treatment protocols for anaphylaxis.",A,"In anaphylactic shock, adrenaline is administered as an intramuscular injection using an auto-injector or prefilled syringe. The recommended dose is 0.5 ml of 1:1000 concentration, which corresponds to 0.5 mg of adrenaline. This concentration provides an adequate dose for immediate treatment while minimizing the risk of vasoconstriction and tachycardia.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},A,"In anaphylactic shock, rapid administration of adrenaline is crucial to minimize severe adverse reactions. A dose of 0.5 ml given as a rapid intravenous drip at a 1:1000 ratio ensures controlled concentration in the bloodstream, preventing complications like hypotheric effects and toxic interference from too much adrenaline. This approach helps maintain blood pressure stability while managing heart rate upswing."
1f6b3a83-ed5e-4d0e-90b3-f740ff95c763,All are used for postpaum hemorrhage except -,Misoprostol,Dinoprostone,Prostaglandin F2 alpha,Oxytocin,1,multi,"Ans. B. DinoprostonePostpaum hemorrhage, the loss of more than 500 mL of blood after delivery, occurs in up to 18 percent of bihs and is the most common maternal morbidity in developed countries. Dinoprostone:Naturally occurring prostaglandin E2 (PGE2). It has impoant effects in labour.It also stimulates osteoblasts to release factors which stimulates bone resorption by osteoclasts.As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour. Indication:For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed aboion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period.In the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).Other indications include improving the cervical inducibility (cervical ""ripening"") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpaum hemorrhage.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Prostaglandin F2-alpha is primarily used for uterine relaxation in situations like uterine inversion or to induce uterine atony, but it is not a preferred medication for treating postpartum hemorrhage (PPH) due to its potential to exacerbate bleeding. Misoprostol (A), Dinoprostone (B), and Oxytocin (D) are all effective options for PPH treatment due to their ability to induce uterine contraction. Prostaglandin F2-alpha's effect of causing uterine contraction is short-lived and may not effectively control severe bleeding, making option C the correct answer.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Dinoprostone is a prostaglandin E2 analog used for labor induction, not typically for postpartum hemorrhage. Misoprostol, prostaglandin F2 alpha, and oxytocin are all used to manage postpartum hemorrhage.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Oxytocin is not used for postpartum hemorrhage. Instead, it is used to stimulate uterine contractions for purposes like inducing labor or enhancing involution of the uterus post-delivery. Options A, B, and C are all used for postpartum hemorrhage as they stimulate uterine contractions to help control bleeding. Misoprostol, dinoprostone, and prostaglandin F2 alpha are all prostaglandins that cause contraction of the uterine muscles and are commonly used to manage postpartum hemorrhage in obstetric practice.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"```json
{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Oxytocin directly causes post-pumal hemorrhage by stimulating hemorrhoid shedding in embryo formation, which affects hemodynamic recovery. Misoprostol reduces blood flow to the penis, and Dinoprosteine affects hormone levels that may contribute to systemic bleeding.""
}
```",C,"Prostaglandin F2-alpha is primarily used for uterine relaxation in situations like uterine inversion or to induce uterine atony, but it is not a preferred medication for treating postpartum hemorrhage (PPH) due to its potential to exacerbate bleeding. Misoprostol (A), Dinoprostone (B), and Oxytocin (D) are all effective options for PPH treatment due to their ability to induce uterine contraction. Prostaglandin F2-alpha's effect of causing uterine contraction is short-lived and may not effectively control severe bleeding, making option C the correct answer.",B,"Dinoprostone is a prostaglandin E2 analog used for labor induction, not typically for postpartum hemorrhage. Misoprostol, prostaglandin F2 alpha, and oxytocin are all used to manage postpartum hemorrhage.",D,"Oxytocin is not used for postpartum hemorrhage. Instead, it is used to stimulate uterine contractions for purposes like inducing labor or enhancing involution of the uterus post-delivery. Options A, B, and C are all used for postpartum hemorrhage as they stimulate uterine contractions to help control bleeding. Misoprostol, dinoprostone, and prostaglandin F2 alpha are all prostaglandins that cause contraction of the uterine muscles and are commonly used to manage postpartum hemorrhage in obstetric practice.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},D,"Oxytocin directly causes post-pumal hemorrhage by stimulating hemorrhoid shedding in embryo formation, which affects hemodynamic recovery. Misoprostol reduces blood flow to the penis, and Dinoprosteine affects hormone levels that may contribute to systemic bleeding."
416729b9-8f0b-45d1-aa27-6674dacb9975,"At low infusion rates of 3-5 mcg/kg/min, what action is produced by dopamine?",Vasoconstriction,Increased renal blood flow,Increased cardiac contractility,Decreased blood pressure,1,single,"Ans: B. Increased renal blood flow(Ref: Goodman Gilman 12/e p355; KDT 7/e p134. 6/e p507)Action of dopamine:At low concentrations (2 to 5 mcg/kg per minute):Primarily acts on vascular D1 receptors.Mainly renal, mesenteric & coronary beds.By activating adenylyl cyclase a raising intracellular cyclic AMP concentrations.D1 receptor stimulation a Vasodilation.Increases in glomerular filtration rate, renal blood flow & Nat+ K+ - ATPase pump.",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Dopamine at low infusion rates (3-5 mcg/kg/min) primarily stimulates dopamine receptors, leading to vasodilation in the renal and mesenteric blood vessels. This action enhances renal blood flow and promotes natriuresis, which contributes to the lowering of blood pressure. The increased renal blood flow is a direct result of dopamine's action on dopaminergic receptors, making option B the correct answer. Options A, C, and D are incorrect because vasoconstriction and increased cardiac contractility are seen at higher doses of dopamine (5-15 mcg/kg/min), while decreased blood pressure is more of a secondary effect of increased renal blood flow.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""At low infusion rates of 3-5 mcg/kg/min, dopamine acts on dopamine receptors, producing vasodilation, particularly in the renal and mesenteric vessels, thereby increasing renal blood flow.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""At low infusion rates of 3-5 mcg/kg/min, dopamine primarily causes increased renal blood flow. This is due to the activation of dopamine-1 (D1) receptors in renal vasculature, leading to vasodilation and increased perfusion of the kidneys. Vasoconstriction (Option A) occurs at higher doses, and increased cardiac contractility (Option C) is seen at higher doses as well. Decreased blood pressure (Option D) is not produced at low infusion rates, as it would require higher doses to overcome the increased renal blood flow.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"The correct answer is **D) Decreased blood pressure**.

**Reasoning:** At low dopamine infusion rates (3-5 mcg/kg/min), dopamine signals are reduced. This weakens associative learning and induces a decrease in blood flow, leading to decreased blood pressure when the brain releases NADK upon detecting low blood flow.

```json
{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Low dopamine levels during 3-5 mcg/kg/min inhibit associative learning, reducing GABA activation. This weakens heart rate and contractility, resulting in decreased blood pressure due to reduced blood flow from the brain.""
}
```",B,"Dopamine at low infusion rates (3-5 mcg/kg/min) primarily stimulates dopamine receptors, leading to vasodilation in the renal and mesenteric blood vessels. This action enhances renal blood flow and promotes natriuresis, which contributes to the lowering of blood pressure. The increased renal blood flow is a direct result of dopamine's action on dopaminergic receptors, making option B the correct answer. Options A, C, and D are incorrect because vasoconstriction and increased cardiac contractility are seen at higher doses of dopamine (5-15 mcg/kg/min), while decreased blood pressure is more of a secondary effect of increased renal blood flow.",B,"At low infusion rates of 3-5 mcg/kg/min, dopamine acts on dopamine receptors, producing vasodilation, particularly in the renal and mesenteric vessels, thereby increasing renal blood flow.",B,"At low infusion rates of 3-5 mcg/kg/min, dopamine primarily causes increased renal blood flow. This is due to the activation of dopamine-1 (D1) receptors in renal vasculature, leading to vasodilation and increased perfusion of the kidneys. Vasoconstriction (Option A) occurs at higher doses, and increased cardiac contractility (Option C) is seen at higher doses as well. Decreased blood pressure (Option D) is not produced at low infusion rates, as it would require higher doses to overcome the increased renal blood flow.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},D,"Low dopamine levels during 3-5 mcg/kg/min inhibit associative learning, reducing GABA activation. This weakens heart rate and contractility, resulting in decreased blood pressure due to reduced blood flow from the brain."
07c14e46-ad2b-4fde-8652-bd47b36e69ab,Vasopressin antagonist acts on which pa of the nephron?,Proximal convoluted tubule,Distal convoluted tubule,Coical collecting tubule,Medullary collecting duct,3,single,Answer- D (Medullary collecting duct)'The mechanism by which vasopressin exes its anti-diuretic effect is activated by V2 receptors and involves the inseion of aquaporin-2 into the apical (luminal) membranes at the principle cells of the collecting duct.',Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Vasopressin antagonists, also known as V2 receptor antagonists, work by blocking the action of vasopressin (ADH or antidiuretic hormone) in the kidneys. Vasopressin primarily acts on the cortical collecting tubule (CCT) to increase water reabsorption. By antagonizing vasopressin, these drugs decrease water reabsorption in the CCT, leading to increased urine production and reduced water reabsorption in the kidney. This mechanism allows vasopressin antagonists to play a crucial role in treating conditions such as hyponatremia and hyponatremic syndrome of heart failure.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Vasopressin antagonists act on the medullary collecting duct, where vasopressin (ADH) normally increases water permeability, promoting water reabsorption. Antagonists inhibit this action, increasing water excretion.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Vasopressin, also known as antidiuretic hormone (ADH), regulates water reabsorption in the nephron. Its receptor is primarily present in the V2 subtype, localized in the principal cells of the medullary collecting duct. Therefore, vasopressin antagonists act on the medullary collecting duct (Option D) to inhibit ADH action and promote diuresis.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Vasopressin antagonist drugs act on the proximal convoluted tubule of the loop of缩窄 (loop of IV), where they block the interaction between glomeruli, thereby increasing the filtration rate in both regions but reducing collection from the collecting ducts.""
}
}",C,"Vasopressin antagonists, also known as V2 receptor antagonists, work by blocking the action of vasopressin (ADH or antidiuretic hormone) in the kidneys. Vasopressin primarily acts on the cortical collecting tubule (CCT) to increase water reabsorption. By antagonizing vasopressin, these drugs decrease water reabsorption in the CCT, leading to increased urine production and reduced water reabsorption in the kidney. This mechanism allows vasopressin antagonists to play a crucial role in treating conditions such as hyponatremia and hyponatremic syndrome of heart failure.",D,"Vasopressin antagonists act on the medullary collecting duct, where vasopressin (ADH) normally increases water permeability, promoting water reabsorption. Antagonists inhibit this action, increasing water excretion.",D,"Vasopressin, also known as antidiuretic hormone (ADH), regulates water reabsorption in the nephron. Its receptor is primarily present in the V2 subtype, localized in the principal cells of the medullary collecting duct. Therefore, vasopressin antagonists act on the medullary collecting duct (Option D) to inhibit ADH action and promote diuresis.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},A,"Vasopressin antagonist drugs act on the proximal convoluted tubule of the loop of缩窄 (loop of IV), where they block the interaction between glomeruli, thereby increasing the filtration rate in both regions but reducing collection from the collecting ducts."
604ef1a2-7595-4718-9f8c-12292063e19f,Which of the following anti-tubercular drug can cause ophthalmological toxicity?,Isoniazid,Rifampicin,Ethambutol,Pyrazinamide,2,single,"Ethambutol side effect: causes Red Green color blindness (Ophthalmological toxicity) Isoniazid side effects: Neurotoxicity, Hepatotoxicity. Pyrazinamide side effects: Hyperuricemia (gouty ahritis). Rifampicin side effects: Hepatotoxicity, orange red urine and tears etc.",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Ethambutol is an anti-tubercular drug that can cause ophthalmological toxicity, specifically optic neuritis leading to visual disturbances or even blindness. This toxicity is dose-dependent and reversible once the drug is discontinued. In contrast, Isoniazid causes peripheral neuropathy as its major toxic effect, Rifampicin causes liver toxicity, and Pyrazinamide is associated with hepatotoxicity. Therefore, among the given options, Ethambutol is the correct choice for causing ophthalmological toxicity.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Ethambutol can cause ophthalmological toxicity, particularly optic neuritis, leading to blurred vision and color vision changes. This is a well-documented side effect of ethambutol, making it the correct choice.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Ethambutol (option C) is known to cause ophthalmological toxicity, particularly optic neuritis. This is due to its ability to accumulate in the eye tissue, leading to irreversible vision loss if left untreated. This adverse effect is rare but significant, necessitating regular monitoring of patients' vision during treatment with ethambutol. The other options, Isoniazid, Rifampicin, and Pyrazinamide, are not associated with such ophthalmological toxicity.""
}",Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},"The correct option for the question ""Which of the following anti-tubercular drug can cause ophthalmological toxicity?"" is A) Isoniazid.

**Reasoning:** Isozid is an anti-TB drug that binds to tuberculin in the eyes, preventing bacterial replication there. High doses or continuous use can lead to ophthalmological effects like photopsis and dry eyes. Ethambutol (C), on the other hand, inhibits TB in the skin and eye but has less impact on eye inflammation or photopsis compared to isoniazid.",C,"Ethambutol is an anti-tubercular drug that can cause ophthalmological toxicity, specifically optic neuritis leading to visual disturbances or even blindness. This toxicity is dose-dependent and reversible once the drug is discontinued. In contrast, Isoniazid causes peripheral neuropathy as its major toxic effect, Rifampicin causes liver toxicity, and Pyrazinamide is associated with hepatotoxicity. Therefore, among the given options, Ethambutol is the correct choice for causing ophthalmological toxicity.",C,"Ethambutol can cause ophthalmological toxicity, particularly optic neuritis, leading to blurred vision and color vision changes. This is a well-documented side effect of ethambutol, making it the correct choice.",C,"Ethambutol (option C) is known to cause ophthalmological toxicity, particularly optic neuritis. This is due to its ability to accumulate in the eye tissue, leading to irreversible vision loss if left untreated. This adverse effect is rare but significant, necessitating regular monitoring of patients' vision during treatment with ethambutol. The other options, Isoniazid, Rifampicin, and Pyrazinamide, are not associated with such ophthalmological toxicity.",ERROR,Error: Error code: 402 - {'error': 'You have exceeded your monthly included credits for Inference Providers. Subscribe to PRO to get 20x more monthly included credits.'},ERROR,"The correct option for the question ""Which of the following anti-tubercular drug can cause ophthalmological toxicity?"" is A) Isoniazid.

**Reasoning:** Isozid is an anti-TB drug that binds to tuberculin in the eyes, preventing bacterial replication there. High doses or continuous use can lead to ophthalmological effects like photopsis and dry eyes. Ethambutol (C), on the other hand, inhibits TB in the skin and eye but has less impact on eye inflammation or photopsis compared to isoniazid."
